



Identification and Characterisation of  
Human Cytomegalovirus-Mediated  









Department of Medicine 
Cambridge Institute for Medical Research 
University of Cambridge 
 
This dissertation is submitted for the degree of 















I hereby declare, that except where specific reference is made to the work of others, the 
contents of this dissertation are original and have not been submitted in whole or in part 
for consideration for any other degree of qualification in this, or any other university. 
 
This dissertation is the result of my own work and includes nothing which is the outcome 
of work done in collaboration except as where specified in the text and 
acknowledgments. 
 
This dissertation does not exceed the specified word limit of 60,000 words as defined by 












Identification and characterisation of human cytomegalovirus-mediated 
degradation of helicase-like transcription factor 
Kai-Min Lin 
Viruses are known to degrade host factors that are important in innate antiviral 
immunity in order to infect successfully. To systematically identify host proteins 
targeted for early degradation by human cytomegalovirus (HCMV), the lab developed 
orthogonal screens using high resolution multiplexed mass spectrometry. Taking 
advantage of broad and selective proteasome and lysosome inhibitors, proteasomal 
degradation was found to be heavily exploited by HCMV. Several known antiviral 
restriction factors, including components of cellular promyelocytic leukemia (PML) were 
enriched in a shortlist of proteasomally degraded proteins during infection. 
A particularly robust novel ‘hit’ was helicase-like transcription factor (HLTF), a DNA 
repair protein that participates in error-free repair of stalled replication forks. HLTF was 
found degraded very early during infection, and its expression remained low throughout 
the course of HCMV lytic cycle. De novo expression of UL145, a previously 
uncharacterized viral protein, was found necessary and sufficient to degrade HLTF via 
recruitment of the cullin 4/DDB1 E3 ligase complex. 
HLTF degradation was reported in human immunodeficiency virus (HIV) infection, 
however the interaction between HLTF and viruses remain largely elusive. The roles of 
UL145 were explored in hopes of understanding functions of HLTF in HCMV infection. 
UL145 was identified as a non-essential immediate early protein, however had a 
possible role in type I interferon (IFN) induction regulation in later stages of HCMV lytic 
progression. As the key host protein to be rescued by UL145 deletion, depletion of HLTF 
was found to transiently impair IFNβ transcription and HCMV infection. I hypothesise 
that HLTF is an undiscovered nuclear viral DNA sensor that triggers an antiviral 
interferon response during viral DNA replication. 
Additionally, work presented here expands the range of powerful screening 
technologies to identify HCMV restriction factor candidates by identifying virally 
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MDA5 melanoma differentiation-associated gene 5 
MDC1 mediator of DNA damage checkpoint protein 1  
MDM2 murine double minute 2  
MDMX murine double minute X  
MED20 mediator of RNA polymerase II transcription subunit 20 




MHC major histocompatibility complex  
MHV68 murine gammaherpesvirus 68  
MIC MHC class I-related chain 
MICA MHC class-I chain-related proteins A  
MIEP major immediate early promoter  
MLKL mixed lineage kinase domain like pseudokinase 
MOI multiplicity of infection  
MORC3 microrchidia CW-type zinc finger 3  
MRN MRE11, RAD50, NBS1  
mRNA messenger RNA 
MS mass spectrometry 
MSK2 mitogen- and stress-activated kinase 2 
mTOR mammalian target of rapamycin 
MuHV-4 murid herpesvirus-4  
MVB multivesicular bodies 
MyD88 myeloid differentiation primary response gene 88  
NACC2 nucleus accumbens-associated protein 2 
NBS1 Nijmegen breakage syndrome 1 
NCE normalised collision energy  
ND10 nuclear domain 10 
NEDD4 neural precursor cell expressed, developmentally down-regulated 4 
NEDD4L NEDD4-like 
NEMO NFκB essential modulator  
NFκB nuclear factor kappa B 
NHEJ non-homologous end joining  




NLGN2 neuroligin 2 
NTase nucleotidyltransferase  
O/N overnight 
OAS1 2’-5’-oligoadenylate synthase 1  
OAS2 2’-5’-oligoadenylate synthase 2 
ORF open reading frame  
oriLyt HCMV origin of DNA replication 
PAGE polyacrylamide gel electrophoresis 
PAMP pathogen-associated molecular pattern 
PARK2 Parkin 2 
PBS phosphate-buffered saline 
PCDHGB2 protocadherin gamma-B2 
PCDHGB5 protocadherin gamma-B5 
PCDHGC3 Protocadherin gamma-C3 
PCNA proliferating cell nuclear antigen  
PCR polymerase chain reaction  
pDC plasmacytoid dendritic cell 
PDZ PSD-95/Dlg/ZO-1 
PDZD11 PDZ domain containing protein 11  
PE phosphatidylethanolamine 
PE phycoerythrin 
pfu plaque forming unit  
PI3K phosphoinositide 3-kinase  
PI3KC3–C1 class III phosphatidylinositol 3-kinase complex I 
PIC Protease Inhibitor Cocktail  




PML promyelocytic leukemia 
pol polymerase 
pp65 phosphoprotein 65 
pp71 phosphoprotein 71 
PRR pattern-recognition receptor 
PSD-95 Postsynaptic density protein 95  
pSFFV spleen focus-forming virus promoter 
pSILAC pulsed SILAC 
PSM peptide spectral matches  
PTPN14 tyrosine-protein phosphatase non-receptor type 14 
PVDF polyvinylidene fluoride  
RALGPS2 Ras-specific guanine nucleotide-releasing factor RalGPS2 
RBM4 RNA binding motif protein 4  
RBPMS RNA-binding protein with multiple splicing 
RBR RING-between-RING  
RBX1 RING box 1 
RBX2 RING box 2 
RGCC regulator of cell cycle RGCC 
RGL2 Ral guanine nucleotide dissociation stimulator like 2  
RhCMV Rhesus cytomegalovirus  
RHIM receptor-interacting protein homotypic interaction motif 
RIG-I RNA helicases retinoic acid-inducible gene I  
RING really interesting gene  
RIPA radioimmunoprecipitation assay  
RIPK1 receptor-interacting serine/threonine protein kinases 1 




RLD regulator of chromatin condensation 1 like domains 
RNA ribonucleic acid 
RNF150 RING finger protein 150 
RNF168 RING finger 168 
RNF8 RING finger 8  
ROC1 regulator of cullin 1 
ROC2 regulator of cullin 2 
RP regulatory particle 
RPA replication protein A  
RPS6KA4 ribosomal protein S6 kinase A4 
rRNA ribosomal RNA  
RS rapid separation 
RSV respiratory syncytial virus 
RT room temperature 
RTK receptor tyrosine kinase 
SAM sterile alpha motif 
SAMHD1 SAM And HD domain containing deoxynucleoside triphosphate 
triphosphohydrolase 1 
SA streptavidin 
SCCMV simian cytomegalovirus 
SCID severe combined immunodeficiency 
SDS sodium dodecyl sulphate  
SD standard deviation  
SEM standard error of the mean 
SETX senataxin 





shRNA small hairpin RNA  
SigA significance A 
SigB  significance B 
SILAC stable isotope labelling by amino acids in cell culture 
siRNA small interfering RNA 
SKP1 S phase kinase-associated protein 1 
SMARCA3 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily A member 3 
SNAP N-ethylmaleimide-sensitive attachment protein 
SNARE SNAP receptor  
SNX16 sorting nexin 16 
SOCS suppressor of cytokine signalling box  
SP100 speckled protein 100 kDa 
SQSTM1 sequestosome 1, also known as p62 
ssDNA single strand DNA 
STAT signal transducer and activator of transcription  
STING stimulator of IFN gene  
STK32B serine/threonine kinase 32B 
STNB1 syntrophin beta 1  
SUGP2 SURP and G-patch domain-containing protein 2 
SURP suppressor of white-apricot homolog, SWAP  
SV40 simian virus 40  
SV5 simian virus V protein 5  
SWI/SNF switch/sucrose non-fermentable 




TANK TRAF-associated NFκB activator 
TBK1 TANK-binding kinase-1  
TCA trichloroacetic acid  
TCEAL4 transcription elongation factor A protein-like 4 
TE Tris-EDTA 
tet tetracycline 
TFAP4 transcription factor AP-4  
TLR toll-like receptor 
TMB tetramethyl-benzidine  
TMT tandem mass tag  
TNFα tumour necrosis factor α  
TOX thymocyte selection-associated high mobility group box protein TOX 
TP53BP1 p53 binding protein 1  
TRAF tumour necrosis factor receptor associated factor 
TRAF6 tumour necrosis factor receptor-associated factor 6  
TRIM32 tripartite motif-containing protein 32 
TRIM56 tripartite motif-containing protein 56 
TRIM5α tripartite motif containing 5 alpha  
TRL terminal repeat long 
tRNA transfer RNA 
TYK2 tyrosine kinase 2 
Ub ubiquitin 
UBC13 ubiquitin-conjugating enzyme 13 
UHPLC ultrahigh performance liquid chromatography  
UL HCMV unique long  




ULK1 unc-51-like autophagy activating kinase 1  
UNG2 uracil-DNA glycosylase 2  
US HCMV unique short 
UV ultraviolet 
VACV vaccinia virus  
V-ATPase vacuolar ATPase 
vIL10 HCMV viral interleukin 10  
VIP36 vesicular integral-membrane protein VIP36 
Vpr HIV viral protein R 
VSP16 vacuolar protein sorting-associated protein 16  
VSV vesicular stomatitis virus  
VZV varicella-zoster virus 
wnt wingless 
WT wild-type  
WWP2 NEDD4-like E3 ubiquitin-protein ligase WWP2 
Xcorr cross-correlation score  
XPA Xeroderma pigmentosum complementation group A  
YAP1 yes-associated protein 1 
YFP yellowish-green fluorescent protein 
ZBED1 zinc finger BED-type containing 1 
ZBP1 Z-form DNA/RNA-binding protein 1  
ZFP36L2 mRNA decay activator protein ZFP36L2 
ZMYND11 zinc finger MYND-type containing 11 
ZNF668 zinc finger protein 668 










Chapter 1. Introduction 
1.1.   Human Cytomegalovirus 
1.1.1. Herpesvirdae family 
Herpesviridae are a family of linear, double-stranded DNA viruses that disseminate 
broadly in nature, infecting a wide range of animals, including mammals, birds, and 
reptiles (Pellett and Roizman, 2013). There are 8 types of herpesviruses having human 
as the primary host, all of which belong to one of the three subfamilies of Herpesvirdae 
(Table 1.1): The Alphaherpesvirinae, the Betaherpesvirinae, and the 
Gammaherpesvirinae (Pellett and Roizman, 2013).  
Alphaherpesviruses have the most variable hosts among herpesviruses, replicate 
relatively fast, and establish latency primarily in sensory ganglia (Smith, 2012). This 
subfamily includes Simplexviruses and Varicelloviruses that have mammalian hosts, 
Mardiviruses and Iltoviruses that have avian hosts, and several reptilian herpesviruses 
that are not classified to any current genus (McGeoch and Gatherer, 2005). Herpes 
simplex viruses (HSV1, HSV2) and varicella-zoster virus (VZV) from this subfamily have 
man as the natural host (Bloom, 2016).  
In comparison, betaherpesviruses, such as human cytomegalovirus (HCMV), human 
herpesvirus 6 (HHV6), and human herpesvirus 7 (HHV7) have restricted host range and 
a prolonged replication cycle (Santos, 2016). Cells infected with primate 
betaherpesviruses frequently become enlarged (cytomegalia) due to the presence of 
intranuclear inclusion bodies. Betaherpesviruses can establish latency in secretory 
glands, lymphoreticular cells, and kidneys (Mocarski, 2007). 
Gammaherpesviruses have the most restricted host range among the three subfamilies, 
mainly have primates and mice as their natural host (Cesarman, 2011). In this subfamily 
Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV) are 




lytically infect in lymphoblastoid cells, and latency is frequently established in lymphoid 
tissue (Tibbetts et al., 2003). 
Even though different herpesviruses have distinct gene expression programs leading to 
diverse pathogenic effects, all members of herpesvirdae share several biological 
properties. Firstly, they all encode viral enzymes for nucleic acid metabolism, DNA 
synthesis, and post-translational protein modification; secondly, virus gene 
transcription, synthesis of viral DNA, and nucleocapsid assembly of herpesviruses occur 
in the host nucleus, and thirdly, herpesviruses establish lifelong latency in their hosts. 
 
Table 1.1. Classification of the human herpesviruses. 
Subfamily Genus Virus 
Alphaherpesvirinae 
Simplexvirus 
Herpes simplex virus 1 (HSV1/HHV1) 
Herpes simplex virus 2 (HSV2/HHV2) 






Human betaherpesvirus 6A (HHV6A) 
Human betaherpesvirus 6B  (HHV6B) 
Human betaherpesvirus 7 (HHV7) 





1.1.2. Human Cytomegalovirus 
Human cytomegalovirus (HCMV) is a ubiquitous betaherpesvirus that persistently 




infection is >80% in Africa, Asia and South America, and 40%-70% in Europe and North 
America (Cannon et al., 2010). The virus has a wide range of tissue tropism including 
endothelial cells, fibroblasts, smooth muscle, and hematopoietic cells, and possesses 
the potential to spread through the circulation system to many organs (Griffiths et al., 
2015). Although primary infection is mostly asymptomatic in healthy individuals, HCMV 
is still the leading cause of congenital infection and may lead to life-threatening diseases 
in immunocompromised patients. Upon primary infection, HCMV effectively evades 
host innate and adaptive immunity and establishes life-long latency, making it an ideal 
model to investigate viral immune evasion (Jackson et al., 2011; Powers et al., 2008). 
Only a few antiviral drugs are currently available in clinical practice, and there is still a 
high demand for antiviral vaccines and safer antiviral treatments to reduce the global 
public health burden caused by HCMV (Anderholm et al., 2016).  
 
1.1.3. Virion structure   
HCMV shares structural properties with other herpesviruses (Figure 1.1). The double-
stranded viral DNA is packed in a stable icosahedral protein nucleocapsid, which is 
surrounded by a thick layer of tegument proteins. HCMV capsids are encapsulated by an 
envelope consisting of host-derived lipid bilayer membrane and viral glycoproteins 
which mediate the attachment and entry to host cells. For instance, the trimeric complex 
gH:gL:gO allows virus to infect fibroblasts while the pentamer 
gH:gL:pUL128:pUL130:pUL131A facilitates entry into epithelial and endothelial cells 






Figure 1.1. Structure of HCMV virion. 
 
1.1.4. Viral genome 
Among all the viruses that have human as the primary host, HCMV has the largest 
genome, with an approximate length of 230 kb (Dolan et al., 2004) and consisting of a 
unique long (UL) region and a unique short (US) region flanked by terminal and internal 
repeats (Figure 1.2). The terminal and internal repeats are reverse complementary to 
each other. The paired sequences flanking UL are known as “b” (terminal repeat long, 
TRL) and “ b’ ” (internal repeat long, IRL), and the sequences flanking US are “ c’ “ (IRS) 
and “c” (TRS), resulting in an overall configuration TRL-UL-IRL-IRS-US-TRS. A short 
redundant region called “a” sequence may come in multiple copies in some strains, 
occurs at both ends of HCMV genome and inversely at the IRL–IRS junction (Mocarski et 
al., 2013).  
 
 
Figure 1.2. HCMV genome structure. 
HCMV genome is comprised of long and short arms. Unique long (UL) sequence is 
flanked by copies of the b sequence (TRL) and inverted b sequence (b’, IRL). Unique 
short (US) sequence is flanked by copies of c sequence (TRS) and inverted c 
sequence (c’, IRS). One or several copies of the a sequence are found at both ends 
or the long/short junction (as inverted a, a’ sequence) where the long and short 
arms join. 
 
Generally, HCMV genes and their products are named in an orderly fashion based on 
their position in the genome, from left to right. However, some viral proteins are given 
names according to their chemical posttranslational modification and molecular weight, 




expression during the course of infection (immediate early proteins IE1 and IE2) (Chee 
et al., 1990; Spaete et al., 1994). 
HCMV encodes for 171 canonical genes, several of which are known to be involved in 
steps of HCMV life cycle, yet the function of many viral gene products remains unknown 
(Van Damme and Van Loock, 2014). Adding to the complexity of HCMV biology, using 
ribosome profiling and transcript analysis, more than 600 previously unreported open 
reading frames were identified and verified, with a proportion verified by protein mass 
spectrometry at the time of study and since (Nightingale et al., 2018; Nobre et al., 2019; 
Stern-Ginossar et al., 2012; Weekes et al., 2014). In addition to protein-coding genes, 
HCMV also produces 23 miRNAs and 4 long non-coding RNAs (RNA2.7, RNA1.2, RNA4.9 
and RNA5.0) whose roles in HCMV life cycle are poorly understood (Dhuruvasan et al., 
2011; Gatherer et al., 2011; Zhang et al., 2007). 
 
1.1.5. Laboratory strains 
Despite having a wide range of tissue tropism, HCMV strains accumulate deletion and 
point mutations when propagated in cell culture (Stanton et al., 2010). Gene-disrupting 
mutations in a set of at least 26 genes are common, contributing to the high genome 
diversity within different HCMV strains (Sijmons et al., 2015a). For example, the large 
fragment of UL/b’ has been replaced by inverted repeat from the left terminus of the 
HCMV genome in highly-passaged, laboratory-adapted strains AD169 and Towne (Cha 
et al., 1996; Chee et al., 1990). AD169 also carries frameshifts of RL5A, RL13 and UL131A, 
resulting in inactivation of these genes (Akter et al., 2003; Davison et al., 2003; Yu et al., 
2002). Towne has mutations that disable RL13 and UL130. Sometimes UL1, UL36, UL40, 
UL42, UL43, US1 and US9 are mutated in heterogeneously maintained laboratory-
propagated stains (Bradley et al., 2009; Dargan et al., 1997; Mocarski et al., 1997; 
Skaletskaya et al., 2001). Although minimally passaged in cell culture, HCMV strains 
Merlin and Toledo still have mutations in at least UL128 and RL13. Merlin UL128 is 
truncated by a single nucleotide substitution that introduces a premature termination 




the UL segment (Davison et al., 2003). Toledo has an in-frame deletion in RL13, and after 
a small number of passages in vitro, Merlin generally develops a frameshift mutation in 
RL13 (Dargan et al., 2010). In comparison with the unpassaged clinical isolates, nearly 
all of the passaged strains have function-disrupting mutations in UL128, UL130, or 
UL131A, and most have mutations in at least one member of the RL11 gene family, such 
as RL13 (Akter et al., 2003; Dolan et al., 2004). Highly productive TB40/E is a low passage 
endotheliotropic strain that has frameshifted UL141, but usually have intact UL128, 
UL130 and UL131A (Sinzger et al., 2008). 
It has been reported that HCMV strains cultured in fibroblasts have improved replication 
and release of progeny virus but attenuated virulence such as the ability to infect 
epithelial and endothelial cells (Revello and Gerna, 2010). Extensive study of the 
commonly mutated genes has suggested the reasons underlying these observations. 
RL13, for instance, is shown to efficiently repress HCMV replication in multiple cell types 
(Stanton et al., 2010). It has also been shown that loss of any one of three components, 
namely protein products of UL128, UL130, and UL131A, of the pentameric complex 
gH:gL:UL128:UL130:UL131A compromises attachment and replication efficiency in 
epithelial and endothelial cells (Hahn et al., 2004; Sinzger et al., 2008; Wang and Shenk, 
2005). The major genetic difference between high passage and low passage strains lies 
in the ~15 kb UL/b’ region, which leads to further attenuation of infectivity. Loss of the 
UL133-UL138 segment suppresses viral replication in hematopoietic progenitors and 
augments replication in endothelial cells (Grainger et al., 2010; Umashankar et al., 2011). 
A study in severe combined immunodeficiency (SCID) mice with human tissue implants 
demonstrate that AD169 has lost the ability to replicate in vivo (Wang et al., 2005). 
 
1.1.6. Latency 
Like other members of the herpesvirus family, one key characteristic of HCMV is its 
ability to establish latency. HCMV latency is associated with host cell type, with 
endothelial cells and myeloid cells are considered as sites for HCMV latency and 




microvascular endothelial cells support latent HCMV infection (Fish et al., 1998). Cells of 
the early myeloid lineage, such as CD34+ hematopoietic progenitor cells and CD14+ 
monocytes derived from CD34+ cells have been shown to harbour latent HCMV in vivo 
(Sinclair and Sissons, 2006). In these cells, viral genome is maintained without 
production of infectious progeny. HCMV reactivation has been extensively studied in 
myeloid cell differentiation, a process in which CD34+ hematopoietic stem cells 
differentiate into mature dendritic cells or macrophages (Poole et al., 2015; Reeves and 
Sinclair, 2013). Regulation of chromatin structure at the major immediate early 
promoter (MIEP) within myeloid cells is considered crucial to HCMV activation (Elder 
and Sinclair, 2019). 
Prior studies have suggested that the HCMV genome resides as a circular episome in 
latently infected cells (Bolovan-Fritts et al., 1999; Slobedman and Mocarski, 1999). Other 
features of HCMV latency include the detectable expression of the latency-associated 
genes and the absence of global viral gene transcription (Elder and Sinclair, 2019; 
Slobedman et al., 2010). This set of latency-associated genes contains UL82 (pp71), 
UL138, glycoprotein UL144, chemokine receptor US28, latency-associated viral 
interleukin 10 (vIL10, UL111.5A), and latency unique natural antigen (LUNA, encoded by 
antisense UL81-82) (Goodrum et al., 2007). Some of these latency-associated transcripts 
are different isoforms of viral transcripts observed in lytic infection. For instance, 
UL111A encodes latency-associated viral interleukin 10 and its isoform found in lytic 
infection (Jenkins et al., 2004). Recent transcriptomic analysis with single-cell RNA 
sequencing on experimental and clinical samples has revealed that a broad spectrum of 
canonical viral lytic genes are expressed in latency, albeit at low expression level (Cheng 
et al., 2017; Shnayder et al., 2018). 
 
1.1.7. Lytic replication cycle 
A typical productive HCMV replication cycle, from infectious virions entering a host cell 
to new progeny virions leaving the cell, takes 48 to 96 hours to complete. In order to 




such as platelet-derived growth factor, heparan sulfate, integrins, and epidermal growth 
factor receptor (EGFR) (Compton et al., 1993; Feire et al., 2004; Wang et al., 2003). 
Depending on the cell type, HCMV enters host cells either through direct fusion at the 
cell surface (fibroblasts) or endocytosis (epithelial and endothelial cells). Large tegument 
protein (UL48), a binding protein (UL47), and facilitate capsid trafficking to the nucleus 
and capsid uncoating (Bechtel and Shenk, 2002; Fuchs et al., 2002). Upon entry, HCMV 
genes are expressed in a temporally regulated cascade, starting with immediate-early 
(IE) genes, followed by early (E) genes, and finally the late (L) genes. Viral genes are 
transcribed by host RNA polymerase II and translated by host ribosomes. 
By 1 hpi, viral genome has been deposited into host nucleus (Rosenke and Fortunato, 
2004). In the nucleus, HCMV genome binds to nuclear domain 10 (ND10, also known as 
PML nuclear body) components, where promyelocytic leukemia protein (PML) and 
speckled protein 100 kDa (SP100), α-thalassemia/mental retardation X-linked (ATRX), 
and death-domain associated protein (DAXX) aggregate (Everett and Chelbi-Alix, 2007; 
Ishov and Maul, 1996). The heterodimer DAXX/ATRX mediates histone deacetylase 
(HDACs) and represses MIEP activity (Maul, 2008; Reeves, 2011; Sinclair, 2010). 
However, pre-released tegument proteins pp71 (UL82) and pUL69 locate to ND10 
bodies and degrades DAXX, initiating the transcription of major IE genes, including IE1 
(UL123) and IE2 (UL122) (Hensel et al., 1996; Sanchez et al., 1998). IE1 protein also 
regulates signal transducer and activator of transcription (STAT) signalling, interacts with 
DAXX and HDAC3, and disrupts ND10 bodies to overcome the chromatin repression of 
MIEP and other viral promoters (Lee et al., 2007; Maul, 2008; Nevels et al., 2011; Tavalai 
and Stamminger, 2011). IE2 is the main activator of the later E and L genes while IE1 act 
as a coactivator. IE2 transactivates promoters through direct interaction with cis 
repression sequence sites on viral DNA, initiating viral gene transcription together with 
RNA pol II and cell cycle-controlling kinases (Kapasi and Spector, 2008; Reeves et al., 
2006). 
E genes are indispensable for viral DNA synthesis. DNA synthesis initiates at the oriLyt 
site situated between the UL57 and UL69 genes at around 18 hpi (Anders et al., 1992; 
Yatim and Albert, 2011). The HCMV replisome consists of UL54-encoded DNA 




encoded single-strand DNA binding protein, and heterotrimeric helicase-primase 
encoded by UL70, UL102 and UL105 (Erice, 1999; Kim and Ahn, 2010; Pari and Anders, 
1993). Gene products of UL112-UL113 (pp34, pp43, pp50, pp84) direct the replisome to 
the viral genome via UL44 (Park et al., 2006). UL84 encodes a betaherpesvirus-specific 
protein (ppUL84) that together with IE2, bind to the oriLyt promoter and facilitate viral 
DNA replication initiation (Colletti et al., 2004; Sarisky and Hayward, 1996).  
L gene products control capsid maturation, DNA packaging, virion maturation, and 
egress from the cell. Capsids are assembled in the nucleus with the products of UL86, 
UL46, UL85, and UL48A. Viral DNA is encapsidated by the terminase complex (UL89, 
UL56, UL51) through a channel formed by pUL104. Nuclear egress of the nucleocapsid 
is mediated by the nuclear egress complex (UL50 and UL53). Like other herpesvirus, 
virions undergo primary envelopment and de-envelopment before joining viral surface 
glycoproteins at cytoplasm and exit cells through exocytosis. (Mettenleiter, 2002; 
Varnum et al., 2004) 
 
 
Figure 1.3. Lytic Cycle of HCMV Infection.  
Infectious particles enter cells by either direct membrane fusion of endocytosis. 
Viral envelope uncoating occurs the same time as membrane fusion with the cell 




nucleocapsid released into the cytosol. The nucleocapsid is translocated towards 
the nucleus along the cytoskeleton, and the viral DNA is released into the cell 
nucleus. HCMV DNA often circulates via annealing of the terminal repeats.  A 
regulated temporal cascade of gene expression is activated. Firstly immediate 
early (IE) genes, followed by early (E) genes, which initiate viral genome replication, 
and late (L) genes, which encode viral structural proteins. Capsid proteins 
translocate back to the nucleus and packaging of the nucleocapsid occurs. 
Acquisition of tegument proteins in the cytosol is followed by envelopment at viral 
assembly complex which contains components of the endoplasmic reticulum (ER), 
Golgi apparatus, and endosomal machinery. More tegument proteins and a viral 
envelope attach to the particles by budding into intracellular vesicles at the AC. 
Mature virions are released along with non-infectious dense bodies through 
exocytosis. Figure and figure legend are adapted from (Jean Beltran and Cristea, 
2014). 
  
Compared to IE-E-L viral gene classification, a new method to describe viral temporal 
classes has been proposed. Using an unbiased proteomics approach coupled with k-
means clustering, 136 canonical and 14 non-canonical HCMV proteins were distributed 
into five classes (Tp1-Tp5) according to their temporal expression profile (Figure 1.4). 
Viral proteins that fall within the same group have similar expression pattern throughout 
infection. In this classification, Tp1 proteins have relative high expression early in 
infection, while Tp5 have highest expression only late in infection (Weekes et al., 2014).  
 
 
Figure 1.4. Temporal classes of HCMV gene expression. 
Figure modified from (Weekes et al., 2014). HCMV proteins were clustered into 5 
temporal classes using k-means method. The average relative expression of each 





1.1.8. HCMV-associated diseases 
Primary HCMV infection is generally asymptomatic in healthy immunocompetent 
individuals, but flu-like or mononucleosis-like symptoms have been reported in very rare 
cases (Sissons and Carmichael, 2002). Sporadic reactivation of HCMV from latency in 
differentiated myeloid cells has been associated with rare cases of cardiovascular 
disease (Simanek et al., 2011), Guillain-Barré syndrome (Orlikowski et al., 2011), and 
glioblastoma (Dey et al., 2015; Dziurzynski et al., 2012), although the oncogenic 
properties of HCMV are highly controversial. In contrast, HCMV causes life-threatening 
complications in immunocompromised, immunosuppressed and immunonaïve patients, 
in particular acquired immunodeficiency syndrome (AIDS) patients, transplant recipients, 
and neonates. 
HCMV infection occurs in approximately 0.5% of live births, and around 10% of 
infections are symptomatic (Britt, 2018). Infants with congenital HCMV infection may 
suffer from rashes, jaundice, retinitis, hepatosplenomegaly, and microcephaly. They are 
at long term risk of mental retardation, vision loss, hearing impairment and seizures 
(Boppana et al., 2013). 
HCMV affects both solid organ transplant recipients and hematopoietic stem cell 
transplant recipients. In general, HCMV is linked to a higher risk of graft rejection, as 
well as increased morbidity and mortality (Gandhi and Khanna, 2004). Patients can 
suffer from HCMV pneumonia, gastrointestinal disease, central nervous system disease, 
hepatitis, retinitis, in addition to CMV syndrome, which is characterised by fever and 
malaise as well as leukopenia, thrombocytopenia, elevated liver enzymes such as 
alanine aminotransferases and aspartate transaminase (Azevedo et al., 2015; Humar 
and Michaels, 2006; Ljungman et al., 2002).  
 
1.1.9. Intervention 
Several antiviral drugs have been clinically approved for the treatment of HCMV 




such as ganciclovir, cidofovir, acyclovir, as well as pyrophosphate analogue foscarnet 
(Krishna et al., 2019). These drugs has been associated with serious dose-dependent 
cytotoxicity. The adversary effects are hematologic, causing neutropenia and 
thrombocytopenia, and nephrotoxic, leading to proximal tubular cell injury and acute 
renal failure (Upadhyayula and Michaels, 2013). In contrast, letermovir is the most 
recent drug to be approved for HCMV treatment. It associates with terminase complex 
UL56 subunit, which overcomes the drug resistance resulting from HCMV mutations in 
UL54 (Marty et al., 2017). However, cases of letermovir resistance have been reported 
(Cherrier et al., 2018). 
 
1.2.  Viral DNA Sensors for Herpesviruses and Viral Counteractions 
1.2.1. Interferon 
Interferons (IFN) are a family of secreted autocrine and paracrine proteins that regulate 
the antiviral immune response. There are three types of interferons. The type I IFN 
family is the largest of 3, comprised of 13 subtypes of IFNα and several single-gene 
products including IFNβ, IFNε, IFNκ, and IFNω in human (Stetson and Medzhitov, 2006). 
These cytokines are rapidly produced upon activation of pattern-recognition receptor 
(PRR). They stimulate the type I IFN receptor on infected and surrounding cells, through 
activation of Janus activated kinases (JAKs), tyrosine kinase 2 (TYK2) and JAK1. (Platanias, 
2005). IFNα is mainly produced by plasmacytoid dendritic cells (pDCs) and macrophages 
while IFNβ is predominantly produced by non-immune cells, such as fibroblasts and 
epithelial cells.  
Type II IFN consists of IFNγ only, predominantly produced by NK cells upon 
phosphorylation of STAT4. IFNγ binds to type II IFN receptor, which associates with JAK1 
and JAK2 (Lee and Ashkar, 2018). The type III IFN family comprises IFNλ1 (interleukin-29, 
IL-29), IFNλ2 (IL-28A), IFNλ3 (IL-28B), and IFNλ4. In contrast to humans, in mice only Ifnl2 
and Ifnl3 are functional; Ifnl1 and Ifnl4 are pseudogenes (Lasfar et al., 2006). Animal 
studies point out that IFNλ response is restricted mainly to mucosal epithelial tissues 




receptor associates with JAK1 and TYK2 (Wack et al., 2015). Activation of the JAK 
signalling cascade results in phosphorylation of STAT2 and STAT1, which form a complex 
with interferon regulatory factor 9 (IRF9), known as the IFN-stimulated gene factor 3 
(ISGF3). Activated ISGF3 translocates to the nucleus and binds to IFN-stimulated 
response elements (ISREs) in DNA to initiate transcription of interferon-stimulated 
genes (ISGs). Type I and type II IFNs also signal through STAT1–STAT1 homodimers that 
bind to IFNγ-activated site (GAS) elements in some ISGs and induces their transcription 
(Platanias, 2005). The phosphoinositide 3-kinase (PI3K)–mammalian target of rapamycin 
(mTOR) pathway and multiple mitogen-activated protein kinase (MAPK) pathways are 
also downstream to type I interferon receptor (Ivashkiv and Donlin, 2014). 
Of these interferons, IFNβ is the best-defined and most broadly expressed type I IFNs. 
Its role during viral infection has been broadly discussed. This thesis focuses on type I 







Figure 1.5. The IFN signalling pathways in regulating ISG transcription. 
The three different classes of IFNs signal through their corresponding receptors, 
leading to phosphorylation of the associated JAKs. For type I and III IFNs, activated 
JAK1 and TYK2 recruit and phosphorylate STAT1 and STAT2. STAT1 and STAT2 then 
recruit IRF9 to form ISGF3. For type II IFNs, the phosphorylated JAK1 and JAK2 lead 
to activation and homodimerisation of STAT1. Both ISGF3 and STAT1 homodimers 
translocate to the nucleus for further phosphorylation at specific serine residues 
of STAT1, thereby achieving full activation. Consequently, ISGs are 
transcriptionally activated by binding of ISGF3 and STAT1 homodimers to ISREs 
and GAS promoter elements, respectively. Conversely, specific phosphatases in 
the nucleus dephosphorylate STAT1 and STAT2 to avoid excessive and detrimental 
IFN responses. Figure and figure legend are derived from (Wang et al., 2017). 
 
1.2.2. Type I interferon production and signalling 
Viral infection is detected by several PPRs in the cells. These sensors recognise viral DNA, 
RNA, or other non-nucleic-acid pathogen-associated molecular patterns (PAMPs) 
including the viral glycoproteins of HSV (Leoni et al., 2012) and the dUTPase of EBV (Ariza 
et al., 2009). The RNA helicases retinoic acid-inducible gene I (RIG-I) and melanoma 
differentiation-associated gene 5 (MDA5) are the major cytosolic RNA sensors (Goubau 
et al., 2013). A broad array of cytosolic DNA sensors detects cytosolic DNA, compared to 
self DNA that mainly locates in the nucleus and mitochondria. The antiviral roles of these 
sensors, particularly DNA sensors are discussed below. 
Toll-Like Receptors (TLRs) 
TLRs are a group of type I transmembrane proteins that use a domain containing leucine-
rich-repeat to recognize PAMPs and activate host defence mechanisms against 
infections. (Kawai and Akira, 2006; West et al., 2006). Among the TLR family, endosome-
residing TLR9 recognises unmethylated CpG-rich DNA that is frequently found in 
microbial genomes (Cornélie et al., 2004; Hemmi et al., 2000; Takeshita et al., 2001). 
There is also evidence showing that TLR9 also senses 2-deoxyribose sugar backbone of 
the viral DNA, indicating that viral sensing of TLR9 could be mostly sequence-
independent (Haas et al., 2008). TLR9 is predominately expressed in endosomes of pDCs, 
B cells, and epithelial cells. Studies in pDC shows that TLR9 recruits myeloid 




nuclear factor kappa B (NFκB) and IRF7, leading to production of inflammatory cytokines 
and type I IFN (Sato et al., 2003).  
Tlr9-/- mice exhibited increased viral titres following MCMV infection, probably due to 
impaired type I IFN and interleukin 12 production, as well as delayed NK cell activation 
(Krug et al., 2004a). Similarly, TLR9 mediates HSV-1 replication through early but not late 
type I IFN response in mice (Krug et al., 2004b; Rasmussen et al., 2007). HSV-2 DNA can 
be recognised by TLR9 and trigger IFNα production in mouse pDCs (Lund et al., 2003). 
Higher viral loads were also observed in Tlr9-/- mice infected with murine 
gammaherpesvirus 68 (MHV68), accompanied with elevated IFNα, IL-12, and IL-6 
secretion (Guggemoos et al., 2008).  
Other TLRs also sense viral components during infections. The endosomal receptors 
TLR3, 7, 8 sense either double-stranded or single-stranded RNA (Kawai and Akira, 2010) 
while cell membrane-bound TLR2 senses viral glycoproteins, such as HCMV envelope 
proteins B and H, upon viral contact with the cell surface (Boehme et al., 2006; Juckem 
et al., 2008).  
RNA polymerase III (RNA Pol III) 
RNA polymerase III is comprised of multiple enzyme subunits that transcribe small stable 
RNAs such as ribosomal 5S RNA (5S rRNA) and tRNA (Dieci et al., 2007), as well as EBV-
encoded small RNA (EBER), viral products important for promoting growth and avoid 
apoptosis for EBV-transformed cells (Howe and Shu, 1989; Iwakiri and Takada, 2010). 
RNA Pol III was demonstrated to use AT-rich DNA and HSV-1 DNA as templates to 
produce 5’ triphosphate RNA molecules that are subsequently recognized by the RIG-I 
RNA sensing mechanism (Chiu et al., 2009). However, RNA Pol III does not participate in 
early recognition of HSV-1 and an RNA pol III-independent sensing pathway was 
reported (Melchjorsen et al., 2010). On the other hand, RNA pol III inhibitor reduces 
IFNα production in human EBV-positive Burkitt’s lymphoma Mutu III cell line in a dose-
dependent manner, indicating a potential role in anti-EBV innate immunity (Ablasser et 
al., 2009). RNA pol III elicits a stimulator of IFN gene (STING)-independent pathway 




factor 3 (IRF3) activation by TANK-binding kinase-1 (TBK1) (Ablasser et al., 2009; Chiu et 
al., 2009). 
DNA-dependent activator of interferon (DAI) 
DAI, also known as Z-form (left-handed helix, instead of the more common B-form right-
handed helix) DNA/RNA-binding protein 1 (ZBP1), was initially described as an inducible 
gene in tumour stroma and activated macrophages by IFNγ. However, studies in the past 
two decades have recognized DAI as an innate sensor of viral infection that regulates 
cell death and antiviral inflammatory responses (Fu et al., 1999; Kuriakose and 
Kanneganti, 2018). Near the N-terminus, DAI encodes two Z-DNA-binding domains that 
bind to nucleic acids, which are critical for an innate immune sensor (Deigendesch et al., 
2006). In 2007, Takaoka and colleagues identified DAI as a cytosolic DNA sensor that 
triggers innate immune responses against bacterial and viral infections. They found that 
to regulate HSV1 infection, DAI recognizes viral dsDNA, recruits TBK1, and induces type 
I IFN via IRF3 (Takaoka et al., 2007). Independent of viral DNA sensing, DAI can also 
suppress HSV1 through regulation of infected cell protein 0 (ICP0) promoter activity 
(Pham et al., 2013). Other than HSV1, DAI is shown to contribute to IFNβ induction 
during HCMV infection via STING signalling pathway, which controls HCMV replication 
(DeFilippis et al., 2010).  
DAI harbours two receptor-interacting protein homotypic interaction motif (RHIM) 
domains, which can interact with RHIM domains of receptor-interacting 
serine/threonine protein kinases 1/3 (RIPK1 and RIPK3), which is required for NFκB 
activation during murine cytomegalovirus (MCMV) infection (Rebsamen et al., 2009). 
RIPK1/3 are involved in regulating signalling of necroptosis, a form of programmed cell 
death characterized by cell swelling and cell membrane rupture, which is considered a 
way to control infection (Nailwal and Chan, 2019). MCMV M45 protein, a viral inhibitor 
of RIPK activation, inhibits MCMV-induced necrosis by targeting DAI-RIPK3 complex with 
its RHIM domain (Upton et al., 2010). Taking advantage of mutant MCMV encoding M45 
with mutated RHIM domain, viral transcription activated by immediate early protein IE3 




Cyclic GMP-AMP synthase (cGAS) 
cGAS belongs to the nucleotidyltransferase (NTase) family, which includes dsRNA 
binding 2’-5’-oligoadenylate synthase 1 (OAS1) and adenylate cyclase. Members of this 
family all have the ability to add nucleotides to substrates such as nucleic acids, proteins, 
and, antibiotics (Aravind and Koonin, 1999). Upon cytosolic DNA activation, cGAS-DNA 
complex dimerises and synthesises cyclic-GMP-AMP (cGAMP) from ATP and GTP. 
cGAMP then serves as a second messenger to STING (Ablasser et al., 2013; Gao et al., 
2013b; Zhang et al., 2013). The ability of cGAS to detect viral infection has been 
investigated in cGas -/- mice and cGAS knockdown cell lines. Loss of cGAS impairs IFNβ 
production upon infection of DNA viruses, including HSV1 (Li et al., 2013b; Wu et al., 
2013), vaccinia virus (VACV) (Schoggins et al., 2014), adenovirus (Lam et al., 2014), 
MHV68 (Schoggins et al., 2014), HCMV (Lio et al., 2016), and MCMV (Lio et al., 2016). 
cGAS can also detect HIV-1 after its genome has been reverse transcribed into DNA (Gao 
et al., 2013a). 
DExD/H-box helicases 
DExD/H-box helicases are a family of proteins that contain the conserved sequence of 4 
amino acids, where the first and second are the negatively charged aspartate and 
glutamate, the third amino acid could be any, and the fourth could be either aspartate 
or the positively charged histidine. This motif is involved in activities such as ATP binding, 
ATP hydrolysis, and nucleic acid binding, and nucleic acid unwinding (Tanner and Linder, 
2001). Several members of this family, namely, DEAD-box helicase 41 (DDX41), DEAH-
box helicase 9 (DHX9), and DEAH-box helicase 36 (DHX36) are implicated with viral DNA 
sensing.   
DDX41 binds to HSV1 DNA and recruits STING in the cytosol to induce type I interferon 
production in myeloid dendritic cells, bone marrow–derived myeloid dendritic cells, and 
human monocyte cell line (Zhang et al., 2011). DHX9 and DHX36 are identified as CpG 
DNA binding partners. In pDC, DHX9 is known to trigger tumour necrosis factor α (TNFα) 
and interleukin 6 (IL6) production and NFκB activation in response to CpG, while DHX36 




virus infection has yet to be confirmed (Kim et al., 2010). Although DEAD-box helicase 3 
(DDX3) contributes in DAI-dependent IFNβ production during HCMV infection, its role 
as HCMV DNA sensor was not examined, but it is rather identified as a phosphorylation 
substrate of TBK1 that conducts DAI sensing activation (Kim et al., 2010).  
DNA-dependent protein kinase (DNA-PK) 
DNA–PK is a nuclear serine/threonine protein kinase comprised of a catalytic subunit 
and a regulatory heterodimer Ku70/Ku80. The protein is well recorded as a DNA damage 
response protein contributing to nonhomologous end-joining (NHEJ) of DNA double-
strand break repair, lymphocyte V(D)J recombination, chromatin structure modulation, 
and telomere maintenance (Smith and Jackson, 1999). In 2012, Ferguson et al 
discovered that in response to immunostimulatory DNA transfection or VACV infection, 
DNA-PK translocates to the cytosol, senses cytosolic DNA, recruits TBK1, and triggers 
type I interferon and antiviral cytokine production via IRF3 activation (Ferguson et al., 
2012). On the other hand, VACV encoded C16 protein, interacts with DNA-PK, inhibiting 
DNA sensing, thus contributing to viral virulence (Peters et al., 2013).   
Interferon-inducible protein 16 (IFI16) 
IFI16 harbours a pyrin domain that interacts with other proteins, and two DNA-binding 
hematopoietic expression, interferon-inducible nature, and nuclear localization (HIN) 
domains (Unterholzner et al., 2010). IFI16 predominantly expresses in the nucleus, it 
recognises herpesviral DNA deposited to the nucleus, such as those of HSV1 (Li et al., 
2012; Unterholzner et al., 2010), HCMV (Gariano et al., 2012; Li et al., 2012), EBV (Ansari 
et al., 2013), and KSHV (Kerur et al., 2011), and promote production of type I IFN and 
proinflammatory cytokine IL1β. Upon viral DNA activation, histone acetyltransferase 
p300 acetylates IFI16 and translocates it to the cytosol, where IFI16 activates signalling 
of IFN via interaction with STING (Unterholzner et al., 2010), and inflammasome via 
interaction with inflammasome adaptor protein apoptosis-associated speck-like protein 
containing a caspase recruitment domain (ASC) (Kerur et al., 2011). 
IFI16 has prominent antiviral restriction function limiting virus replication. It can 




et al., 2015), forming a platform to recruit PML, Sp100, ATRX, and cGAS, thus 
suppressing viral gene transcription and promoting IFN production (Diner et al., 2016; 
Merkl and Knipe, 2019). Additionally, an HCMV study has shown that the viral gene 
repressing function of IFI16 is associated with transcription factor special protein 1 (SP1) 
(Gariano et al., 2012).   
Downstream of cytosolic sensors 
Despite diverse methods to detect viral infection, the downstream signalling following 
these receptors include a few common molecules, including IRF3 and IRF7, which initiate 
IFNα/β gene transcription (Tamura et al., 2008). In some cases, NFκB and activator 
protein 1 (AP-1) participate in IFN production as cofactors (Honda et al., 2006). 
Upstream to the IRFs and NFκB, TBK1 and the inducible inhibitor of NFκB (IκB) kinase ɛ 
(IKKɛ) are responsible for phosphorylation of IRF3 and NFκB respectively (Miyahira et al., 
2009). NFκB induces transcription of proinflammantory cytokines, mainly interleukin 1 
(IL1) and TNFα (Lawrence, 2009). Alternatively, TLR9, DHX9, and DHX36 activate IRFs 
through MYD88 and tumour necrosis factor receptor-associated factor 6 (TRAF6) (Kim 
et al., 2010; Tamura et al., 2008). The adaptor mitochondrial antiviral signalling protein 
(MAVS) and STING are required for RIG-I and MDA5 to activate TBK1. Some DNA sensors, 
including cGAS, IFI16, and DDX41 also activate TBK1 through STING (Barber, 2015). Upon 
activation, STING move from ER to the ER-Golgi intermediate compartment (ERGIC) or 
Golgi apparatus, and this translocation is essential for IFN production (Ishikawa and 






Figure 1.6. Type I interferon production signalling pathway triggered by dsDNA 
sensors. 
Recognition of viral DNA by DNA sensors trigger STING dimerization and 
translocation to the ERGIC or Golgi apparatus. TBK1 and IRF3 are recruited and 
activated. Activation of STING also trigger activation of NFκB via TAK1, which is 
sometimes performed by IKKε instead of TBK1 (Balka et al., 2020). IRF3 and NFκB 
translocate to the nuclear and promote IFNβ transcription. 
 
Evasion of host innate sensing 
In order to successfully establish infection, disease-causing viruses need to adapt many 
strategies to evade multiple lines of host nucleic acid sensing pathways. Herpesviruses 
encode many viral proteins that target the sensors and signalling components of the IFN 
induction pathway. KSHV tegument protein ORF52 and HCMV tegument protein UL31 
interact with nucleotide binding domain of cGAS, thus inhibiting viral DNA recognition 
(Huang et al., 2018; Wu et al., 2015). HSV1 tegument protein UL37 deaminates 
asparagine and glutamine residues in cGAS and inhibits its ability to synthesise cGAMP 
(Zhao et al., 2016). HSV1 endonuclease UL41 selectively degrades cGAS mRNA and 
decreases the presence of cGAS. IFI16 is another DNA sensor herpesviruses target. IFI16 
was directed to proteasomal degradation by HSV1 tegument protein and E3 ubiquitin 
ligase ICP0 (Johnson et al., 2013; Orzalli et al., 2012). HCMV tegument protein UL83 




Besides antagonising the DNA sensors, herpesviruses also interfere with the 
downstream signalling molecules. HSV1 immediate early infected-cell protein 27 (ICP27) 
binds to the activated STING-TBK1 complex and inhibit IRF3 phosphorylation 
(Christensen et al., 2016). Similarly, MHV68 tegument protein open reading frame 11 
(ORF11) interacts with the kinase domain of TBK1 and blocks IRF3 phosphorylation (Kang 
et al., 2014). HCMV tegument protein UL82 and MCMV m152 protein disrupt STING 
translocation from the ER to the Golgi compartment, thus blocking downstream 
signalling (Fu et al., 2017; Stempel et al., 2019). Virus encoded kinases, such as EBV 
BGLF4, VZV ORF47, HSV1 UL13, and MHV68 ORF36, can directly targets IRF3, but with 
different mechanisms. EBV BGLF4 interferes DNA binding activity of IRF3 (Wang et al., 
2009); HSV1 UL13, and MHV68 ORF36 diminish association between IRF3 and the 
transcription activator CREB-binding protein (CBP) (Hwang et al., 2009); VZV ORF47 
prevents IRF3 homodimerization and induction of IFN (Vandevenne et al., 2011). 
 
1.3.  Protein degradation in the cell 
Cellular proteins are maintained in a dynamic state with the levels of proteins 
determined by rates of synthesis and degradation. Since proteins are the key effectors 
of biological process in cells, rapid protein degradation is one of the processes cells 
adapt in response to external stress such as nutrient deprivation, abnormal temperature, 
and chemical stimuli, or internal stress such as organelle dysregulation and intracellular 
infections (Dikic, 2017). In eukaryotic cells, the ubiquitin (Ub)–proteasome pathway and 
the lysosomal proteolysis are the two major pathways that regulates cellular protein 
degradation.  
 
1.3.1. Ubiquitin-proteasome pathway  
Between the two pathways, the ubiquitin-proteasome pathway is the major 
degradation system in the cell. This pathway uses ubiquitin to target proteins that are 




actions that conjugates a chain of poly-ubiquitin to the protein substrate. Within the 
cascade, the ubiquitin-activating enzyme E1 and the ubiquitin-conjugating enzyme E2 
prepare Ub for conjugation, while the ubiquitin ligase enzyme E3  transfer Ub onto 
specific target proteins (Lecker et al., 2006). Depending on the structure, E3 enzymes 
belong to the really interesting gene (RING) family, the homology to HPV E6 protein 
associated protein (E6AP) C terminus (HECT) domain family, or the RING-between-RING 
(RBR) family (Metzger et al., 2014). Ubiquitinated proteins are then hydrolysed by ATP-
dependent proteasomes, which are found in the nucleus and the cytosol of all cells 
(Voges et al., 1999). Proteasomes consist of two major complexes: a catalytic core 
particle (CP, or 20S proteasome) and one or two regulatory particle (RP, or 19S particle) 
attached to core particle terminals. Subunits of RP recognise and cleave Ub tag of target 
proteins while subunits of CP catalyse proteolysis of substrate proteins, generating small 




Figure 1.7. Classification and mechanism of E3 ligases. 
E3 ligases are grouped into three classes according to their structural organisation. 
(Top) The RING E3 ligase has one RING domain and transfers ubiquitin from an E2 
ligase to the substrate. (Middle) The HECT E3 ligase first transfer Ub to a cysteine 




from E2 to the RING domain of the RBR E3 ligase that does not bind the E2, then 
to the substrate.  
 
E3 Ligases  
E3 ligases play an essential role in substrate targeting by binding directly to the substrate 
and interacting with E2-Ub (Figure 1.7). In the case for HECT E3 ligases, ubiquitin is 
transferred from a cysteine active site in E2 to a cysteine residue of the HECT domain, 
which is subsequently transferred to a lysine residue of the substrate (Huibregtse et al., 
1995). RBR domain of RBR E3 ligases contains two proposed RING domains separated 
by a conserved sequence called the in-between-ring (IBR) domain. One of the RING 
domain is responsible to E2 binding while substrates of RBR E3 ligases receive Ub from 
a catalytic cysteine site in the other RING domain, similar to HECT E3 ligases (Wenzel et 
al., 2011). RING E3 ligases carry out Ub transfer directly from E2 to substrates, without 
prior Ub conjugation to E3 (Deshaies and Joazeiro, 2009).  
RING E3 ligases 
RING E3 ligases are the most abundant type of ubiquitin E3 ligases, with ~600 identified 
in humans. They contain either RING domain, which coordinates two Zn2+ ions and helix 
folds to binds E2, or RING-like U-box, which adopts the same RING fold without zinc 
(Metzger et al., 2014). RING E3 ligases can function as monomers (i.e. immune signal-
regulating Casitas B-lineage lymphoma proto-oncogene-b [Cbl-b]) (Lutz-Nicoladoni et al., 
2015), homodimers (i.e. HIV-1 core protein-targeting tripartite motif containing 5 alpha 
[TRIM5α]), heterodimers (i.e. p53-regulating murine double minute 2 [MDM2]-murine 
double minute X [MDMX]) (Shadfan et al., 2012), or protein complexes consisting of 
multiple subunits (i.e. Cullin RING E3 ligases [CRL] and anaphase-promoting complex 
subunits [ANAPC]) (Castro et al., 2005; Petroski and Deshaies, 2005). RING E3 ligases 
have been implicated in immune signalling. For instance, RING E3 ligases tripartite motif-
containing protein 32 (TRIM32) and TRIM56 have been shown to ubiquitinate NFκB 
essential modulator (NEMO) and subsequently activate NFκB kinase β subunit (IKKβ), 




Cullin RING E3 Ligases 
The largest subset of RING E3 ligases functioning as a protein complex are known as CRL. 
They are recognised to be responsible for around 20% of ubiquitin-dependent protein 
degradation in cells (Soucy et al., 2009). All CRLs contain a cullin protein (CUL1, 2, 3, 4A/B, 
5, or 7) serving as scaffold, a RING domain-containing protein (named RING-box 1/2 
[RBX1/2] or regulator of cullin 1/2 [ROC1/2]) that catalyses Ub transfer, and one or more 
adaptor protein(s) that bridge(s) substrate receptors and CULs.  RBX1 is associated with 
most CULs except CUL5, which associates with RBX2 (Kamura et al., 2004). The 
complexity of adaptors and substrate receptors interacting with cullin proteins reflect 
the great capacity of CRL in protein degradation, with over 200 associating substrate 
receptors having been identified (Petroski and Deshaies, 2005). However, cullin proteins 
interact with a specific adaptor protein and substrate receptors containing specific 
protein domain. CUL1 and CUL7 use S phase kinase-associated protein 1 (SKP1) as 
adaptor, which binds to substrate receptors containing F-box (first described in cyclin F). 
CUL2 and CUL5 use Elongin B/C heterodimer as adaptor, with interacts with suppressor 
of cytokine signalling (SOCS) box proteins. CUL4A/B use DNA damage-binding protein 1 
(DDB1) as adaptor, which binds to DDB1- and CUL4-associated factor (DCAF) proteins. 
And finally, the adaptors that bridges between CUL3 and substrates is BTB (bric-a-brac-
tramtrack-broad complex) proteins, without substrate receptors. CUL9 can directly bind 
its own subtract, such as the inhibitor of apoptosis protein survivin (Li et al., 2014; 
Lydeard et al., 2013; Petroski and Deshaies, 2005; Skaar et al., 2013). 
HECT E3 ligase 
There are 28 HECT-containing E3 ligases reported so far. They can be classified into three 
subfamilies based on their N-terminal domain structure: the neuronal precursor cell-
expressed developmentally downregulated 4 (NEDD4) family, the HECT and regulator of 
chromatin condensation 1 like domains (RLD)-containing (HERC), and the “others” 
(Sluimer and Distel, 2018; Wang et al., 2020). The NEDD4 family members all contain an 
N-terminal single Ca2+-binding C2 domain followed by several WW domains responsible 
for substrate recognition. Depending on their binding partners, HECT E3 ligases have 




proteasomal degradation of dishevelled (Dvl) protein, the central component of 
wingless (wnt) signalling in embryo development and tissue homeostasis (Ding et al., 
2013). Upon T cell activation, c-Jun N-terminal kinases (JNK) phosphorylates and 
activates E3 ubiquitin-protein ligase Itchy homolog (ITCH), which then ubiquitinates 
transcription factors AP-1 and c-Jun, and leads to their degradation (Fang et al., 2002; 
Gao et al., 2004). HERC family is characterised by the presence of RLD domain, which 
acts as guanine nucleotide-releasing factor for small GTPase in membrane trafficking 
(Sánchez-Tena et al., 2016). HERC2 protein ubiquitinates the Xeroderma pigmentosum 
complementation group A (XPA) protein and promotes nucleotide excision repair (NER) 
pathway (Kang et al., 2010). One member of the “other” HECT E3 ligase, HECT, UBA and 
WWE domain containing 1 (HUWE1), naturally targets the tumour suppressor p53 for 
degradation (Chen et al., 2005), and is found overexpressed in sever types of tumour 
(Adhikary et al., 2005). 
RBR E3 ligase 
Fourteen RBRs are identified in humans so far, but only Parkin 2 (PARK2), human 
homolog of Ariadne (HHARI), and the heterotrimeric linear ubiquitin chain assembly 
complex (LUBAC) have been well studied. Mutation of PARK2 is responsible for 
autosomal recessive juvenile Parkinsonism (Kitada et al., 1998). It regulates 
mitochondrial clearance by targeting mitochondrial membrane proteins (Jin and Youle, 
2012). HHARI interacts with the eukaryotic mRNA cap binding protein, translation 
initiation factor 4E homologous protein (4EHP) and leads to its polyubiquitination, 
therefore affecting protein translation (Tan et al., 2003).  LUBAC contains three hetero 
subunits, two of which have RBR domain but only HOIL1-interacting protein (HOIP, also 
known as RNF31) is catalytically active (Kirisako et al., 2006; Tokunaga et al., 2009). 
LUBAC is involved in tumour necrosis factor (TNF)-mediated NFκB activation by linear 
ubiquitination of NEMO (Spit et al., 2019). This linear Ub chain serves as a scaffold for 
the inhibitor of NFκB kinase (IKK) complex to gather. Transactivation of IKK β subunit 
(IKKβ) then phosphorylates IκB protein, leading to its degradation and the subsequent 





1.3.2. Viral interference of proteasome-mediated degradation 
As obligate intracellular pathogens, viruses often reprogram host cellular processes to 
favour their infection and replication. A number of viral proteins are known to exploit 
the proteasomal degradation pathway and direct host proteins to destruction via 
proteasome. Inhibition of proteasome activities has been shown to impede replication 
of DNA viruses such as HSV1, HCMV, VCAV, hepatitis B virus, and adenovirus (Bandi et 
al., 2010; Delboy et al., 2008; Gupta et al., 2013; Satheshkumar et al., 2009; Tran et al., 
2010b), which is suggestive of the necessity of virally-induced proteasome activities 
during a permissive infection. Proteasomal degradation mediates multiple stages of viral 
cycle starting from entry, as demonstrated in HSV1 and KSHV (Delboy and Nicola, 2011; 
Delboy et al., 2008; Greene et al., 2012), to virion egress, as demonstrated in HIV-1 
(Meng and Lever, 2013). 
Herpesviruses have evolved to evade host immunosurveillance and establish lifelong 
latency. One of the cellular mechanisms viruses exploit is the proteasome degradation 
machinery. Presentation of viral peptide major histocompatibility complex (MHC) allows 
T lymphocytes to eliminate infected cells. To subvert this, some viral proteins, such as 
EBV nuclear antigen 1 (EBNA1), and KSHV latency-associated nuclear antigen 1 (LANA1) 
contain different repeat motifs that interfere with host proteasomal processing 
(Bennett et al., 2005; Kwun et al., 2007). HCMV US2 and US11 effectively target MHC 
class I and class II molecules in endoplasmic reticulum (ER) for proteasomal degradation 
(Wiertz et al., 1996a; Wiertz et al., 1996b). 
Innate immunity includes a cascade of signal transduction during viral infection, 
resulting in transcription of antiviral genes via activation of transcription factors such as 
AP-1, NFκB, and IRF.  A gammaherpesvirus, murid herpesvirus 4 (MuHV 4) encodes 
latency associated protein ORF73, which recruits a CRL5 complex and leads to 
degradation of NFκB subunits (Rodrigues et al., 2009). VZV ORF61, a protein containing 
a RING E3 ubiquitin ligase domain, binds and ubiquitinates phosphorylated IRF3, leading 
to its proteasome-mediated degradation (Zhu et al., 2011). In response to interferon 
treatment, PML NBs aggregate in the nucleus and components of them, such as SP100, 




functions (Everett and Chelbi-Alix, 2007). The HSV-1 ICP0 protein harbours a RING E3 
ubiquitin ligase domain that targets PML. A similar function can be performed by MHV68 
ORF75c, despite the requirement of PML SUMOylation prior to this ubiquitination 
(Sewatanon and Ling, 2013). HCMV targets STING and STAT2 for proteasomal 
degradation, which dampens interferon production and interferon response 
respectively (Kim et al., 2017; Le et al., 2008). 
In addition to immune pathways, viruses also regulate other cellular process through 
proteasomes. One example is HCMV UL21a-induced degradation of anaphase-
promoting complex (APC) subunits, a cellular E3 ubiquitin ligase that regulates multiple 
cell cycle regulatory proteins, and favours viral DNA replication (Fehr et al., 2012). 
Oncogenic HPV E6 protein hijacks HECT E3 ligase E6AP, resulting in ubiquitination and 
degradation of p53 (Howley, 2006). 
 
1.3.3. Lysosomal proteolysis 
Lysosomes are single lipid bilayer membrane organelles containing acid hydrolases that 
aim to break down macromolecules such as proteins, DNA, RNA, polysaccharides, and 
lipids (Luzio et al., 2007). They are characterised to have a relative low pH to allow 
hydrolases to function; this low pH is maintained by vacuolar ATPase (V-ATPase), which 
deliver protons into lysosomes and endosomes (Maxson and Grinstein, 2014). 
Lysosomal membrane proteins (LMPs) are associated with acidification of the lysosomal 
lumen, membrane fusion, and substrate transportation, thus also essential to lysosomal 
function. The most abundant LMPs are lysosome-associated membrane proteins 
(LAMP1 & LAMP2) and tetraspanin (CD63) (Eskelinen et al., 2003). Despite their 
intracellular catabolic role, there is growing evidence indicating that lysosomes also 
have roles in membrane repair, nutrient metabolism, protein secretion, and pathogen 
defence (Settembre et al., 2013).  Defective lysosome functions can lead to a variety of 
diseases, most of them are neurodegenerative, including Parkinson's, Alzheimer's, and 
Huntington's diseases, as well as cancer, cardiac disease, and infections (Levine and 




namely endocytosis (pinocytosis, phagocytosis, and receptor-mediated endocytosis) 
and autophagy, each has distinctive initiation features but both end with lysosomal 
fusion and destruction of content inside the vesicle. 
 
Endocytosis-lysosome degradation 
Endocytosis describes a general process where invagination of the plasma membrane 
internalises substances such as fluid, receptor-ligand complexes, membrane proteins, 
nutrients, cell debris, as well as some bacteria and viruses inside a cell (Huotari and 
Helenius, 2011). There are various mechanisms of internalisation, which can be 
categorised by the involvement of the vesicle coating protein clathrin and the fission 
GTPase dynamin (Thottacherry et al., 2019). Subsequent to internalisation, protein 
cargos are mostly transported to early endosome, where they are sorted for recycling 
back to the plasma membrane, sending to the trans-Golgi network, or lysosomal 
degradation (Jovic et al., 2010). Ubiquitination of the protein cargo is recognised by 
endosomal sorting complex for transport (ESCRT) machinery to allow sorting to the 
lysosomal degradation pathway (Raiborg and Stenmark, 2009). Downstream of the 
pathway, intralumenal vesicles encasing the protein cargo form inside early endosome 
at the perinuclear region. Early endosome thus matures into late endosome, also known 
as multivesicular bodies (MVB) (Huotari and Helenius, 2011). Lysosome interacts with 
late endosome in an initial transient (kiss-and-run) fashion, but eventually full fusion 
occurs and components inside intralumenal vesicles are exposed to lysosomal hydrolysis 
(Luzio et al., 2007). Lysosomal trafficking and fusion are controlled by membrane-
associated Rab GTPases (i.e. RAB5 and RAB7) and N-ethylmaleimide-sensitive 






Figure 1.8. Protein degradation via endocytosis. 
Ubiquitinated membrane protein is internalised through endocytosis (most 
commonly receptor-mediated endocytosis) and transferred to the early 
endosome. The ubiquitin tag is sequentially associated with endosomal sorting 
complex required for transport (ESCRT) protein complexes ESCRT-0, I, and II. 
Ubiquitin is removed by endosome-associated deubiquitinating enzyme recruited 
by ESCRT-III. The ub-free membrane protein is eventually encased as the luminal 
vesicles of the endosome through the activity of ESCRT-III. Luminal vesicles marks 
the maturation of early endosome into late endosome, which subsequently fuses 
with lysosome. The proteases inside lysosome break down the membrane protein. 
 
Autophagy-lysosome pathway 
While membrane proteins are degraded via the endosome-lysosome system, 
intracellular proteins can reach the lysosome through autophagy, a catabolic process 
where proteins, damaged organelles, or intracellular pathogens are engulfed by a 
double-membrane structure (autophagosome), which eventually fuse with the 
lysosome for degradation. Macroautophagy, the best well studied form of autophagy, 
initiates with activation of unc-51-like autophagy activating kinase 1 (ULK1) complex, 
followed by the recruitment of the class III phosphatidylinositol 3-kinase complex I 
(PI3KC3–C1) (Hurley and Young, 2017). Subunits of PI3K-C1, Beclin 1 (BECN1) and 
phosphatidylinositol 3-kinase vacuolar protein sorting-associated protein 34 (VPS34) 




from the endomembrane system (Simonsen and Tooze, 2009). The serine/threonine 
kinase mTOR inhibits ULK1 activation, thus is an important regulator of autophagy (Kim 
and Guan, 2015). Two autophagy-specific systems of ubiquitin-like proteins control the 
early events of autophagosome formation (Shpilka et al., 2012). One conjugates 
autophagy protein 12 (ATG12) to ATG5, which then associate with ATG16L1. The other 
(ATG7 and ATG3) conjugates a phosphatidylethanolamine (PE) to the light chain 3 (LC3), 
turning cytosolic LC3-I into lipidated LC3-II (Nakatogawa, 2013). Lipidated LC3-II 
commonly serves as a marker for autophagosome formation as it is embedded within 
the lumen of the autophagosome (Kabeya et al., 2000). Both events cause the 
phagophore to curve while extending, enclosing targets for degradation in either 
random or selective manner. An example of selective autophagy is observed with 
autophagy receptor p62 (sequestosome 1, SQSTM1), which function as a bridge 
between polyubiquitinated protein aggregate and LC3-II (Bjørkøy et al., 2005). Finally, 
the closed pharophore forms autophagosome, fuses with a lysosome, and the luminal 
contents are degraded (Tong et al., 2010). 
The autophagic and endocytic pathways intersect when autophagosomes fuse with late 
endosomes, forming an amphisome (Tooze et al., 2014). This convergence of 
autophagosome and endocytic pathways is verified by early electron microscopy studies 
(Eskelinen et al., 2011). Amiphisomes eventually fuse with lysosomes, forming 
autolysosomes and contents within are hydrolysed. The process is mediated by small 
Rab GTPase proteins and SNAREs, which are the common regulators of fusion between 





Figure 1.9. Overview of autophagy. 
Autophagy initiates by the formation of phagophore that expands and engulfs 
autophagic cargo to form autophagosome. Mature autolysosomes form by 
directly fusion with the lysosome. In some cases, late endosomes fuse with 
autophagosome and form amohisomes, which are then fused with lysosomes. The 
classical regulator of autophagy is mTORC1, which negatively regulates autophagy 
by inhibiting the ULK1 complex. Autophagosome maturation in the late stage of 
autophagy is governed by various factors including SNAREs, HOPS complex, Rab7, 
GABARAPs, and ATG14L, amongst others. Figure and figure legend adapted from 
(Palhegyi et al., 2019). 
 
1.3.4. Viral subversion of lysosomal degradation 
Viral subversion of endocytosis pathways 
Although direct fusion between virus envelope and plasma membrane is an established 
method for viral entry, most viruses, including non-enveloped ones, take advantage of 
endocytosis mechanisms to enter a host cell. Subsequent to binding of viral surface 
glycoprotein to cell surface receptor, induction of such as receptor tyrosine kinases 
(RTKs) and integrins results in endocytic internalisation of the viral particle (Mercer and 
Helenius, 2012). Clathrin-mediated endocytosis is the most common mechanism for 
virus to enter through endocytosis. This mechanism is utilised by many viruses, such as 




HCMV (Compton et al., 1993; Halary et al., 2002), adenovirus 2 (Wickham et al., 1993), 
and Vaccinia virus (Husain and Moss, 2005). KSHV (Valiya Veettil et al., 2010), respiratory 
syncytial virus (RSV) (Krzyzaniak et al., 2013), and Ebolavirus (Chandran et al., 2005) can 
enter cell through phagocytosis, with the endocytic pathway mediated by actin and Rho 
GTPases (Sobhy, 2017). To evade lysosomal destruction of viral particles, engulfed 
viruses often disrupt endosome membrane to release capsid or other viral contents to 
the cytosol. Enveloped viruses can achieve this by carrying out membrane fusion, 
resulting from conformational changes of viral glycoprotein induced by low pH, 
proteolytic cleavage by cathepsins, or redox reactions (Harrison, 2005). On the other 
hand, processed structural proteins of non-enveloped viruses break free from 
endosomes by either sequestering the hydrophilic head of lipid molecules or inserting 
inside the hydrophobic layers, resulting in membrane disruption or pore formation 
respectively (Agosto et al., 2006; Brabec et al., 2005; Hinz and Galla, 2005; Seth, 1994). 
Viral subversion of autophagy 
Autophagy is generally described as a cell innate defence against viral infection through 
directly engulfing viral particles invading the cell. Other antiviral actions carried out by 
autophagy have been reported. Ubiquitinated capsid proteins of Togaviruses, Sindbis 
virus and Chikungunya virus, as well as non-structural Tat protein of human 
immunodeficiency virus type 1 (HIV1) are recognised by p62/SQSTM1 and targeted for 
selective autophagy (Judith et al., 2013; Orvedahl et al., 2010; Sagnier et al., 2015). 
Autophagy also promotes MHC I molecules presentation of HSV-1 glycoprotein gB and 
MHC class II presentation of EBV-encoded latent protein EBNA1, promoting clearance 
of the virus by T lymphocytes (English et al., 2009; Paludan et al., 2005). However, 
Herpesviruses have co-evolved with the host and successfully subvert autophagy. 
A crosstalk between innate viral sensing and autophagy was reported in HSV-1 infection. 
Early induction could be observed during early infection of HSV1, prior to de novo viral 
protein expression (McFarlane et al., 2011; Tallóczy et al., 2006). Myeloid differentiation 
primary response protein (MyD88), downstream of TLR2 and TLR9 activation, was 
required for this early activation of autophagy during HSV-1 infection (Cai et al., 2013; 




replication (Siracusano et al., 2016). Upon HSV-1 infection, BECN1 binds to cytosolic viral 
DNA sensor cGAS, and this interaction inhibits cGAMP and type I IFN production (Liang 
et al., 2014).  As HSV1 lytic cycle progresses, autophagy was inhibited through 
interaction of viral neurovirulence protein ICP34.5 with BECN1, as well as US11 with a 
protein kinase (PKR) upstream to BECN1 activation (Lussignol et al., 2013; Orvedahl et 
al., 2007; Tallóczy et al., 2002). Autophagy adaptor p62/SQSTM1 and mitophagy adaptor 
optineurin for proteasomal degradation, which are targeted by HSV1 viral protein ICP0 
for proteasomal degradation, mediate ISG56 production and viral replication (Waisner 
and Kalamvoki, 2019). However, blocking the autophagic pathway via targeting ATG5 
did not significantly alter the replication of HSV1 (Alexander et al., 2007).  
Early autophagosome induction was also observed in HCMV infection. Shortly after 
HCMV enters the infected fibroblast, HCMV DNA triggers lipidation of LC3 and 
autophagosome formation (Chaumorcel et al., 2012; McFarlane et al., 2011). This is later 
inhibited by two BECN1-binding viral proteins, TRS1 and IRS1 (Chaumorcel et al., 2012; 
Mouna et al., 2016). However, autophagy is considered essential to HCMV viral 
assembly. Even though autophagy does not affect viral gene expression, it is involved in 
cytoplasmic envelopment of HCMV viral particles (Taisne et al., 2019; Zimmermann et 
al., 2020). This proviral role of autophagosome formation is also observed in EBV-
infected cells. Upon lytic reactivation, EBV lytic transactivator Rta and Zta induce 
formation LC3-positive vesicles in the cytosol (Hung et al., 2014; Nowag et al., 2014). 
This accumulation results from inhibition of fusion between autophagosome and 
lysosome, and this is important for EBV lytic gene expression and replication (Granato 
et al., 2014). 
Viral manipulation of lysosomes 
While most herpesvirus have evolved ways to subvert complete autophagy, MCMV 
harnesses the degradative power of autophagy. MCMV M45 protein targets NEMO of 
NFκB, directing it to autophagosome and promote its degradation (Fliss et al., 2012). 
Since NFκB promotes expression of proinflammatory cytokines, this viral exploitation 
implies an effective method of MCMV to combat antiviral inflammatory response. One 




ligands through lysosomes. HCMV US20 targets natural killer group 2D ligand (NKG2DL) 
MHC class-I chain-related proteins A (MICA) for degradation in lysosomes (Fielding et al., 
2014; Fielding et al., 2017). Natural cytotoxicity receptor NKp30 ligand B7-H6 is depleted 
by viral gene US18 and US20 through lysosomes (Charpak-Amikam et al., 2017; Fielding 
et al., 2017). Given these ligands are cell surface membrane proteins, their degradation 
likely takes the endocytosis-lysosome pathway. 
 
1.4.  DNA repair 
The DNA integrity in the cells is constantly challenged from both endogenous and 
exogenous sources, and eukaryotic cells have adapted elaborate pathways to maintain 
genetic stability. For a single nucleotide error, base excision repair enzymes remove 
damaged bases, mismatch repair proteins recognize wrong base incorporation errors, 
and nucleotide excision repair machinery removes bulky DNA adducts. For double 
strand breaks (DSB), cells repair the DNA backbone via homologous recombination (HR) 
and non-homologous end joining (NHEJ). Cells activate multiple signalling pathways, 
collectively known as the DNA damage response (DDR), to deal with complex DNA 
lesions. DNA-PK, ataxia telangiectasia-mutated (ATM), and ATM and Rad3-related (ATR) 
are the three major kinases involved in DDR signalling transduction. (Sirbu and Cortez, 
2013) 
When DNA damage occurs, ATM and ATR phosphorylate H2AX, a variant of the histone 
2A protein family, producing γH2AX (Dickey et al., 2009; Fernandez-Capetillo et al., 
2004). Together with ATM-activated the mediator of DNA damage checkpoint protein 1 
(MDC1), γH2AX-MDC1 serves as a scaffold to recruit DNA repair proteins. For example, 
RING ubiquitin ligases RING finger 8 (RNF8) and RNF168, as well as an E2 enzyme 
ubiquitin-conjugating enzyme 13 (UBC13), are recruited to ubquitinate histones at 
double strand break (Al-Hakim et al., 2010). Ubiquitylation at the DSB sites then 
promote the aggregation of the DSB repair proteins breast cancer 1 (BRCA1) and p53 
binding protein 1 (TP53BP1), which directs HR or NEJH respectively (Davalos et al., 2004; 




In the presence of DNA damage, the cell cycle undergoes arrest. ATR activates 
downstream checkpoint kinase 1 (CHK1), ATM activates kinase CHK2, which both then 
phosphorylates p53, releasing it from its repressing binding factor mouse double minute 
2 homolog (MDM2) (Matsuoka et al., 2000; Maya et al., 2001; Shieh et al., 2000). p53 
subsequently induces a number of genes, including p21, a cyclin-dependent kinase 
inhibitor, and suppresses Cyclin E/ cyclin-dependent kinase 2 (CDK2) kinase activity, 
resulting in G1 arrest (Macleod et al., 1995). CHK2 activation also phosphorylates S-
phase inducer phosphatase cell division control protein 25 homolog A (CDC25A) and 
causes cell division control protein 2 homolog A (CDC2A) to be ubiquitinated and 
degraded. CDC25A therefore cannot remove inhibitory phosphorylation from CDK2, and 
this hinders Cyclin A/CDK2 and Cyclin E/CDK2 function in S phase progression (Bartek 
and Lukas, 2001; Xiao et al., 2003). In a similar fashion, another phosphatase CDC25C is 
targeted by activated CHK1 and CHK2, leading to Cyclin B1/CDK1 inactivation, and 
eventually causes G2 arrest (Abraham, 2001; Peng et al., 1997). 
 
1.4.1. DNA repair and herpesviruses 
Growing evidence has shown that herpesviruses have evolved to selectively activate or 
deactivate pathways in DDR to benefit their own replication. HSV-1, for instance, 
requires ATM activation to initiate viral replication. However, ATM activation is not 
required for HSV-2 replication (Shirata et al., 2005). Activated ATM then phosphorylates 
multiple downstream targets including Nijmegen breakage syndrome 1 (NBS1), CHK2, 
and p53. ATM activation also causes DSB repair protein MRE11, RAD50, NBS1 to 
accumulate at HSV replication sites, forming a MRN complex that is crucial for HSV-1 
replication (Lilley et al., 2005; Shirata et al., 2005). Another study also demonstrates that 
HR repair proteins such as replication protein A (RPA), RAD51, and NBS1 that participate 
in the host DDR are recruited at ND10 region, in association with ssDNA binding protein 
UL29 and viral replication protein UL42 (Wilkinson and Weller, 2004). On the other hand, 
ICP0 E3 ligase, an important factor for HSV lytic reactivation, promotes the degradation 
of RNF8 and RNF168 to prevent full ATM activation, thus promotes viral transcription, 




As an oncogenic herpesvirus, it has been well accepted that EBV induces genome 
instability to promote tumorigenesis (Gruhne et al., 2009a; Gruhne et al., 2009b; 
Kamranvar et al., 2007). During latency, EBNA1 promotes the generation of reactive 
oxygen species that cause DNA damage, EBNA3C disrupts CDK-Rb-E2F pathways, and 
latent membrane protein 1 (LMP1) inhibits CHK2 through ATM down-regulation (Chen 
et al., 2008; Nikitin et al., 2010; Parker et al., 2000). All of these reduce host DNA repair 
and introduce genome lesions. However, following reactivation, an ATM-dependent 
DDR is induced, and MRN complex is recruited at the replication site (Kudoh et al., 2005). 
Similar to HSV-1, HR proteins such as RPA, RAD51 and RAD52 are recruited to the viral 
replication site, in association with EBV polymerase processivity factor early antigen 
diffuse component (EA-D, encoded by BMRF1) and ssDNA binding protein BALF2 during 
viral replication (Kudoh et al., 2009). Although DNA repair mechanisms are activated, 
cell cycle is still bypassed during lytic cycle. Mechanically, EBV IE lytic transactivator Zta 
recruits functional CUL2- and CUL5-RING ligases that rapidly promote p53 ubiquitylation 
and proteasome-mediated degradation. The absence of p53 thereby promotes cell 
proliferation (Sato et al., 2009a; Sato et al., 2009b). Zta has also been shown to bind 
directly to TP53BP1, which is required for optimal virus replication (Bailey et al., 2009). 
HCMV viral proteins have also been found to modulate cellular DNA repair factors. Early 
during infection, IE1 induces p53 accumulation at the post-transcriptional level. IE1 also 
activates ATM, resulting in p53 activation and therefore cell cycle arrest (Castillo et al., 
2005; Gaspar and Shenk, 2006; Shen et al., 1997). NBS1 is also activated at early times 
post-infection (Luo et al., 2007). Growing evidence has led to the conclusion that ATM 
activation, regardless of the magnitude of ATM phosphorylation, is required for efficient 
HCMV replication (Gaspar and Shenk, 2006; Li et al., 2011; Luo et al., 2007; Shen et al., 
1997). During 24 hpi and 48hpi, viral DNA replication reaches to its peak, γH2AX, p53 
and MRN complex are recruited to the viral replication site (Bryant et al., 2009; Haince 
et al., 2008). One study has pointed out UL35 associates with deubiquitinase USP7 as 
well as with components of the CUL4-DCAF1 E3 ubiquitin ligase complex to increase 
H2AX levels, leading to cell cycle arrest (Salsman et al., 2012). In later time points during 




assembly point in the cytosol, where CHK2 is colocalised with virion structural proteins 
(Gaspar and Shenk, 2006). 
Like all other kinase signalling cascades, DDR is regulated in a temporal and spatial 
manner. High resolution analysis that can allow the investigation of protein interaction 
within small time frames is required to further understand the interwoven relationship 
between herpesviruses and host DNA repair mechanism. 
 
1.4.2. Helicase-like transcription factor (HLTF) 
HLTF, also known as SWI/SNF-related matrix-associated actin-dependent regulator of 
chromatin subfamily A member 3 (SMARCA3) participates in error-free post-replication 
DNA damage tolerance, allowing damaged DNA to continue to replicate. HLTF has a 
RING domain close to its C-terminus that allows it to serve as a ubiquitin E3 ligase for 
polyubiquitination of chromatin-bound proliferating cell nuclear antigen (PCNA) (Motegi 
et al., 2008; Unk et al., 2008) (Figure 1.10A). HLTF also has double-stranded DNA 
translocase activity that can regress replication fork-like structures (Achar et al., 2011; 
Blastyák et al., 2010). A study also demonstrates that in an ATP-independent manner, 
HLTF facilitates DNA strand invasion and the formation of a D-loop structure, which pairs 
the nascent DNA and the 3’ end of the invading strand that can be used by a polymerase 
for further DNA extension (Burkovics et al., 2014). The N-terminus of HLTF harbours a 
DNA-binding HIP116 Rad5p N-terminal (HIRAN) that specifically interact with 3’ ssDNA 






Figure 1.10. Structure and DNA repair mechanism of HLTF. 
(A) Domain organisation of HLTF protein. Closed to the N-terminus, HLTF bears a 
DNA-binding HIP116, Rad5p, N-terminal (HIRAN) domain. Seven helicase domains 
span across HLTF. HLTF also contain a nuclear localisation signal (NLS) site within 
two helicase domains and a RING domain near the C-terminus that ubiquitinates 
PCNA. Full-length HLTF consists of 1009 amino acid. Amino acids 58-174 are 
identified as HIRAN domain (Hashimoto et al., 2017). (B) Mechanism of HLTF DNA 
repair, adapted from (Kile et al., 2015). On sensing a DNA leision, HLTF unwind 
helixes of replicated DNA segments, regression the fork. HIRAN domain of HLTF 
binds to ssDNA of leading strand to the lagging strand synthesised from 
undamaged host template. 
 
HLTF can be found in brain, heart, kidney, liver, lung, pancreas, placenta and skeletal 
muscle tissues (Ding et al., 1996; Gong et al., 1997)). Its expression is generally low in 
colon cancer, gastric cancer and cervical adenocarcinoma, and a truncated HLTF lacking 
the RING domain can be found in head and neck cancers (Dhont et al., 2016). HLTF has 
also been shown to activate expression of cellular genes, such as human plasminogen 
activator inhibitor-1 and β-globin, through regulating their promoter activities (Ding et 
al., 1996; Mahajan and Weissman, 2002). 
In 2016, two independent studies both demonstrated that HLTF was directed by HIV 
viral protein R (Vpr) to degradation via the CUL4-DDB1-DCAF1 complex (Hrecka et al., 
2016; Lahouassa et al., 2016). In this E3 ligase complex, CUL4 serves as the platform, 




to be important for G2/M transition in mouse cells (Helmer et al., 2013a; Helmer et al., 
2013b), Vpr-mediated down-regulation of HLTF isn’t involved in Vpr-induced G2 cell 
cycle arrest (Hrecka et al., 2016; Lahouassa et al., 2016). Plus, HLTF doesn’t affect HIV 
replication in macrophage (Lahouassa et al., 2016). In other words, the function of HLTF 
in virus infection remains a mystery. 
 
1.5.  Multiplexed proteomic analysis screening of host protein 
degradation during early HCMV infection 
To actively search for host proteins targeted for degradation during early HCMV 
infection, the lab developed a systematic method taking advantage of tandem mass tag 
(TMT)-based multiplexed proteomic analysis (Figure 1.11) before I stated my PhD 
project. TMT labelling allows analysis of multiple samples in a single mass spectrometry 
experiment. The first screen, “inhibitor screen”, adapted the protease inhibitor MG132 
and the lysosome inhibitor Leupeptin (Figure 1.11A). It measured protein abundance 
throughout early infection in the presence or absence of inhibitors and identified 
proteins whose down-regulation was aborted with treatment of inhibitors. “Rescue 
ratio” was obtained by comparing protein abundance during HCMV infection ± inhibitor 
with protein abundance during mock infection ± inhibitor to assess the effect of inhibitor. 
The method of significance A was used to estimate the p-value that each ratio was 
significantly different to 1 (Cox and Mann, 2008). Values were calculated and corrected 
for multiple hypothesis testing using the method of Benjamini-Hochberg in Perseus 
version 1.5.1.6 (Cox and Mann, 2008). 
The second screen was designed to circumvent the off-target effects of these inhibitors 
by coupling the approaches of TMT labelling and pulsed stable isotope labelling by 
amino acids in cell culture (SILAC). Different SILAC media were applied to cells pre- and 
post-infection (Figure 1.11B). Protein synthesis and degradation could thus be traced by 
quantifying peptides labelled with different SILAC isotopes. Experiments were done over 
6h and 18h of infections. With respect to protein concentration, protein degradation 




The rate of protein decline in mock- and HCMV-infected samples was therefore 
estimated using exponential regression in Excel and the formula: [relative protein 
abundance] (t) = eKdeg ∙ t where Kdeg is the rate constant for degradation, and should be 
negative for degraded proteins. A degradation ratio was calculated by rdeg = 
KdegHCMV/Kdegmock. In cases where Kdegmock was greater than 0, a fold change (FCCMV) in 
protein abundance in the HCMV-infected sample at 6 or 18 hpi was instead used, 
defined by FCHCMV = e-Kdeg(CMV) ∙ t. P-values of  rdeg (Kdegmock <0)and FCCMV (Kdegmock >0) 
were estimated and corrected for multiple hypothesis testing using the method of 
Benjamini-Hochberg (Benjamini and Hochberg, 1995). A protein was considered down-
regulated if KdegHCMV/Kdegmock > 1.5 (Kdegmock <0) or FCHCMV > 1.5 (Kdegmock >0). 
The third screen examined transcriptional regulation and protein level changes during 
early HCMV infection. Here samples collected for proteomic analysis were 
simultaneously collected for RNA-sequencing (Figure 1.11C). Protein fold change 
(FCprotein) was obtained by comparing the protein abundance during HCMV infection 
with the protein abundance during mock infection at 24 and 72 hpi The RNA sequencing 
experiment was performed in biological triplicate at 0, 24 and 72 h after infection. Mean 
was calculated for normalised reads per kilobase million (RPKM) values for each time 
point (0, 24, 72 h). RNA fold change (FCRNA) at 24h was calculated from mean 
RPKM24h/mean RPKM0h. A similar value was calculated for 72 h data. The k-means 
method was used to cluster proteins into 7 classes based on the similarity of kinetic 
protein/RNA expression profiles. One of the cluster was enriched in proteins known to 
be degraded during HCMV infection, including the NK-activating ligand CD112/nectin 





Figure 1.11. Quantitative proteomic/transcriptomic methods identify host 
factors degraded by HCMV. 
Schematics (A) inhibitor screen, (B) pSILAC analysis, and (C) RNA/protein screen. 
 
1.5.1. Protein with E3 ligase domain was targeted for degradation during HCMV 
infection 
With high confidence, 35 proteins were identified to be rapidly degraded during HCMV 
infection. They sufficed at least two of the three screening criteria: (1) significantly 
rescued by MG132 at 12, 18, or 24 hours post infection (MG132 “rescue ratio” was >1.5 
and p<0.01) in the first inhibitor screen (appendix table 1); (2) significant faster 
degradation rate over 6 h or 8 h HCMV infection compared to mock infection (rdeg or 
FCCMV with p<0.05) in the second pSILAC screen (appendix table 2); (3) A protein was 
considered degraded at 24 hpi or 72 hpi if its protein fold down-regulation by HCMV >1.5 




Several host proteins on that shortlist are reported HCMV restriction factors, such as 
MORC3, SP100 ANAPCs. This suggested that other proteins on this list might have 
antiviral functions. I applied DAVID software (Huang da et al., 2009) to determine which 
pathways were enriched among degraded proteins from the three screens.  “Ubiquitin-
mediated proteolysis” was the only significantly enriched pathway (p=0.03) within the 
“high-confidence” shortlist, and included 6 ubiquitin E3 ligases (ANAPC1, ANAPC4, 
ANAPC5, NEDD4L, TRAF6, ITCH). A comprehensive search of all 35 “high-confidence” 
proteins for E3 ligase activity identified one additional E3 ligase, HLTF. Degradation of 
ANAPCs, NEDD4L, TRAF6, and ITCH during HCMV infection has been described 
previously (Koshizuka et al., 2018; Koshizuka et al., 2016; Kumari et al., 2017; Weekes et 
al., 2014). HLTF was chosen as the follow-up target since its HCMV-mediated 
degradation has not yet been reported. 
 
1.5.2. HLTF was identified to be degraded via proteasome during HCMV infection 
HLTF was one of the targets that fit all the screen criteria. It was rescued by MG132; its 
degradation rate was faster during HCMV infection, and the down-regulation was post-
transcriptional (Figure 1.12). This suggested that HLTF might play a key functional role 
in early viral infection, possibly being degraded by the virus to evade antiviral restriction. 
 
Figure 1.12. HLTF was identified as one of the top “hits” to be degraded by 
HCMV. 
HLTF results from (A) inhibitor screen, (B) pSILAC analysis, and (C) RNA/protein 






HLTF was found rapidly degraded during early HCMV infection. I postulated that HCMV 
deliberately targeted HLTF for proteasomal degradation and that HLTF had unexplored 
antiviral potentials that hindered HCMV replication.  
 
1.5.4. Aims of this project 
1. Elucidate the mechanism of HLTF degradation (Chapter 3). 
2. Explore the roles of HLTF in HCMV infection (Chapter 4). 








Chapter 2. Materials and Methods 
2.1.  Molecular Biology 
2.1.1. DNA Preparation 
E. coli cells containing plasmid to propagate were cultured in Luria-Bertani (LB) broth 
(10 g/l peptone, 5 g/l yeast extract, 10 g/l NaCl, autoclaved) for 16 h at 37  ̊C with 
constant agitation before being pelleted with centrifugation at 5000 xg, 10 min, room 
temperature (RT). DNA plasmids were extracted with Plasmid Mini Kit (QIAGEN) 
according to instructions from the manufacturer. Briefly, cells were lysed in alkaline 
solution containing RNase A and subsequently naturalized with acetic acid. Plasmid DNA 
released from cells was then collected in DNA-binding columns, washed with ethanol-
containing solution, and eluted with sterile double-distilled water (ddH2O). HCMV 
bacterial artificial chromosome plasmid (BACmid, provided by Dr. Richard Stanton, 
School of Medicine, University of Cardiff) was prepared using Plasmid Midi Kit (QIAGEN), 
with which the eluted DNA was additionally precipitated with isopropanol, washed with 
ethanol-containing washing buffer, and air-dried before dissolved in sterile ddH2O. 
 
2.1.2. Molecular Cloning 
Restriction enzyme cloning 
In order to make plasmid constructs expressing small hairpin RNA (shRNA), two 
oligonucleotides (Table 2.1) were annealed with each other by heating up to 95°C for 30 
sec to remove secondary structure and then cooling down to room temperature. The 
resulting product has sticky ends of BamHI and EcoRI (New England Biolabs), and was 
ligated with shRNA lentiviral vector pHRSIREN (from Professor Paul Lehner, CIMR, 
University of Cambridge) digested with the two restriction enzymes. Vectors were 
treated with shrimp alkaline phosphatase (New England Biolabs) at 37 °C for an hour 





The resulting products were then transform into Alpha-select silver efficiency 
complement E. coli cells (Bioline) that have endA and recA1 mutations to increase 
plasmid yield and minimize DNA recombination respectively.  
Gateway cloning 
Temperate phages integrate genomes into the bacterial host chromosome during the 
lysogenic phase with site-specific recombination reactions (Landy, 1989). In these 
integrative recombinations, DNA with specific sequences on the phage (attP) and 
bacterial chromosomes (attB) are recombinase substrates, resulting in products 
containing specific sites (left and right, attL and attR). V5-tagged UL145 expressing 
lentiviral plasmid was constructed with the Gateway recombination cloning system 
(Thermo) (Figure 2.1), which is developed with the site-specific recombination reactions 
from bacteriophage λ.  
AttB site-flanked V5-tagged UL145 DNA was generated with polymerase chain reaction 
(PCR) using UL145 expressing plasmid as the template (provided by Professor Gavin 
Wilkinson, University of Cardiff as part of a library of recombinant adenovirus expression 
vectors containing coding sequences for a large subset of HCMV proteins), primers 
(Table 2.1), and PfuUltra II Fusion HS DNA Polymerase (Agilent). The thermocycle 
programme was performed as below: 
Activation 95 °C for 2 min 
Denature 95 °C for 20 sec 
Annealing 60 °C for 20 sec 
Elongation 72 °C for 30 sec 
Return to the denature step for 24 repeats 
Extra elongation 72 °C for 3 min 
DNA products were then isolated by agarose gel electrophoresis and gel extraction with 
QIAquick Gel Extraction Kit (QIAGEN).  
BP recombination reaction was performed with attB-flanked UL145-V5 DNA, pDONR223 




Clonase enzyme mix (containing integrase from bacteriophage λ and E. coli integration 
host factor protein) in Tris-EDTA buffer (TE, pH 8.0) overnight (O/N) at room RT. The 
recombination product was transformed into cddB sensitive E. coli, and those 
transformed with UL145 containing plasmid survived selection on spectinomycin 
selection LB agar plates.  pDONR223-UL145-V5 was propagated with mini prep 
(subsection 2.1.1). 
LR recombination reaction was performed with pDONOR223-UL145-V5, lentiviral vector 
pHAGE (containing attR-flanked ccdB and puromycin resistance gene), and LR clonase 
enzyme mix (integrase and excisionase from bacteriophage λ and E. coli Integration host 
factor protein) in TE (pH 8.0) O/N at RT. 
 
Figure 2.1. Generating UL145-V5 expressing plasmid with Gateway system. 
Schematics of BP (top panel) and LR (bottom) reactions from Gateway 
recombination cloning system.  
Using the same method, full length and N-terminal deletion HLTF overexpression 
plasmids were generated with primers described in Table 2.1 and pCDNA3-HLTF as the 






Confirmation of insert sequence was performed with Sanger sequencing from the 
service of Genewiz (Takeley, Essex, UK) using the primers in Table 2.1. 
 
Table 2.1. Oligonucleotides used in molecular cloning. 
Name Sequence (5’ to 3’) 
















HLTF shRNA 1- top gatccGCAGGTGGAGTTGGTTTGAATTTCAAGAGAATTCAAACCAACTC
CACCTGCTTTTTTg 




HLTF shRNA 2 - top gatccTGTGGTTGGACTACGCTATTATTCAAGAGATAATAGCGTAGTCCA
ACCACATTTTTTg 























expression - reverse 
GGGGACCACTTTGTACAAGAAAGCTGGGTTTACGTAGAATCAAGACCT
AGGAGC 
HLTF full length 
expression- forward 
ggggacaagtttgtacaaaaaagcaggctATGTCCTGGATGTTCAAGAG 


























2.1.3. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) 
Total RNA extraction 
Total RNA of cells was extracted with RNeasy Mini Kit (Qiagen) according to 
manufacturer’s instruction. Briefly, cells were lysed with RNA lysis buffer containing high 
concentration of chaotropic salt. Nucleic acids were precipitated with ethanol and RNA 
binds to silica-based column. RNA was collected with elution of RNase-free H2O after the 
column had been washed with ethanol-containing solution for three times. 




Complementary DNA was synthesized using GoScript Reverse Transcriptase (Promega) 
according to manufacturer’s instruction. RNA with secondary structure resolved under 
5 min at 70°C was annealed with random hexamers (0.5 µg per µg of RNA) on ice. The 
resulting primed RNA was then mixed with 5X reaction buffer, MgCl2 (to final 
concentration of 2 mM), nucleotide mix (final concentration 0.5 mM each dNTP), RNasin 
ribonuclease inhibitor (20 units), and reverse transcriptase. First strand complementary 
DNA (cDNA) was then synthesised at 42°C for an hour. Finally, the reverse transcriptase 
was inactivated at 70 °C for 15 min. 
Quantitative polymerase chain reaction (qPCR) 
Quantitative PCR was performed with TaqMan assays (Thermo) to measure the relative 
mRNA abundance of interferon (IFN) β and GAPDH. Diluted cDNA was mixed with 2X 
TaqMan universal PCR master mix, and TaqMan probe specific for target gene. The 
thermal programme was performed with 7500 Real-Time PCR machine (Thermo) as 
below: 
Activation 95 °C for 10 min 
Denature 95 °C for 15 sec 
Annealing and elongation 60 °C for 1 min 
Return to the denature step for 39 repeats 
For qPCR assays targeting genes other than IFNβ, SYBR green assay was performed. DNA 
samples were mixed with 2X Fast SYBR Green Master Mix (Thermo) and respective 
primers (Table 2.2). The thermocycle programme was performed as mentioned above, 
plus a melt curve analysis to validate that the amplified DNA segment was homogeneous. 
The thermal programme of melt curve analysis was carried out as below: 
Denature 95 °C 10 sec 
Annealing 60 °C 1 min 
Melting 60 °C to 95 °C at the rate of 0.05 °C/sec 
Hold 95 °C 15 sec 





Table 2.2. Primer sequence used for SYBR green qPCR.  
Primer name Sequence 5’ to 3’ 
UL145 - Forward CCCATCATGCGTCGTATCAC 
UL145 - Reverse CCGACTGATCTAGCCTACGG 
GAPDH - Forward AGGGCTGCTTTTAACTCTGGT 
GAPDH - Reverse CCCCACTTGATTTTGGAGGGA 
gB - Forward  CTGCGTGATATGAACGTGAAGG 
gB - Reverse ACTGCACGTACGAGCTGTTGG 
Genomic GAPDH - Forward CCTCTGACTTCAACAGCGACAC- 
Genomic GAPDH - Reverse TGTCATACCAGGAAATGAGCTTGA 
MIEP - Forward TGGGACTTTCCTACTTGG 
MIEP - Reverse CCAGGCGATCTGACGGTT 
OriLyt – Forward 1 GGGGAGTGTCTACAGGGCTA 
OriLyt – Reverse 1 GTCAGGGGTCACGTGAGAAG 
OriLyt – Forward 2 ACACCATCGAATGTGGCGAT 
OriLyt – Reverse 2 ACCAGGAAAGCTGTCTACGC 
OriLyt – Forward 3 TTCCACTAGAGGCGGTCAGT 
OriLyt – Reverse 3 GAGCGGTAATTTTCCACCGC 
Human globin β promoter 
(HGBP)- Forward 1 
TAAGCCAGTGCCAGAAGAGC 
HGBP – Reverse 1 GATGGCTCTGCCCTGACTTT 
HGBP- Forward 2 CCAGAAGAGCCAAGGACAGG 
HGBP – Reverse 2 GCTCCTGGGAGTAGATTGGC 
HGBP- Forward 3 TCCAACTCCTAAGCCAGTGC 




Genomic GAPDH – Forward 
(ChIP) 
CAATTCCCCATCTCAGTCGT 




2.1.4. Stable cell generation with lentiviral transduction 
Lentiviral plasmid and lentiviral helper plasmids (VSVG [envelope], TAT1B [viral 
transactivator], MGPM2 [group-specific antigen and polymerase], CMV-Rev1B 
[regulator of virion proteins expression]) were transfected into simian virus 40 (SV40) 
large T antigen transformed human embryonic kidney cells (HEK293T) using TransIT-293 
transfecting reagent (Mirus) to pack lentiviruses, which subsequently transduced 
plasmid containing target genes into human telomerase reverse transcriptase 
immortalized foreskin fibroblast (HFFF-TERT) or HEK293T. Transduced cells were 
selected with puromycin (hygromysin for pHRSIREN transduced cells) for 2 weeks before 
experiments.  
 
2.1.5. Small interference RNA (siRNA) Knockdown 
HEK293T cells were transfected with a pool of CUL4A siRNAs (L-012610-00, Dharmafect) 
or a pool of non-targeting siRNAs (D-001810-10, Dharmafect) with DHARMAfect 1 
Transfection Reagent (T-2001, Dharmafect) giving a final siRNA concentration of 25 nM. 
Cellular lysates were harvested 48 h post transfection for Western blot. 
 
2.1.6. Western blot 
Whole cell lysis 
Trypsinised cells were neutralized with complete DMEM, washed with phosphate-
buffered saline (PBS: 137 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, and 2 mM KH2PO4) 




Signaling Technology) supplemented with complete EDTA-free protease inhibitors 
(Roche), homogenized by sonication (Diagenode Bioruptor), and centrifuged at 12000 
xg for 10 min at 4 °C to obtain soluble protein extracts. Protein concentration was 
determined using a microplate bicinchoninic acid (BCA) assay kit (Thermo).  
Trichloroacetic acid (TCA) precipitation 
For cell lysates processed with 6M guanidine, undigested protein was precipitated with 
ProteoExtract Protein Precipitation Kit (Merck) according to the manufacturer’s 
instruction. Briefly, protein sample was mixed and incubated with TCA-containing 
solution for an hour at -20 °C. Protein pallet was collected with centrifugation for 10 min 
at 10,000 xg, 4 °C, washed with ice-cold acetone three times, and air dried by Speed vac. 
Protein lysate was reconstitute with 2% sodium dodecyl sulphate (SDS) solution (2% SDS, 
63 mM Tris pH 6.8). 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Fifty micrograms of protein lysates were mixed with 6X protein loading dye (0.375 M 
Tris pH 6.8, 12% SDS, 60% glycerol, 0.6M dithiothreitol [DTT], and 0.06% bromophenol 
blue), denatured at 95 °C for 10 min, and loaded onto 4–20% acrylamide precast gel 
(Bio-Rad). Gel electrophoresis was performed under 100 V in running buffer (25 mM Tris, 
190 mM glycine, 0.1% SDS) until proteins were separated as indicated by protein 
molecular weight marker (Bio-Rad).  
Immunoblot 
Separated proteins were then transferred from a gel to a polyvinylidene fluoride (PVDF) 
membrane (0.45 μm pore) in cold transfer buffer (25 mM Tris, 190 mM glycine, 20% 
methanol) under 350 mA of electricity for 90 min. The resulting membrane was 
incubated in blocking buffer (4% skim milk in PBS) at room temperature for an hour and 
cut into strips accordingly. The membrane was washed briefly with washing buffer (20 
mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20) and then probed with antibody against 
HLTF (1:1000, rabbit polyclonal, Abcam), HCMV IE1/2 (1:1000, mouse monoclonal 




(1:10000, mouse monoclonal [686613], R&D Systems) at 4 °C for 16 hours. Blots were 
subsequently washed at room temperature 6 times for 10 min each to remove unbound 
antibodies. A secondary probing was done using near-infrared fluorescent antibodies 
(1:10000, LI-COR) against mouse or rabbit immunoglobin at room temperature for an 
hour. Afterwards, blots were then again washed 6 times for 10 min each before 
visualization on Odyssey Imaging Systems (LI-COR). Western blot images were processed 
through the software Image Studio Lite (LI-COR). 
 
2.1.7. Firefly luciferase reporter assay 
In 96-well opaque plates, 293T cells were transfected with reporter plasmid (pGL3-
pIFNβ-Luc, provided by Professor Geoff Smith [University of Cambridge]; pGL4-NFκB-
Luc2, purchased from Promega; pGL3-ISRE-Luc; Provided by Dr. Ceri Fielding [Cardiff 
University]) and internal control plasmid pHAGE-GFP (provided by Professor Paul Lehner 
[University of Cambridge]) using TransIT-293 transfecting reagent (Mirus). Two days 
post-transfection, cells were treated with relevant stimuli (Sendai virus, tumour necrosis 
factor α, interferon α) to induce promoter activities. Six hours post induction, cell culture 
was replenished with fresh SF DMDM and cells were lysed with Bright-Glo Luciferase 
Assay plus substrate (Promega) in to a final concentration of 30%. Luminescence and 
GFP fluorescence was read with microplate reader (Tecan SPARK) after incubation at RT 
for 5 min. Cell-free SF DMEM was used as blank, and readings from these wells were 
used for noise subtraction.  
 
2.1.8. Chromatin immunoprecipitation assay 
Sample preparation 
Chromatin immunoprecipitation (ChIP) assays were performed with Imprint Chromatin 
Immunoprecipitation Kit (Sigma) according to manufacturer’s instruction. Infected cells 
were washed once with PBS, resuspended in PBS, mixed with fresh formaldehyde at a 
final concentration of 1%, and incubated at RT for 5 min. Glycine was added to a final 




5 min. After medium removal and ice-cold PBS wash, cell nuclei were extracted with 
Nuclei Preparation Buffer lysis (200 µL/106 cells), vigorously vortexed, and centrifuged 
(180 xg, 5 min, 4 °C). Cell nuclei were then lysed with shearing buffer (100 µL/106 cells) 
containing protease inhibitor cocktail (PIC) (10 µL PIC/1 ml Shearing Buffer), incubated 
on ice for 10 min with occasional vortex. DNA was sheared by water-cooled sonication 
(Diagenode Bioruptor), with 40 cycles of “on” 30 sec and “off” 30 sec. 
Protein/DNA Immunoprecipitation 
Diluted clarified supernatant was incubated with relevant diluted (10 µg/ml, 1ml/106 
cells) antibody (αHLTF rabbit polyclonal [Abcam], αhistone H3 rabbit polyclonal [Abcam], 
rabbit IgG [Sigma]), in provided strip well O/N at 4 °C with constant rocking. After 
immunoprecipitation, the wells were washed with IP Wash Buffer for 6 times and Tris-
EDTA Buffer once. 
De-crosslinking 
The wells were then incubated with DNA Release Buffer containing Proteinase K (1ml 
Proteinase K/40 ml DNA Release Buffer) at 65 °C for 15 min. Reversing Solution was then 
added for a further incubation of 90 min at 65 °C to de-crosslink protein-DNA complex. 
DNA Purification 
DNA purification was performed with the provided DNA-binding silica-based column and 




Cells were lysed on ice in mammalian cell lysis buffer (MCLB) (50 mM Tris pH 7.5, 300 
mM NaCl, 0.5 % [v/v] NP-40, 1 M DTT) supplemented with complete EDTA-free protease 
inhibitors (Roche). Samples were tumbled for 15 min at 4 °C on a tube roller, then 
centrifuged at 16,100 x g for 15 min at 4 °C. Protein concentration was determined with 




V5 beads immunopreciptation 
Bead slurry made up of monoclonal anti-V5 conjugated agarose resin (Thermo) in MCLB 
was incubated with the cell lysate for 3 h at 4 °C on a rotating mixer. Thirty µl of 50% 
(v/v) bead slurry was added per mg of protein lysate. Beads were subsequently washed 
with ice-cold MCLB 7 times, followed by 7 ice-cold PBS (pH 7.4) washes. Washes were 
performed in Pierce Spin Columns (Thermo) placed in a vacuum manifold (Promega). 
Protein bound to the beads was eluted in 250 μg/ml V5 peptide (Thermo) in PBS at 37 °C 
for 30 min with constant shaking. 
HLTF immuniprecipitation 
Cell lysate was incubated with anti-HLTF (2.5 ug per mg of lysate, rabbit polyclonal, 
Abcam) O/N at 4 °C in a rotating mixer (Stuart). The antibody bound HLTF complexes 
were then immunoprecipitated with protein A-Sepharose beads (Thermo) for 2 h at 4 °C 
on a rotating mixer. Beads were subsequently washed with ice-cold MCLB and PBS 7 
times each in Pierce Spin Columns (Thermo) placed in a vacuum manifold (Promega). 
After washes, the immunoprecipitated complexes were eluted in 2% SDS solution at 
95°C for 5 minutes to detach the complexes from the beads. Eluted protein samples 
were subjected to immunoblot analysis (subsection 2.1.6) or proteomic mass 
spectrometry analysis (section 2.4. ). 
 
2.2.  Cell Biology 
2.2.1. Cell lines and cell culture 
All cells (HFFF-TERT, 293T) were cultured with complete DMEM supplemented with 10% 
foetal calf serum (Gibco), 100 U/ml penicillin, and 100 μg/ml streptomycin (Sigma) in 
humid incubators with 5% CO2 at 37 °C. To make cell stocks, low-passage cells were 
resuspended in freezing buffer (10% dimethyl sulfoxide [DMSO] in foetal calf serum) and 
placed into a 4 °C isopropanol-containing freezing container (Mr. Frosty, Thermo), which 





2.2.2. Immunofluorescence Microscopy 
HFFF-TERT cells were seeded on a sterile coverslip O/N to allow cells to adhere to the 
glass surface. Cells were subsequently infected with HCMV for 24 h and treated with 10 
µM MG132 on coverslips for 12 h prior to harvest. Harvested cells were then cross-linked 
with fixation buffer (Biolegend), permeabilised with ice-cold methanol, and blocked with 
Human TruStain FcX (Biolegend). Two primary antibodies were used: rabbit anti-HLTF 
(ab17984, Abcam) and mouse anti-V5 (MA5-15253, Thermo). Secondary antibodies 
were anti-mouse Alexa Fluor 488 (4408S, Cell Signaling) and anti-rabbit Alexa Fluor 647 
(A31573, Thermo). Cell nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI) 
(Cell Signaling). Stained cells were mounted with ProLong Gold antifade mountant 
(Thermo). Fluorescence was observed using a confocal microscope (Zeiss LSM 710). 
Images were processed with Zeiss Zen software (Blue edition, version 2.3).  
 
2.2.3. Flow Cytometry 
Cell fluorescence analysis 
Cell fluorescence, either from fluorescent proteins or proteins stained with fluorescent 
dye, was analysed with FACSCalibur cell analyser (BD Biosciences) and CellQuest PRO 
software (BD Biosciences). LSRFortessa cell analyser (BD Biosciences) and FACS DIVA 
software (BD Biosciences) were used for near-infrared fluorescent protein 713 (iRFP713) 
reading. Samples were fixed with fixation buffer (Biolegend) and adjusted to an 
approximate cell concentration of 5 x 105 cells/ml before subjecting to cell analysers.  
Cell sorting 
Infected cells were trypsinised, pelleted and resuspended in DMEM to reach 
approximate cell concentration of 106 cells/ml.  Cells were sorted into infected and 
uninfected populations according to GFP intensity with FACSMelody cell sorter (BD 
Biosciences). Flow speed were adjusted so that more than 80% of the cells could be 
processed. 




Raw data (FSC files) collected from analysers are processed with FLOWJO software 
(version 10, BD biosciences). 
 
2.2.4. Enzyme-linked immunosorbent assay (ELISA) 
96-well-based ELISA assay 
Interferon beta released into cell culture medium was measured with a human IFNβ 
ELISA Kit (PBL Assay Science) according to manufacturer’s instructions. Briefly, diluted 
cell culture supernatant was mixed with a buffer containing biotinylated secondary 
antibody, and incubated in assay well coated with IFNβ antibody for 2 h with constant 
rocking. After aspiration and washing three times, streptavidin conjugated horseradish 
peroxidase (HRP) was added to the well, and incubated for 30 min with constant rocking. 
Tetramethyl-benzidine (TMB) is the substrate, which was added to the well after it was 
washed thoroughly. This incubation was performed in the dark without agitation for 30 
min. Finally, the reaction was terminated with stop solution and the absorbance at 450 
nm was determined using a microplate reader (Tecan Spark) within 5 min after the 
addition of the stop solution. By plotting the standard curve, which was serial dilution 
of recombinant human IFNβ expressed in mammalian cells, the IFNβ concentration in 
the supernatant can be calculated. 
Multiplex Bead-based ELISA assay 
Supernatant of infected cells was analysed with Legendplex multiplex ELISA kit 
(Biolegend) to measure 13 human proteins, including interferons (α, β, γ, λ1 and λ2/3), 
interleukins (1β, 6, 8, 10, 12), TNFα, interferon-inducible protein 10 (IP-10, CXCL10) and 
granulocyte macrophage colony-stimulating factor (GM-CSF). Beads are differentiated 
by size and internal fluorescence intensities. Each bead is conjugated with a specific 
antibody on its surface and serves as the capture bead for that particular analyte. When 
a selected panel of capture beads is mixed and incubated with a sample containing 
target analytes specific to the capture antibodies, each analyte will bind to its specific 




each detection antibody in the cocktail will bind to its specific analyte bound on the 
capture beads, thus forming capture bead-analyte-detection antibody sandwiches. 
Streptavidin-phycoerythrin (SA-PE) is subsequently added, which will bind to the 
biotinylated detection antibodies, providing fluorescent signal intensities in proportion 
to the amount of bound analytes. Beads sizes and their FITC and PE intensities were 
measured with FACSCalibur cell analyser (BD Biosciences) and data were processed with 
Legendplex software (Biolegend). 
 
2.3.  Virology 
2.3.1. Viruses 
All HCMV strains used in this project can be found in Table 2.3. RCMV 1111 strain was 
provided by Dr. Peter Tomasec (School of Medicine, Cardiff University), all the other 
strains were generated and provided by Dr. Richard Stanton (School of Medicine, Cardiff 
University).  
 
Table 2.3.Complete list of HCMV used in this project  
Virus name Identifier Mutations 
WT Merlin RCMV 1111 Mutated RL13 and UL128 
ΔUL145 Merlin RCMV 1814 Mutated in RL13 and UL128; UL145 deletion 
WT Merlin UL36-
GFP 
RCMV 2582 Mutated in RL13 and UL128; UL36-P2A (self-









RCMV 2270 Mutated in RL13 and UL128; tetracyclin-regulated 







RCMV 2571 Mutated in RL13 and UL128; tetracyclin-regulated 
RL13 and UL128; UL36-P2A-GFP; UL145 deletion 
WT Merlin 
UL145-V5 
Not assigned Mutated in RL13 and UL128; UL145-V5 
WT AD169-GFP RCMV288 UL/b’ deletion; mutated RL5A, RL13, UL36 and 
UL131A; UL32-GFP 
 
Sendai virus was (ATCC VR-907) purchased from ATCC and used after it was thawed, 
aliquoted, and stored at -70 °C. 
 
2.3.2. Virus infection 
HCMV 
Virus stock was diluted with 37 °C serum-free (SF) Dulbecco's modified Eagle medium 
(DMEM, Sigma) according to the desired multiplicity of infection (MOI) and added 
directly to the cells. Cells were incubated at 37 °C with 5% CO2 and constant rocking for 
2 h before substituting virus-containing DMEM into complete DMEM. 
Sendai virus 
For Sendai virus (ATCC VR-907) infection, virus was diluted in 1:40 with SF-DMEM, and 
the viral mix was added to the cell (30 µl for a 96-well plate well). Cells were incubated 
at 37 °C with 5% CO2 and constant rocking for 2 h before substituting viral mix into 
complete DMEM. 
 
2.3.3. Viral production 
HFFF-TERT cells were infected with a low-passage stock of HCMV Merlin strain at 
approximately MOI 0.01 for 14 days or until plaques were clearly visible to cover 70% of 




sustain cell viability and viral production. Virus-containing media was concentrated 
through high-speed centrifugation at 10,000 rpm (Beckman Coulter JAL-16.25 rotor, 
approximately 10,000 xg) at 35 °C for 2 h. Centrifuge brakes were turned off to avoid 
virion rupture and disruption of pallet formation. Virions were then resuspended in 
small volume of complete DMEM and aliquots were frozen at -70 °C. 
 
2.3.4. Virus titration 
Titration of non-GFP viruses 
Intracellular staining of HCMV IE1/2 was used to determine virus titre. Virus stocks were 
serially diluted by 4-fold 4 times and used to infect HFF-TERT cells. Forty-eight hours 
post infection, cells were detached with trypsin, neutralized with complete DMEM and 
briefly washed once with PBS. Then, cells were fixed with fixation buffer (Biolegend) at 
4 °C for 30 min, and permeabilised with ice-cold methanol on ice for 15 min. To remove 
non-specific binding of antibodies, permeable cells were treated with human TruStain 
FcX Fc receptor blocking solution (Biolegend) at 4 °C for 30 min. Subsequently, cells were 
incubated with antibody targeting HCMV IE1/2 (1:1000, mouse monoclonal [6F8.2], 
Millipore) at 4 °C for 30 min, followed by a PBS wash before labelling with anti-Mouse 
IgG conjugated with Alexa Fluor 647 (1:5000, Thermo). After another PBS wash, cells 
were subjected to fluorescence-activated cell sorting analysis using FACSCalibur (BD 
Biosciences) to determine the percentage of IE1/2 positive cells. The number of IE1/2 
positive cells represented the number of HCMV infected cells, which was adapted to 
calculated plaque forming unit (PFU) in the viral stocks.  
The Poisson distribution was used to predict the percentage of cells receiving a given 
number of infectious particles at different multiplicities of infection (MOI) (Condit, 2013). 





In this equation, P(k) is the probability that a cell is infected with k infectious particles 




According to the Poisson distribution, observation of 33% of infected cells implies more 
than 95% of these cells received only 1 virion. Therefore, dilutions with less than 33% 
infection population were used to estimate the input virion assuming all the infected 
cells are IE1/2 positive and 1 PFU equals 1 IE1/2 producing unit. The average of 
estimated virion amount from different dilutions was used as titre. An example is shown 
in Figure 2.2. 1:1024 and 1:4096 resulted in an infection population of less than 33% 
(5.1% and 0.84% respectively) and the average titres from these two dilutions was used 
to estimate the HCMV stock titre. 
 
Figure 2.2. Example of a WT Merlin HCMV titration with intracellular IE1/2 
staining.  
(A) Histogram of IE1/2 intensity of wild-type (WT) Merlin HCMV serial dilution 
infection. Each infection was performed in biological duplicate. The percentage of 
IE1/2 positive cells were indicated on the top right corner of the graph. (B) The bar 
graphs representing the virus titre calculated in each dilution. The error bars 
represent the standard deviation between the two duplicates. Average of 1:1024 
and 1:4096 results was used as the titre of the tested virus. 
 
Titration of GFP viruses 
For GFP tagged viruses, the percentage of GFP positive cells were quantified with 






2.3.5. Viral DNA Replication Assay 
Cells were infected with Merlin HCMV at the indicated MOI. At multiple time points post 
infection, infected cells were rinsed with PBS for 3 times to remove extracellular DNA 
and harvested using trypsin. Genomic DNA of these cells were extracted using DNeasy 
Blood & Tissue Kits (QIAGEN) according to instructions from manufacturer. The 
extraction principle is to lyse cells by vortex in the presence of detergent and protease. 
Nucleic acid was then precipitated with ethanol and collected with DNA binding columns. 
Finally, DNA was dissolved in sterilized ddH2O after washing with ethanol-containing 
buffers. Extracted DNA was then analysed targeting viral gB gene and human genomic 
GAPDH with SYPR green qPCR described in subsection 2.1.3. 
 
2.3.6. Virus Growth Curve Analysis 
HFFF-TERT cells were infected with wild type or UL145-deleted GFP-encoded Merlin 
HCMV at MOI of 1. Cells were incubated with serum free DMEM for 24 h prior to 
infection. For a T25 experiment, 1x106 cells are seeded and viral mix were replaced with 
2 ml complete DMEM, supernatant was collected daily and stored at -70°C. Virus titre 
was determined as previously described. In some experiments, spare viral mix was 
collected and tittered together with supernatant as “day 0”.  
 
2.4.  Proteomics 
2.4.1. Whole Cell Lysate Protein Digestion 
Cells were washed with PBS once, typrsinised, neutralised with complete DMEM, 
pelleted, and lysed with 200 μl lysis buffer (6M Guanidine/50 mM HEPES pH 8.5) per T25 
flask. Cells were then sonicated for 2.5 min at constant 4°C cooling with Bioruptor Pico 
(Diagenode), and cell debris was removed by centrifuging at 21,000 xg for 10 min at 4°C. 
To reduce protein, DTT was added and samples were incubated for 20 min at room 




(IAA) and incubated 20 min at room temperature in the dark. Excess IAA was quenched 
with DTT for 15 min. Protein samples were then digested with LysC protease at a 1:100 
protease-to-protein ratio for 3 h at room temperature after Guanidine concentration 
was lowered to 1.5M with 200 mM HEPES (pH 8.5). Guanidine concentration was further 
lowered to 0.5M and Trypsin was then added at a 1:100 protease-to-protein ratio 
followed by overnight incubation at 37 °C with constant shaking. Trypsin was quenched 
with 5% formic acid. Samples were then centrifuged at 21,000 xg for 10 min at at 4°C to 
remove undigested protein. Peptides were subjected to octadecyl carbon chain (C18) 
solid-phase extraction (SPE, Sep-Pak, Waters) and dried with speed-vac (Thermo).  
For small-scale peptide extraction, instead of Sep-Pak, an in-house SPE column called 
StageTips were made with 200 µl pipette tips and tiny disks made of C18 bound beads 
embedded in a Teflon mesh (Thermo) (Rappsilber et al., 2007).  
 
2.4.2. Peptide Labelling with Tandem Mass Tags (TMT) 
Desalted peptides were dissolved in 200 mM HEPES (pH 8.5) and peptide concentration 
was measured by microBCA kit (Thermo). TMT reagents (0.8 mg) were dissolved in 43 μl 
anhydrous acetonitrile to make stocks and 3 μl was added to 25 μg of peptides at a final 
acetonitrile concentration of 30% (v/v). Following incubation at room temperature for 1 
hr, the reaction was quenched with 0.3% (v/v) hydroxylamine. Equal amount of TMT-
labelled samples were combined and subjected to C18 SPE and dried with speed-vac 
before subjected to mass spectrometer.  
 
2.4.3. Stable isotope labeling by amino acids in cell culture (SILAC) 
Specific isotopes of L-Lysine-dihydrochloride and L-Arginine-hydrochloride were added 
into DMEM without arginine or lysine (DMEM for SILAC, Thermo), supplemented with 
10% dialysed FCS (Thermo), 100 U/ml penicillin (Sigma), 100 μg/ml streptomycin (Sigma), 
and 280 mg/l L-proline (Sigma). Excess proline was added to prevent arginine-to-proline 
and affecting arginine concentration. Before adding to SILAC medium, dialysed FCS was 




um filter to remove insoluble proteins. “Heavy” SILAC medium was supplemented with 
151.3 mg/l 13C15N2-lysine and 88 mg/l 13C615N4-arginine (CK Isotopes Limited); “medium” 
SILAC medium was supplemented with 148.7 mg/l 2H4-lysine and 86.5mg/l 13C6-arginine 
(CK Isotopes Limited); “light” SILAC medium contained natural 146 mg/l lysine and 84 
mg/l arginine (Sigma). Cells were grown for seven passages in respective SILAC medium 
before experiments. 
 
2.4.4. Offline high pH reversed phase fractionation (HpRP) 
Liquid chromatography (LC) is a technique that separates different components within 
a mixture using a column which allows components to diffuse across at different rates. 
In reversed-phase high-performance LC (HPLC), a high pressure pump generates a 
constant flow of solvent called mobile phase that passes through a column containing 
absorbent silica particles coated with hydrophobic alkyl chains that interacts with 
peptides, called stationary phase. An autosampler introduces the sample into the mobile 
phase before entering the stationary phase in HPLC. Ultrahigh performance liquid 
chromatography (UHPLC) uses particles with diameter less than 2 µm to increase 
separation efficiency. 
In order to increase sample resolution on mass spectrometer, TMT-labelled peptides 
were subjected to HpRP fractionation using an Ultimate 3000 rapid separation (RS) nano 
UHPLC system (Thermo) and 12 fractions were generated. The system is equipped with 
a Kinetex Evo C18 column (Phenomenex) that has 2.1 mm in internal diameter (ID) and 
25 cm in length, is filled with C18 bound silica particles (stable at pH 1-12) with diameter 
of 1.7 μm. Mobile phase was made up of HPLC grade H2O, acetonitrile, and ammonium 
formate (pH 10). The concentration of ammonium formate was maintained at 20 mM 
while concentration of acetonitrile gradually increased along the fractionation elution 
programme. Starting from 2.7% (v/v), acetonitrile concentration increased to 21% in the 
first 10 minutes, to 36% after 24 min 15 sec of elution, then to 51% after 33 min of 
elution. The acetonitrile concentration was subsequently increased to and maintained 
at 90% for 10 min to wash the column. The flow rate was 400 ml/min and the elution 




collected into 96 well microplates using the integrated fraction collector. Fractions were 
recombined orthogonally in a checkerboard fashion, combining alternate wells from 
each column of the plate into a single fraction, and commencing combination of 
adjacent fractions in alternating rows. Wells were excluded prior to the start or after the 
cessation of elution of peptide-rich fractions, as identified from the UV trace. This 
resulted into two sets of 12 combined fractions, which were dried in a vacuum 
centrifuge and resuspended in 10 ml solvent (4% acetonitrile and 5% formic acid) prior 
to LC-MS3. 
 
2.4.5. Liquid chromatography coupled with multi-stage mass spectrometry (LC-MS3)  
At the LC stage, sample went through Ultimate 3000 RSLC nano UHPLC, which is 
equipped with a 300 μm ID x 5 mm Acclaim PepMap μ-Precolumn (Thermo) and a 75 
μm ID x 50 cm 2.1 μm particle Acclaim PepMap RSLC analytical column (Thermo). 
Loading solvent was 0.1% formic acid and analytical solvent contained HPLC grade H2O, 
acetonitrile, and formic acid. Samples were loaded at 5 ml/min for 5 min in loading 
solvent before beginning the analytical gradient. Formic acid concentration was 
maintained at 0.1% during the analytical gradient while concentration of acetonitrile 
gradually increased. All separations were carried out at 55°C.  
Mass spectrometry data were acquired using Orbitrap Lumos mass spectrometer 
(Thermo), which uses electrospray to charge peptides into positively-charged ions for 
analysis. An Orbitrap is an ion trap mass analyser that consists of two outer electrodes 
that form a barrel and a spindle like electrode in the middle (Figure 2.3). The electrodes 
create electromagnetic fields that cause ions to oscillate around the central electrode. 
During oscillation, each ion's motion induces a current in the outer electrodes due to 
electrostatic attraction, allowing detection of the oscillation frequency using Fourier 
Transform, which decomposes the induced current value over time into sine(sin) and 
cosine(cos) components over frequencies. The oscillation frequency is inversely 











In this equation, T is the period of oscillation, ω is the frequency, m is the mass of the 
ion, z is the charge of the ion, and k is a constant proportional to the potential difference 
between the central and the outer electrodes. Different ions oscillate at different 
frequencies, resulting in their separation. (Scigelova et al., 2011; Zubarev and Makarov, 
2013) 
Besides an Orbitrap, the system has quadrupole mass filters, which select ions with 
specific m/z with 4 rod-shape electrodes, and a collision‐induced dissociation chamber, 
where fast moving ions collide with neutral gas and fragment into b‐ (contain N-terminus) 
and y‐ (contain C-terminus) type ions (Figure 2.3). Together both compartments allow 
an Orbitrap Lumos to perform tandem mass spectrometry (MS/MS, or MS2), which is 
pivotal for peptide sequence identification. For TMT experiments, an MS3 analysis was 
followed after MS2, in which MS2 ions were selected for higher energy collisional 
dissociation (HCD) and small m/z fragment reporter ions from TMT tags were quantified. 
TMT-based analysis used a MultiNotch MS3-based method (McAlister et al., 2014). MS1 
scans were surveyed between 380-1500 Thompsons (Th, a unit of m/z), with mass 
resolving power (resolution) of 120,000, automatic gain control (AGC) target of 2x105, 
and maximum injection time of 50 ms. Ions that had the counts of 5x103 counts and 
above triggered MS2 analysis, with Quadrupole isolation at an isolation width of 0.7 Th, 
normalised collision energy (NCE) set to 35% for CID fragmentation, 1.5x104 AGC target, 
and 120 ms maximum injection time. The top 6 MS2 ions were selected for HCD 
fragmentation (NCE 65%) in MS3. MS3 resolution was 60,000, with an AGC target of 
1x105 and a maximum accumulation time of 150 ms. The entire MS/MS/MS cycle had a 
target time of 3 sec. Dynamic exclusion was set to +/- 10 ppm for 70 sec. 
LC-MS2 was used to analyse SILAC samples. The parameters were slightly different to 
TMT experiments. MS1 scans read 300-1500 Th, with resolution of 120,000, AGC target 
4x105, and maximum injection time of 50 ms. MS2 fragmentation was trigged on 
precursors 5x104 counts and above. Quadrupole isolation at an isolation width of m/z 




110, 5x104 AGC target, 60 ms maximum injection time. Dynamic exclusion was set to +/- 
10 ppm for 60 sec. 
 
 
Figure 2.3. Schematic of a quadrupole coupled Obitrap LC-MS2. 
Image is derived from Thermos website for Q Executive MS. Electrospray (bottom 
right) charged peptides. S-lens focuses charged ions. Quadrupole selects ions with 
specific m/z. C-trap retains ions before entering Orbitrap. HCD cell breaks down 
peptide ions for MS2 or MS3 analysis. Orbitrap measure m/z through oscillating 
frequency.  
  
2.4.6. Protein quantification data analysis 
Peptide identification  
The SEQUEST algorithm is a search programme that compares tandem mass spectra of 
peptides against peptide sequences from a sequence database. The correlation score is 
given to identify the possible peptide sequence of tandem mass spectra of peptides (Eng 
et al., 1994). Mass spectra were processed using ‘‘MassPike’’, which is a SEQUEST-based 
software for quantitative proteomics, developed by Professor Steven Gygi and 
colleagues at Harvard Medical School. The data format mzXML is a format that allows 
open storage and exchange of mass spectroscopy data. In MassPike, MS spectra were 
converted to mzXML format using an extractor built upon Thermo Fisher’s RAW File 




extraction and conversion, with additional customisations that are specific to ion trap 
and Orbitrap mass spectrometry and essential for TMT quantitation. These 
customisations consider ion injection times for each scan, Fourier Transform-derived 
baseline and noise values calculated for every Orbitrap scan, isolation widths for each 
scan type, scan event numbers, and elapsed scan times. 
Acquired mass spectra were searched against a combined protein sequence database 
that includes human proteins, HCMV proteins, and possible protein contaminants that 
might be introduced to samples. Human protein database was acquired from the human 
Uniprot database (Downloaded on 26th January, 2017). The HCMV protein database was 
assembled from the HCMV strain Merlin Uniprot database, noncanonical human 
cytomegalovirus ORFs described by Stern-Ginossar et. al. (Stern-Ginossar et al., 2012), a 
six-frame translation of HCMV strain Merlin filtered to include all potential ORFs of ≥8 
residues (delimited by stop-stop rather than requiring ATG-stop). A database comprised 
of common contaminants included nonhuman protein such as bovine serum albumin 
and porcine trypsin, and annotated human protein contaminants such as keratins. 
Searches were performed using a 20 ppm precursor ion tolerance. Fragment ion 
tolerance was set to 1.0 Th. 
Modifications were set to account for mass shifts caused by IAA treatment, TMT 
labelling, and SILAC labelling. IAA treatment induces carbamidomethylation of cysteine 
residues and increases peptide mass by 57.02146 Dalton (Da). TMT labelling adds 
229.162932 Da to lysine residues and peptide N-termini. In SILAC labelling, “heavy” 
lysine increases mass by 8.01420 Da, “heavy” arginine by 10.00827 Da, “medium” lysine 
by 4.02511 Da, and “medium” arginine by 6.02013 Da. Oxidation of methionine residues 
(15.99492 Da) was also considered even for the absent of H2O2 or other strong oxidants 
in our experiments. 
Peptide identification was executed in the order of the ranks using cross-correlation 
score (XCorr), as the correctness of peptide spectral matches (PSMs) decreased along 
the ranks. A target-decoy strategy was employed to ensure the quality of peptide 
identification (Elias and Gygi, 2007).  A decoy database was generated by reversing the 




a reverse sequence peptide occurred, it was predicted that another peptide had already 
been falsely identified. Peptide identification terminated before the total false discovery 
rate reached 2% (presumably 1% from identification of reverse sequence peptide and 
1% from peptides that were truly falsely identified). Correct and incorrect spectral 
matches were distinguished from one another using linear discriminant analysis based 
on several parameters including XCorr (number of matching peaks in MS2 scan) of the 
top possible peptide, the XCorr difference between top and second possible peptide 
(ΔCn), precursor mass error (derived from the difference between predicted MS1 
reading and the obtained reading), and the charge state. 
Protein assembly 
Protein assembly was performed by principles of parsimony to produce the smallest set 
of proteins necessary to account for all observed peptides, meaning in cases of 
redundancy, shared peptides were assigned to the protein sequence with the most 
matching peptides. 
Protein quant  
Following fragmentation, each TMT tag produces reporter ions with specific mass, which 
were surveyed in low m/z area of the MS3 spectrum. The maximum intensity nearest to 
the theoretical m/z of each reporter ion was used. Proteins were quantified by summing 
TMT reporter ion counts across all matching peptide-spectral matches. If a TMT 
experiment uses n (number) types of TMT tags, more than n-1 TMT channels missing 
and/or a combined signal-to noise ratio of less than 25n across all TMT reporter ions are 
considered poor quality of MS3 spectra. PSMs with poor or no MS3 spectra were 
excluded from quantitation. Protein quantitation values were exported for further 
analysis in Excel. 
For SILAC analysis, quantitation was performed at the MS1 level by comparing the 
intensities of the precursor ions that were differently labelled by different SILAC medium. 
 




The data analysis of protein expression fold change included calculation of the 
significance of the fold change. Significance was calculated with PERSEUS software (Max 
Planck Institute of Biochemistry), using its Significance A/Significance B function. The 
significance A algorithm determines a standard deviation (SD) of a group of fold changes 
and calculates a p-value for each fold change based on this SD. The more the fold change 
deviates from the mean of this group according to SD, the lower significance A value this 
fold change has. For example, if 8000 proteins are quantified, 8000 fold changes (FCs) 
respective to a treatment are calculated. The significance algorithm first determines the 
standard deviation of FCs from all up-regulated proteins (FC>1) and the standard 
deviation of FCs from all down-regulated proteins (FC<1).The significance p-value of a 
given fold change is assigned according to how this fold change deviates from 1 (FC=1, 
no change).  
Proteins with higher ion intensity are considered better quantified and the p-value are 
more significant. Significance B includes intensity as part of the p-value calculation, and 
splits ratio values into groups of 350 proteins according to their intensity. The SD / 
significance calculation is then performed within each group. All Significance A and B 
values are subsequently adjusted for multiple hypothesis testing using the method of 
Benjamini-Hochberg (Benjamini and Hochberg, 1995). 
 
2.4.8. Pathway Analysis 
The database for annotation, visualisation and integrated discovery (DAVID, version 6.8 
http://david.ncifcrf.gov/) was used to determine pathway enrichment (Huang da et al., 
2009). A given cluster was searched against a background of all proteins quantified 
within the relevant experiment, using default settings provided by this website. 
 
2.4.9. Amino acid sequence alignment and secondary structure prediction 
Amino acid sequence alignment of UL145 orthologues in primate cytomegaloviruses 




Secondary structure predictions were performed with Jpred 4 
(http://www.compbio.dundee.ac.uk/jpred/) 
 
2.4.10. Gene clustering 
Hierarchical clustering was performed using Cluster 3.0 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/). The clustering results are 
visualized with Java TreeView (http://jtreeview.sourceforge.net/).  
 
2.5.  Statistics 
For flow cytometry, ELISA and most of qPCR experiments, data were derived from 
duplicates and standard deviation (SD) was calculated to show the variability of 
measurements. For luciferase reporter assays and 4 qPCR experiments (Figs 4.2A, 4.6, 
4.8A, 4.12) where n>2, standard error of the mean (SEM) was calculated to show how 
far the sample mean of the data is likely to be from the true population mean. Statistical 
analyses of proteomic experiments are described in subsection 2.4.7. For comparative 
studies in Chapter 5, linear trend lines (y-intercept was set to zero) and correlation 





Chapter 3. HLTF degradation mechanism 
during HCMV infection  
HLTF was identified as one of the top targets for HCMV degradation in our proteomics 
screen. The first part of this project was to investigate how HCMV directs HLTF for 
proteasomal degradation during early infection. Study of the degradation mechanism 
will provide insights into how HCMV orchestrates host factors during infection and help 
to identify ways to counteract HLTF downregulation during infection. Results in this 
chapter showed that HLTF was targeted by HCMV UL145 protein for proteasomal 
degradation via cullin 4 (CUL4) E3 ligase. 
3.1.  Verification of HLTF proteasomal degradation 
First, the results from proteomic experiments were validated with conventional 
molecular biology method Western blot. HFFF-TERT cells were infected with Merlin 
HCMV and harvested at 12, 24, 48 hours post infection (hpi). Twelve hours before each 
harvest, normal cell culture medium was replaced with complete DMEM with 10 μM 
MG132. Along the infection time course, HLTF was downregulated starting at 12 hpi, 
and its protein level remained low at 24 hpi and 48 hpi. (Figure 3.1 A&B) At 12 hpi, it 
was clear that MG132 blocked HLTF down-regulation. However, HCMV-mediated down-
regulation of HLTF was far less prominent at 24 and 48 hpi, possibly because HLTF had a 
rather fast degradation rate during mock infection. During the course of HCMV infection, 
HLTF protein gradually decreased during mock infection (light blue bars Figure 3.1B), but 
this decrease was not observed under MG132 treatment (dark blue bars Figure 3.1B). 
The immunoblot results correlated with the previous proteomic MG132 inhibitor screen 
performed by Dr. Katie Nightingale (Figure 3.1C). In these TMT based experiments, 
MG132 rescued HCMV-mediated down-regulation of HLTF at 12, 24, and 48 hpi. Since 
the experiments were performed separately, degradation of HLTF over time in mock 
infection could not be observed. 
During HCMV infection, 12 h of MG132 treatment resulted in different amounts of HLTF 




regulation during HCMV infection observed in the RNA sequencing. HLTF RNA level 
increased by 2 fold from 12 hpi to 24 hpi, and remained increased at 72 hpi (Figure 
1.12C), this could be contributing to why there was more HLTF protein rescued at 48 hpi 







Figure 3.1. HLTF expression during HCMV infection under MG132 treatment.  
(A) Western blot analysis of HLTF expression within 48 hours of Merlin HCMV 
infection. MOI was 5 for this experiment. IE1/2 expression indicated HCMV 
infection while GAPDH was stained as a loading control. (B) Western blot signal 
quantification was performed by measuring the median fluorescence intensity of 
HLTF and normalised by that of internal control GAPDH. Relative HLTF was 
calculated according to the highest HLTF/GAPDH value, in this case mock infection 
with MG132 at 24 hpi. (C) TMT-based proteomic analysis of HLTF during HCMV 
infection with MG132 described in subsection 1.5.2. HFFF-TERT cells were 
incubated with dexamethasone-containing serum free DMEM for 24 h. Cells were 
subsequently infected with Merlin strain HCMV at MOI of 10 for 12, 24, and 48 h. 
Twelve hours prior to harvest, infected cells were treated with 10 µM MG132 until 
harvest. 
 
3.2.  Identification of UL145 as the viral factor regulating HLTF 
degradation  
Next, I wished to find out whether HLTF down-regulation was specifically caused by viral 
factors. If HLTF down-regulation results from expression of an HCMV protein, it could 
suggest that HCMV deliberately decreased HLTF expression and that HLTF degradation 
was not a cellular response to HCMV infection. In this section, UL145 of UL/b’ region was 





3.2.1. Block deletion virus 
HCMV encodes over 170 proteins and it is difficult to check the effect of each viral 
protein one by one. Therefore, I took advantage of the lab-adapted AD169 strain, which 
bears a block mutation in the UL/b’ region. As shown in Figure 3.2, AD169 infection did 
not lead to HLTF down-regulation, implying that viral protein that was responsible for 
HLTF degradation was encoded within UL/b’ region. Moreover, expression of HLTF was 
higher in AD169-infected cells in comparison with uninfected cells at both 24 and 72 hpi. 
This indicated that one of the factors encoded by the UL/b’ segment (or one of the other 
factors mutated in the AD169 compared to Merlin genome) led to degradation of HLTF. 
Furthermore, given the increased level of HLTF expression during infection with AD169 
virus compared to Merlin, it is possible that viral infection in the absence of an 
antagonist encoded within UL/b’ actually induced HLTF expression.  
 
 
Figure 3.2. Immunoblots of Merlin- or AD169-infected HFFF-TERT.  
(A) Western blot analysis of HLTF expression when HFFF-TERT were infected with 
Merlin or AD169 at MOI = 5 for 24 and 72 hr. E1/2 expression is HCMV infection 
indicator while GAPDH served as loading control. (B) Western blot signal 
quantification was performed by measuring the median fluorescence intensity of 
HLTF and normalised by that of internal control GAPDH. Relative HLTF was 
calculated according to the highest HLTF/GAPDH value, in this case AD169 





3.2.2. Single gene deletion virus 
To determine which individual proteins target HLTF for degradation, a library of HCMV 
mutants with deletions of single canonical genes in UL/b′ was generated by our 
collaborators at Cardiff University. Dr. Peter Tomasec infected the cells and collected 
the infected cells into guanidine lysis buffer. I carried out trichloroacetic acid (TCA) 
precipitation to concentrate the protein, and immunoblot to test the effects of single 
gene deletion on HLTF degradation. Only deletion of UL145 rescued expression of HLTF 
(Figure 3.3A). Overexpression of a C-terminally V5-tagged UL145 (UL145-V5) was 
sufficient to downregulate HLTF, and expression of HLTF protein was rescued by MG132. 
Together both experiments showed that UL145 was necessary and sufficient to down-
regulate HLTF. MG132 also increased expression of UL145 protein, which suggested that 
UL145 was naturally degraded (Figure 3.3B). However, UL145 synthesis was more 
significant compared to degradation so overall UL145 protein accumulated along the 
infection time course (Figure 4.2 D). 
 
 
Figure 3.3. UL145 was necessary and sufficient to down-regulate HLTF. 
(A) HFFF cells were infected with Merlin strain HCMV with UL/b′ single gene 
deletion at MOI of 5 for 72 h. Cell lysates were subjected to Western blot analysis 
probing HLTF, IE1/2, and GAPDH. (B) HFFF-TERT cells stably overexpressing UL145 
were treated with 10 µM MG132 for 12 h. Immunoblots probing HLTF, UL145-V5, 





To visualise this finding using another approach, HFFF-TERT cells were infected with 
Merlin HCMV bearing V5 tagged to UL145 C-terminus. Cells were subjected to 
immunoflourescent confocal microscopy probing V5 and HLTF. As shown in Figure 3.4, 
cells expressing UL145 had drastically decreased HLTF expression compared to those 
without. UL145 was only detected in the nuclei of cells and HLTF was predominantly 









HFFF-TERT cells were infected with recombinant Merlin strain HCMV with a C-
terminal UL145 V5 tag at MOI of 0.1. Cells were harvested 24 h post infection and 
subjected to immunofluorescent staining probing HLTF and V5. Cell nuclei were 
stained with DAPI. Stained cells were observed under a confocal microscope. The 
scale bar in the bottom right figure is 10 µm. 
 
3.3.  UL145-induced HLTF degradation via cullin 4A E3 ligase  
Since UL145 was identified as the main contributor to HLTF degradation, it was 
important to elucidate the mechanism of HLTF proteasomal degradation induced by 
UL145. Studying the degradation pathway might enable discovery of druggable targets 
if HLTF had antiviral functions. In summary, we found that UL145 recruited cullin 4A E3 
ligase to tag HLTF with ubiquitin, which led to destruction of HLTF via the proteasome. 
 
3.3.1. UL145 was associated with Cul4A and DDB1 
To identify cellular factors interacting with UL145, I performed a SILAC 
immunoprecipitation in HFFF-TERT stably expressing UL145-V5 with Dr. Katie 
Nightingale. I labelled HFFF-TERT stably expressing UL145-V5 with “medium” SILAC 
medium and HFFF-TERT stably expressing Gateway vector control with “light” SILAC 
medium. We carried out co-immunoprecipitation experiment to immunoprecipitate 
UL145-V5 and its associated proteins from UL145-expressing cells using anti-V5 agarose 
beads. Mass spectrometry was performed by Dr. Robin Antrobus from CIMR proteomics 
core and proteomic data were analysed by Dr. Nightingale. Results showed that cullin 4 
RING E3 ligase complex subunits such as CUL4A, DDB1 were abundantly associated with 






Figure 3.5. SILAC IP identified proteins associated with UL145 in HFFF-TERT cells 
(A) Schematic diagram of the experimental procedure. (B) The fold enrichment of 
each protein immunoprecipitated with UL145-V5 is shown. P values were 
estimated using significance A algorithm, then corrected for Benjamini-Hochberg’s 
multiple hypothesis testing method. Proteins enriched with p < 0.05 are shown in 
the graph. 
 
3.3.2. UL145 might be weakly associated with HLTF 
To identify proteins associated with HLTF in the presence of UL145, I attempted to 
overexpress HLTF and UL145 with lentiviral transduction and then immunoprecipitated 
HLTF. I cloned full-length HLTF with a C-terminal hemagglutinin (HA) tag into a lentiviral 
expression vector and transduced it into HFFF-TERT cells. After selection, cells were 
subjected to RT-qPCR and Western blot analysis. Transduction of HLTF resulted in more 
than 40 fold increase in HLTF transcripts (Figure 3.6A), however the increase in HLTF 
protein expression was minimal (Figure 3.6B&C). MG132 did not substantially increase 
HLTF protein expression compared to DMSO alone, suggesting that the failure of 
overexpression might have occurred at the translation level as compared to the 
transcriptional or post-translational levels.  
I started a collaboration with Dr. Jinwoo Ahn from Department of Structural Biology at 




Vpr recruits HLTF to the CRL4-DCAF1 E3 ligase (Zhou et al., 2017). Dr. Ahn advised me to 
express an N-terminus deletion of HLTF to minimise miss-folding of HLTF during ectopic 
expression of HLTF. I cloned a segment of HLTF sequence carrying 1-54 amino acid 
deletion (amino acids 58-174 are the HLTF DNA binding HIRAN domain, Figure 1.10A) 
into a lentiviral expression vector and transduced it into HFFF-TERT cells. After selection, 
cells were subjected to immunoblot analysis. Despite this, cells transduced with the N-
terminal HLTF deletion plasmid did not express more HLTF protein (Figure 3.6 D&E). 
 
 
Figure 3.6. Attempts of HLTF overexpression. 
(A) RT-qPCR analysis of HLTF transcripts in HFFF-TERT-HLTF cell line compared to 




deviation (SD) for technical duplicates.  (B) HFFF-TERT-HLTF and its control were 
treated with 10 µM MG132 or DMSO control. Cells were harvested 12 h after 
treatment for Western blot analysis probing HLTF. GAPDH was used as internal 
control. (C) Immunoblot quantitation of median HLTF signal intensity after it was 
normalised to GAPDH. (D) Western blot analysis of HFFF-TERT transduced to full 
length (FL) or N terminus deletion (NTD) HLTF. GAPDH was used as internal loading 
control. (E) Relative HLTF quantification of immunoblots showed in (D). 
Overexpressing full-length and N-terminal deletion HLTF-HA with lentiviral 
transduction was attempted twice each. Representative results from 2 
experiments are shown.  
 
Overexpressing HA-tagged HLTF was not successful. In order to study the proteins 
associate with HLTF in the presence of UL145, I performed a SILAC IP with cells stably 
expressing UL145 and treated with MG132 and immunoprecipitating endogenous HLTF. 
MG132 treatment was in place to make sure the amount of HLTF immunoprepicitated 
was sufficient for analysis. HLTF and its associated proteins were immuniprecipitated 
from SILAC labelled cell lysates. Analysis of these proteins from HFFF-TERT cells and 293T 
cells was performed. Figure 3.7 revealed proteins that had higher affinity with HLTF in 
UL145-expressing cells compared in control cells. In 293T cells, where endogenous HLTF 
expression is higher (Figure 3.7D), UL145 was observed to be associated with HLTF. 
However, this interaction was not observed in HFFF-TERT. Furthermore, none of the 
proteins identified from either IP was associated with the ubiquitin conjugation system 
and therefore these SILAC experiments did not add to the understanding of how UL145 
degrades HLTF during HCMV infection. DAVID analysis of the proteins associated with 
HLTF in both immunoprecipitations revealed that HLTF bound to different sets of 
proteins in the presence of UL145 in HFFF-TERT and 293T cells. HLTF was associated with 
nucleosome and ribosomal proteins in 293T cells while HLTF bound to poly(A) RNA 
binding proteins in HFFF-TERT cells (Table 3.1). These might either indicate subtleties of 
differentially expressed proteins in each cell type, or could theoretically indicate 
differences of HLTF protein function. However, since UL145 induces HLTF degradation 
and this analysis was performed with MG132 treatment, interpretation of this part of 






Figure 3.7. SILAC IP identified protein associated with HLTF in MG132-treated 
UL145 expressing HFFF-TERT and 293T cells. 
(A) Schematic diagram of the experimental procedure. (B)(C) The fold enrichment 
of each protein immunoprecipitated with HLTF in (B) HFFF-TERT cells and (C) 293T 
cells is shown. P values were estimated using significance A values, then corrected 
for multiple hypothesis testing. Proteins enriched with p < 0.05 are shown in the 







Table 3.1. DAVID analysis of pathway enrichment among proteins identified by 
SILAC IP immunoprecipitating endogenous HLTF in MG132-treated UL145 cells. 
A given cluster identified in was always searched against a background of all 
human proteins from Uniprot database. Benjamini-Hochberg adjusted p values 
are shown for each pathway. 
Pathway Benjamini p value 
Proteins associated with HLTF in MG132-treated UL145 expressing HFFF-TERT 
poly(A) RNA binding 0.0028 
isopeptide bond 0.0051 
Proteins associated with HLTF in MG132-treated UL145 expressing 293T 
nucleosome assembly 6.30E-10 
chromosome 3.60E-09 
cytosolic large ribosomal subunit 0.0005 
5'-deoxyribose-5-phosphate lyase activity 0.0023 
 
To attempt to further validate the direct association of HLTF and UL145 as observed in 
293T SILAC IP, HLTF and its associated proteins under the influence of UL145 were 
immunoprecipitated from MG132 treated 293T cells stably expressing UL145 and 
subjected to Western blot. As shown in Figure 3.8, even though abundant HLTF protein 
was immunoprecipitated, UL145 was not seen to be interacting with HLTF. Conventional 







Figure 3.8. Conventional IP showed that UL145 is not strongly associated with 
HLTF. 
293T cells stably expressing UL145 were treated with 10 µM MG132 for 12 h 
before lysis with RIPA buffer. HLTF and associated proteins were 
immunoprecipitated with anti-HLTF rabbit polyclonal antibody, and analysed with 
SDS-PAGE and Western blot. Percentage of input protein immunoprecipitated by 
anti-HLTF antibody was calculated according to the median band intensity of the 
corresponding 10% input. 
 
3.3.3. CUL4A was responsible for UL145-induced HLTF degradation 
Small interfering RNA (siRNA) specific for CUL4A was transfected into UL145 
overexpressing 293T cells to validate the involvement of CUL4A in UL145-mediated HLTF 
degradation. Dr. Katie Nightingale transfected a pool of CUL4A siRNAs or a pool of non-
targeting siRNAs into 293T cells overexpressing UL145-V5 or vector control and collected 
resulting cell lysates 48 h post transfection. I performed Western Blot analysis probing 
HLTF, CUL4A, and UL145-V5. As shown in Figure 3.9, knocking down CUL4A partially 
rescued HLTF downregulation, suggesting that UL145 directed CUL4A to target HLTF. 







Figure 3.9. siRNA treatment of CUL4A disrupted UL145-mediated HLTF 
degradation. 
Immunoblot showing HCMV UL145 downregulates HLTF in a CUL4A-dependent 
manner. 293T cells stably expressing UL145-V5 or vector control were treated with 
control siRNA, or siRNA against CUL4A for 48 h. Representative results from 2 
experiments are shown. 
 
3.3.4. UL145 harbours a potential DDB1 binding domain 
UL145 has no homologues in murine cytomegaloviruses, but in several other primate 
cytomegaloviruses, homologues can be found. Alignment of amino acid sequences of 
these homologues revealed high degree of similarity, in a clustered order correlated to 
the phylogenetic order of the hosts (Figure 3.10). Professor Andrew Davison (MRC-
University of Glasgow Centre for Virus Research) performed secondary structure 
predictions on these UL145 proteins. Four helixes were predicted to be conserved 
among UL145 protein from different strain of CMV, suggesting that they could be 
important in HLTF degradation. Structural analysis of CUL4-DDB1-DCAF E3 ligase 
complex revealed substrate binding receptor DCAF proteins interact with DDB1 through 
an α-helix, which was identified in other DDB1 interacting viral proteins such as simian 








Figure 3.10. Amino acid sequence alignment of UL145 homologs in primate 
cytomegaloviruses. 
(A) Amino acid sequences of UL145 from two low passage HCMV strains (Merlin 
and Toledo) were clustered and compared with other primate CMV species 
including Panine herpesvirus 2 (also known as Chimpanzee cytomegalovirus 
[CCMV]), Simian cytomegalovirus (SCCMV) and Rhesus cytomegalovirus (RhCMV). 
Fully conserved residues are in red font. Sequence alignment was derived using 
Clustal Omega (B) Secondary structure predictions by Jpred 4. H, helical regions; E, 
extended regions. 
 
3.4.  Discussion 
3.4.1. Viral exploitation of CUL4 E3 Ligase 
HIV1 has been reported to reprogram the CUL4 E3 ligase complex to facilitate viral 
replication. HIV1 encodes an accessory protein Vpr that hijacks CRL4 E3 ubiquitin ligase 
complex to degrade several DNA repair proteins, such as uracil-DNA glycosylase 2 (UNG2) 
(Bouhamdan et al., 1996), structure-specific endonuclease MUS81 (Laguette et al., 
2014), and HLTF (Hrecka et al., 2016; Lahouassa et al., 2016). Although its role in HIV1 
restriction has not been fully explored, studies have shown that they are related to HIV1 
genome replication (Yan et al., 2018; Yan et al., 2019). For the case of HIV-1 Vpr, the 
viral protein bridges the target substrate and a common CUL4 substrate receptor, DDB1 
and CUL4-associated factor 1 (DCAF1). CUL4A and CUL4B are Interchangeable for HIV 
Vpr action through the CRL4 Complex (Sharifi et al., 2014). CUL4B could also be 




Other viral protein such as SV5, which induces rapid turnover of STAT1 and STAT2 
(Didcock et al., 1999; Ulane and Horvath, 2002), and HBx (Leupin et al., 2005), interact 
with DDB1 mimicking DCAF. Structural analysis reveals that these viral proteins harbour 
an α-helical motif, which shares structure but not sequence homology with a α-helix 
found in the DCAFs (Li et al., 2010). The same helix domain is found in UL145, which 
might be the mechanism via which UL145 exploits the CRL4 E3 ligase complex to degrade 
HLTF. 
 
3.4.2. UL145 exploitation of CUL4A E3 ligase 
Here HLTF was suggested to be directed to be proteasomally degraded by UL145, but 
the interaction was not observed with conventional immunoprecipitation of 
endogenous HLTF and Western blot. A recent publication discovered that UL145 targets 
STAT2. UL145 directly binds to STAT2 and loads it onto CUL4 complex, serving as a bridge 
between STAT2 and DDB1 (Le-Trilling et al., 2020). The paper also identified a conserved 
helix in UL145 (Figure 3.10) resembling the DCAF helix domain that binds to DDB1 (Le-
Trilling et al., 2020). My current model for UL145-induced HLTF degradation is depicted 
as Figure 3.11. In this model, CUL4A serves as the scaffold, DDB1 is the adaptor protein, 
and UL145 acts as substrate receptor that captures HLTF. RBX1 is the E3 ligase that 
transfer ubiquitin from E2 to HLTF. However, I lacked convincing evidence to show that 
UL145 was bound to HLTF during degradation. There might be mechanisms other than 
CRL4 that participated in HLTF degradation. For instance, deubiquitylating enzyme 
ubiquitin-specific protease 7 (USP7) is found responsible to HLTF protein stability in 
adenocarcinomic human alveolar basal epithelial A549 cells (Qing et al., 2011). There 
might be an undiscovered correlation between UL145 and USP7. Further discussion on 












Chapter 4. Function of HLTF during HCMV 
infection 
Human cytomegalovirus (HCMV) has been reported to degrade host factors to create a 
suitable intracellular environment for replication. For example, HCMV immediate-early 
protein IE1 targets nuclear domain (ND10) component SP100 for degradation to 
antagonise acetylation of histones associated with the HCMV major IE promoter (MIEP), 
thus promoting viral gene transcription (Kim et al., 2011). Another HCMV immediate-
early protein IE2 induces stimulator of interferon genes (STING) degradation and 
reduces interferon (IFN) β production (Kim et al., 2017). Helicase–like transcription 
factor (HLTF) was rapidly degraded by HCMV viral protein UL145, suggesting that UL145 
may need to degrade HLTF to facilitate HCMV replication. One of the aims of this project 
was to explore the roles of HLTF during early HCMV infection. Here the function of both 
UL145 and HLTF in HCMV infection were investigated. 
 
4.1.  HLTF had antiviral restriction ability during early HCMV infection 
To investigate how depletion of HLTF affects HCMV infection, Dr. Katie Nightingale 
adapted an assay previously deployed to examine the role of ND10 components in 
HCMV restriction (Tavalai et al., 2011) (Figure 4.1A). To identify HCMV-infected cells, Dr. 
Richard Stanton (Cardiff University) cloned enhanced GFP (EGFP) as a C-terminal fusion 
with the immediate-early gene UL36, with a self-cleaving porcine teschovirus-1 2A (P2A) 
peptide releasing the reporter GFP following synthesis. Immediate early protein UL36 
was chosen because it was the 4th most abundantly expressed viral proteins within the 
first 6 h of infection, after IE1, IE2 and UL135. Dr. Richard Stanton performed a series of 
experiments with UL36-P2A GFP virus and found out that the insertion of GFP did not 
impede UL36 function to block Fas-mediated apoptosis (Nightingale et al., 2018). I 
generated HFFF-TERT cells stably expressing short hairpin RNA (shRNA) to knockdown 
HLTF (Figure 4.1B). SP100 acts to restrict HCMV infection and was selected as a positive 




expression in four independent experiments (Figure 4.1C). At low MOI, knockdown of 
HLTF significantly increased the efficiency of virus infection (Figure 4.1C). This effect was 
highly dependent on the viral dose (Figure 4.1D). At MOI of 0.1, the infection rate 
difference between shRNA cells and shControl cells was no longer detectable, 
suggesting that the antiviral activity of SP100 and HLTF was efficiently overcome (Figure 
4.1D). The enhancement of HCMV infection at low MOI was confirmed using five 
independently derived clustered regularly interspaced short palindromic repeats 
(CRISPR)/Cas9 knockdown lines for both SP100 and HLTF (cell lines generated by Dr. Ben 
Ravenhill, Alice Fletcher-Etherington, and Lior Soday from the lab). Expression of SP100 
and HLTF was substantially reduced in these cells, and HCMV infection was 
correspondingly significantly enhanced in these cells (Figure 4.1E&F). This suggested 
that HLTF might act to inhibit the efficiency of early HCMV infection at a low MOI 
infection, similar to that of the recognized HCMV restriction factor SP100. However, viral 
restriction provided by HLTF was not dose-dependent. For instance, HLTF knockout 
efficiency in polyclonal CRISPR/Cas9 cell line 1 was better than cell line 3, but cell line 3 







Figure 4.1. HLTF restricts early HCMV infection. 
(A) Schematic of the restriction assay. shRNA or CRISPR/Cas9 was used to stably 
knock down HFFF-TERT for a putative restriction factor or control. Cells were 
infected at low MOI with UL36-P2A-GFP virus, and the percentage of GFP+ cells 
determined at 24 h. (B) Stable expression of shRNA targeting all Sp100 isoforms 
and HLTF were confirmed with immunoblot. (C) HLTF restricts early HCMV 
infection. Application of the restriction assay at low moi (0.003 and 0.01) to HFFF-
TERT independently transduced with two different shHLTF vectors suggested that 
HLTF restricted infection at least as potently as Sp100. p-values were estimated 
using a two-tailed t-test (n=3). **p<0.005, ***p<0.0005. (D) In four independent 
experiments, flow cytometry was used to determine the percentage of GFP-
expressing shSP100 cells in comparison to shControl cells after 24 h of infection, 
conducted with a range of MOI. Representative results from one experiment are 
shown. Values shown are mean +/- standard error of the mean (SEM). p-values for 




two-tailed t-test (n=3). *p<0.05 (for both Sp100 and HLTF where indicated). (E) 
Five independent polyclonal CRISPR/Cas9 Sp100 and HLTF HFFF-TERT cell lines 
were generated, each employing integrated gRNAs with different target 
sequences within a given gene. Control cells expressing non-targeting gRNAs were 
generated in a similar manner. (F) Infection at MOI of 0.01 identified a substantial 
increase in viral replication in knock-down compared to control cells. P values 
were estimated using a two-tailed Student’s t-test (n=3). *p<0.05, **p<0.005, 
***p<0.0005, ****p<0.00005. 
 
4.2.  Characterisation of UL145  
HLTF was targeted by the undercharacterised viral protein UL145. It was therefore 
crucial to explore the function of UL145 in HCMV infection. UL145 locates in the highly 
variable UL/b’ region. The adjacent genes UL144 and UL146 have high sequence 
variability and are considered genetic mutation hotspots of HCMV (Lurain et al., 1999; 
Sijmons et al., 2015b). Despite the physical proximity to these highly variable regions, 
analysis of UL145 from different clinical HCMV isolates and laboratory strains showed 
that UL145 is highly conserved, sharing over 95% sequence identity (Sun et al., 2007). 
The function of many UL/b’ genes has been proposed and tested through 
experimentation. For example, UL144 encodes a structural homologue of tumour 
necrosis factor (TNF) receptor and regulates B and T lymphocyte attenuator (BTLA) 
(Benedict et al., 1999; Šedý et al., 2013). UL146, encodes viral C-X-C motif chemokine 
ligand 1 (CXCL1) that serve as neutrophil attractant and is able to induce calcium 
mobilization and degranulation in neutrophils (Heo et al., 2015; Lüttichau, 2010; Penfold 
et al., 1999). However, the function of UL145 had not been explored. 
 
4.2.1. Temporal expression of UL145 during HCMV infection 
UL145 was identified as an immediate early gene in an analysis of infection of HCMV 
clinical strain MOLD (Raftery et al., 2009). As for HCMV’s MIEP, the promoter of UL145 
gene is active without the requirement for expression of other HCMV proteins, and 
UL145 protein enhances MIEP activity (Raftery et al., 2009). This finding coincides with 




considerable amount of UL145 transcript was detected at 6 hpi (Figure 4.2A). In the 
previous pulsed SILAC experiment, SILAC medium containing “heavy” isotopes was 
added upon HCMV infection, and protein synthesis could be quantified by measuring 
proteins labelled with these heavy isotopes (Figure 1.11B). Protein analysis with SILAC 
labelled HCMV infection lysate showed that these UL145 mRNA were translated into 
detectable UL145 protein (Figure 4.2B, performed by Dr. Katie Nightingale). TMT based 
proteomics analysis of a complete lytic cycle (Figure 4.2D, (Weekes et al., 2014)) and 
corresponding RNA sequencing of samples from the same collection (Figure 4.2C, 
performed by Dr. Michael Weekes and Dr. Peter Tomasec [University of Cardiff]) 
revealed that UL145 continued to increase throughout HCMV lytic progression. 
 
 
Figure 4.2. Temporal expression of UL145 during HCMV infection. 
(A) HFFF-TERT cells were infected with Merlin strain HCMV at MOI of 1 for 
indicated time interval and then subjected to RT-PCR. Error bars show SEM for 
technical quadruplicates. (B) SILAC label revealed viral protein UL145 synthesis 
with in the first 18 hours of HCMV infection (MOI=5) in HFFF-TERT. (C) (D) HFFF 
cells were infected with Merlin strain HCMV at MOI of 10 and harvested at 






4.2.2. Global proteome analysis of UL145 deletion virus 
In order to understand the function of UL145 in HCMV infection, in an initial experiment, 
Dr. Katie Nightingale compared the protein changes in wild-type and ΔUL145 HCMV 
infections via proteomic analysis (Figure 4.3) with infection lysates produced by Dr. 
Peter Tomasac (University of Cardiff). HFFF cells were infected with Merlin strain WT or 
ΔUL145 HCMV at MOI of 10 for 72 h, and ratios comparing protein abundance during 
wild-type and ΔUL145 HCMV infection were calculated to monitor proteins changes 
related to UL145 deletion. As expected, UL145 deletion “rescued” HLTF down-regulation. 
Besides HLTF, deletion of the UL145 gene rescued expression of another DNA repair 
protein, the tumour protein p53 binding protein 1 (TP53BP1) (Callen et al., 2013), 
suggesting that UL145 may have wider roles in modulating the DNA-damage response. 
Notably, this data suggested that UL145 modulated expression of several interferon-
inducible proteins, including SP100, viral RNA sensor 2'-5'-oligoadenylate synthetase 
OAS2 and OAS3, and GTP-binding protein MX2. IFN signalling mediated STAT2 and HIV-
1 restriction factor SAM and HD domain containing deoxynucleoside triphosphate 
triphosphohydrolase 1 (SAMHD1) (Laguette et al., 2011) were also rescued by UL145 






Figure 4.3. Protein expression fold change induced by UL145 deletion. 
HFFF cells were infected with Merlin strain WT and ΔUL145 HCMV at MOI of 10 
for 72 h. The x-axis represents the fold change of protein expression in ΔUL145 
virus infection compared to wild-type Merlin infection in log 2 scale. The y-axis 
represents the intensity of the protein detected, which is the average of signal to 
noise, in log 10 scale. The colour of the dots represents the significance B of the 
fold change (Benjamini-Hochberg-corrected p-value). Proteins that were rescued 
by UL145 deletion are shown on the right side of the graph. 
 
4.2.3. Proteomic analysis on UL145 effects of HCMV lytic progression 
From this initial data, I performed a follow up analysis on how UL145 deletion affected 
HCMV proteins. Viral protein expression in ΔUL145 infection was compared to wild-type 
Merlin infection to calculate fold change. As shown in Figure 4.4, all of the viral proteins 
identified to have significant decreased when UL145 was deleted were Tp5 proteins 
(subsection 1.1.7), suggesting that the role of UL145 might be to inhibit the expression 
of true late genes. HLTF is part of the post-replication DNA repair machinery and the 
protein most substantially “rescued” upon infection with UL145 deletion virus 
compared to Merlin strain WT HCMV. It is possible that HLTF affects viral DNA replication 




The proposed functions of viral proteins that were down-regulated more than 2 fold in 
UL145 deletion is summarised in Table 4.1. UL145 expression modulated expression of 
virion structural proteins and viral factors that are associated with capsid trafficking and 
envelopment. Therefore, it could be inferred that UL145 might regulate the expression 
of these late genes and may therefore influence viral progeny production. 
 
 
Figure 4.4. Volcano plot of Tp-classfied viral protein fold change and its fold 
change significance in ΔUL145 virus infection. 
The x-axis represents the fold change of viral protein expression in ΔUL145 virus 
infection compared to wild-type Merlin infection in Log 2 scale. The y-axis 
represents the significance of the fold change (p-value) in log 10 scale. The colour 





Table 4.1. Viral proteins that were down-regulated due to UL145 deletion. 
The name, Tp class, Tr class (classifications from (Weekes et al., 2014)), and the 
proposed function (derived from (Mocarski et al., 2013)) of viral proteins that were 
down-regulated by more than 2 fold. 
Viral Protein Tp Class Tr Class Proposed Function 
UL53 Tp5 Tr5 Nuclear egress 
UL32 Tp5 Tr5 Nucleocapsid-proximal stabilization protein 
UL33 Tp5 Tr5 Virion envelope 
UL147 Tp5 Tr5 Putative chemokine 
UL83 Tp5 Tr5 Major tegument; suppresses interferon response 
UL46 Tp5 Tr5 Capsid triplex component 1; interacts with UL85 
UL100 Tp5 Tr5 8-transmembrane ptoein; virion envelope gp; role 
in envelopment 
UL74 Tp5 Tr5 Virion envelope gP; delivery and release of virions 
UL85 Tp5 Tr5 Capsid triplex component 2; interacts with 
TRI1/UL46 
UL94 Tp5 Tr5 Tegument, Secondary envelopment in association 
with pp28 




4.2.4. HCMV titration in HLTF CRISPR cell lines 
The foundation for comparative studies between WT and ΔUL145 was virus titration. 
The two viruses had to be titred together and further experiments were performed with 
this information to ensure that comparable amounts of infectious virions were added to 
WT and ΔUL145 infections. In the previous restriction assay, depletion of HLTF resulted 
in increased HCMV infection (Figure 4.1). On the other hand, ΔUL145 failed to degrade 




HCMV failed to degrade might lead to underestimation of ΔUL145 virus titre in WT HFFF-
TERT infection. Therefore, titrations of two separate batches of WT and ΔUL145 HCMV 
were performed in WT and monoclonal HLTF CRISPR knock-out HFFF-TERT cells. 
If HLTF affected ΔUL145 titration, I should observe lower titre ratio comparing WT to 
ΔUL145 (WT/ΔUL145). However, titre ratios generated in different cells were similar in 
two biological duplicates (Table 4.2). Results from both batches revealed that titration 
in monoclonal HLTF CRISPR knock-out HFFF-TERT cells was not substantially different 
from titration in WT HFFF-TERT cells. Therefore, titration results using WT HFFF-TERT 
cells were used in experiments and further WT and ΔUL145 HCMV titration was 
performed only in WT HFFF-TERT cells. 
 
Table 4.2. HCMV titration in WT and HLTF CRISPR cell lines 
Two batches of Merlin strain WT and ΔUL145 HCMV containing UL36-P2A-GFP 
were titred in in WT and monoclonal HLTF CRISPR knock-out HFFF-TERT cells with 
methods described in subsection 2.3.4. Results and the titre ratio of WT/ΔUL145 
in the same type of cells are listed here. 
Batch 1 
Virus titre (PFU/ml) WT ΔUL145 Titre ratio WT/ΔUL145 
Titration in  WT HFFF-TERT 2.14 X 107 1.15 X 107 1.86 
Titration in HLTF CRISPR 
HFFF-TERT (1B1) 
1.73 X 107  7.52 X 106 2.30 
Batch 2 
Virus titre (PFU/ml) WT ΔUL145 Titre ratio WT/ΔUL145 
Titration in  WT HFFF-TERT 1.99 X 107  6 X 107 0.332 
Titration in HLTF CRISPR 
HFFF-TERT (5B1) 
1.68 X 107  5.1 X 107 0.329 
 
 
4.2.5. UL145 and HCMV replication 
The decrease of late HCMV proteins in UL145 deletion hinted that UL145 might impair 




proteins were affected. The infectivity of ΔUL145 in comparison with WT HCMV was 
analysed with growth curve analysis. HFFF-TERT cells were infected with GFP-encoded 
ΔUL145 or its WT control at MOI of 1. Supernatant were collected at multiple time points 
and the virus concentration of each collection was measured altogether by infecting 
HFFF-TERT cells in 24-well plates and FACS determination of infected GFP positive cells 
(Figure 4.5A).  
Four independent experiments were carried out, with biological duplicates (A and B) 
being set up each time. Infectious particles were detected 3 days post infection. As 
shown in Figure 4.5B results were not consistent. In 6/8 (75%) times, ΔUL145 produced 
fewer infectious particles at the first measured time point after the completion of a lytic 
cycle (day 4 in the first experiment [top left], and day 5 in the other three). This low 
virion production of the first lytic cycle was also observed with WT HCMV, but only 1/8 
(12.5%, third experiment [bottom left]). However, at day 7 or 8 post infection, all 
ΔUL145 infections produced as many infectious particles as WT infections. This 
suggested that UL145 was not an essential viral gene in HCMV replication and UL145 
might possibly affect the first cycle of viral replication, although the effect was not 
evident after a day or two. 
I took a number of steps to make sure I had infected cells with comparable titres of WT 
and ΔUL145 viruses. After the first growth curve experiment, I thought that the effect of 
UL145 deletion on HCMV replication might be subtle and it was crucial to have similar 
amount of virions for the infections. Even though the viruses used in the experiment had 
been titred at least twice, separate flasks of cells were generated for parallel infection 
and harvested on day 2 post infection starting from experiment 2. In experiment 3 and 
4, a proportion of the infection mix was saved and stored with the supernatant 
collections and titred together. There were always less than 12% difference on the input 










Figure 4.5. Growth curve analysis of ΔUL145 HCMV compared to WT. 
(A) Schematic of the growth curve assay. HFFF-TERT cells stably expressing 
tetracycline (tet) were incubated with serum-free DMEM for 24 h to induce a 
reversible cell cycle arrest prior to infection with HCMV-GFP at MOI of 1. The 
Merlin strain viruses encoded tet-regulated (tet-on) UL128 and UL36-P2A-GFP. 
Supernatants from the infected cells were collected and replenished at indicated 
time points. Virus titration of the supernatant and the viral mix was performed in 
24-well plates seeded with HFFF-TERT-tet cells. Percentage of GFP positive cells 
reflected the percentage of infected cells which was used to calculate virus titre. 
(B) Results of four independent growth curve analysis are shown here, each 
analysis was performed in biological duplicate. In the latter two analyses 
(experiments 3&4), a portion of infection mix was stored and titred together with 
the supernatant collections to show that the amount of input viruses was 
comparable. Error bars show SD for technical duplicates in virus titration. In the 
second experiment (experiment 2), technical duplicates were not included and 
therefore no error bar is shown. (C) Percentages of GFP positive cells were 
measure in parallel at day 2 post infection for experiments 2, 3&4. 
 
4.2.6. Viral DNA replication 
The preliminary proteomics analysis of ΔUL145 HCMV suggested that UL145 
downregulated two post DNA replication repair proteins, HLTF and TP53BP1. It was 
therefore possible that UL145 had an important modulatory role in viral DNA replication. 
To test this, HFFF-TERT cells were infected with ΔUL145 and its WT control at two 
different MOIs and HCMV DNA copy number was measured. The amount of HCMV gB in 
DNA samples was compared with a HCMV BACmid to calculate viral DNA copy number 
using SYBR green qPCR. I validated my assay by performing a serial dilution of BACmid 
to test HCMV gB primers over a range of dilutions. This method can accurately detect 
copy numbers within the range of 10-10,000,000 (Figure 4.6A). As shown in Figure 4.6 
B&C, viral DNA of ΔUL145 replicated at a rate not substantially different from WT, 
producing three times more viral DNA at 3 days post infection. This result implied that 
the potential, albeit inconsistently observed regression in virus production in the first 
lytic cycle observed in ΔUL145 was not caused by a defect in viral DNA replication.  
Interestingly, after 36 hpi, DNA replication rates seemed to be comparable between the 
two viruses, as the DNA replication curves were nearly parallel at both MOIs, suggesting 




A further experiment with shHLTF HFFF-TERT cell lines and ΔUL145 HCMV revealed that 
genome replication of ΔUL145 was not affected by HLTF. Knocking down HLTF with 
shRNA did not have unidirectional effect on ΔUL145 DNA replication. shHLTF2-
expression cells exhibited improved knockdown efficiency compared to shHLTF1 cells 
(Figure 4.1B) and facilitated ΔUL145 genome replication, while ΔUL145 produced less 







Figure 4.6. Viral DNA replication assay suggested that the rate of replication of 
ΔUL145 HCMV and WT viral DNA was similar. 
(A) HCMV BACmid was serially diluted by 10 fold according to its copy number. 
The conversion from DNA concentration to HCMV copy number was calculated 
using an online calculator to determine the number of copies of a template 
(http://cels.uri.edu/gsc/cndna.html) with the BACmid size (243,724bp). The 
relative gB expression, in Log 10 scale, was normalized with the lowest gB 
expression (10 copies of HCMV). (B&C) HFFF-TERT cells were infected with WT and 
ΔUL145 HCMV (Merlin non-GFP viruses) at MOI of (B) 0.1 and (C) 0.01. Total DNA 
of infected cells was extracted and HCMV gB DNA fragments in each sample 
collection were measured with SYBR green qPCR. Genomic GAPDH was used as 
internal loading control for qPCR. HCMV copy number was calculated with HCMV 
BACmid as standard. Viral DNA replication curve is shown in log 10 scale on the 
left and the viral DNA ratio between ΔUL145 and WT is shown on the right. Error 
bars show SEM for technical triplicates. 
 
 
Figure 4.7. Viral DNA replication assay of ΔUL145 in shHLTF cells. 
HFFF-TERT cells stably expressing shRNA targeting HLTF were infected WT with 




DNA of infected cells was extracted and HCMV gB DNA fragments in each sample 
collection were measured with SYBR green qPCR. Genomic GAPDH was used as 
internal loading control for qPCR. Fold change were calculated against ΔCt value 
of control 1 at 24 hpi. Error bars show SD for biological duplicates of infection. 
 
Overall, UL145 is expressed during the earliest phases of HCMV infection. Deletion of 
UL145 did not substantially affect HCMV viral DNA replication, suggesting that 
restriction by HLTF might occur at a different level. Further work including repeats of the 
experiments shown in Figure 4.6 and Figure 4.7 is required to validate these conclusions. 
 
4.3.  Interferon regulation by UL145 and HLTF 
Several interferon inducible proteins, such as SP100, OAS2, OAS3, MX2, were rescued 
by UL145 deletion (Figure 4.3), suggesting UL145 might decrease interferon production 
during HCMV infection. It is possible that UL145 degraded HLTF to attenuate type I 
interferon production and promoted viral infection as seen in the previous restriction 
assay with HLTF knockdown and knockout cells Figure 4.1. To test this hypothesis, the 
ability of ΔUL145 to induce IFNβ was explored compared to WT HCMV, and the 
involvement of HLTF was investigated with HLTF knockdown or knockout cell lines. This 
part of the project is still ongoing and will need more work as discussed in the later 
section of this chapter and chapter 6. 
 
4.3.1. Kinetics of IFNβ induction during HCMV infection 
The type I IFN response to HCMV infection is complicated, with various mechanisms 
triggering IFNβ transcription. In particular, TLR2 and CD14 detect viral glycoprotein gB 
and gH (Boehme et al., 2006; Compton et al., 2003); cGAS, TLR9, IFI16, and ZBP1 detect 
viral dsDNA (DeFilippis et al., 2010; Li et al., 2013a; Paijo et al., 2016). On the other hand, 
there are multiple counteractions deployed by the virus to subvert IFNβ activation. 
HCMV tegument protein UL83 (pp65) exerts multifaceted regulation on IFNβ. Both IRF3 




by UL83 (Abate et al., 2004; Browne and Shenk, 2003). Moreover, UL83 binds to IFI16 
and cGAS, and directly supresses their detection of HCMV DNA (Biolatti et al., 2018; Li 
et al., 2013a). Another tegument protein, UL82 (pp71), negatively affects IFNβ induction 
by disrupting STING translocalisation, an essential step for IRF3 activation (Fu et al., 
2017). STING is affected by glycoprotein US9 as well, inhibiting IRF3-medicated IFNβ 
activation (Choi et al., 2018). In addition, IE2 is considered the master suppressor of IFNβ 
induction. It has been shown to keep NFκB from binding to the IFN-β promoter 
16378994, and direct STING to proteosomal degradation (Kim et al., 2017). 
Using Merlin WT GFP virus, I found that IFNβ transcription was found being induced at 
early time points of infection, and then dampened at later time points (Figure 4.8A). The 
drop of IFNβ protein production experienced a delay compared to transcripts (Figure 
4.2B). At 24 hpi, IFNβ protein remained high when transcription activity had already 
fallen. Two reasons may contribute to this. First and mostly, IFNβ protein has much 
longer half-life of 16 h (Harari et al., 2015), in respect to a shorter half-life of 4 h observed 
with IFNβ mRNA (Abe et al., 2012). Secondly, the rate HFFF cells taking up IFNβ protein 
may also affect the amount of available for ELISA measurement.  
In different experiments, I detected peak IFNβ transcription at different time points. A 
more rapid peak IFNβ response was observed in the experiments shown in Figure 4.9 
and Figure 4.13, with induction already dampened by 12 hpi. Therefore, it is crucial to 
consider the time of sample harvest when analysing IFNβ induction during HCMV 
infection carefully. In a single experiment, infection with AD169 strain HCMV, the 
observed increase in IFNβ mRNA was more substantial that observed with Merlin strain 
HCMV (Figure 4.9 compared to Figure 4.8). More biological replicates should be included 
in order to fully characterise how IFNβ mRNA and protein are regulated during HCMV 
infection, with different strains. However, this optimisation experiments were 
performed as a result of less-than-convincing data resulting from other IFNβ 
experiments, which might be one of the reasons I have not yet generated convincing 





Figure 4.8. IFNβ induction time dependent kinetics during HCMV lytic cycle.  
HFFF-TERT cells were infected with Merlin WT HCMV-GFP (Merlin with tet-on 
UL128) at MOI of 1. (A) Infected cells were collected at multiple time points as 
indicated, and subjected to RT-qPCR (Taqman) probing IFNβ using GAPDH as 
internal control. Fold change was calculated setting time 0 collection as 1. Error 
bars show SEM of technical triplicates. (B) In a separate experiment, supernatant 
of infected cells were collected and processed with IFNβ ELISA measurement. 




Figure 4.9. IFNβ transcriptional induction by AD169 at 6 and 12 hpi. 
HFFF-TERT cells were infected with AD169 strain HCMV-GFP at MOI of 5 for 6 and 
12 hours. RT-qPCR (Taqman) probing IFNβ using GAPDH as internal control was 
performed setting mRNA abundance of mock infection at 6 hpi as 1. 
 
4.3.2. UL145 may modulate IFNβ induction                                                                                                                                                   
HFFF-TERT cells were infected with WT and ΔUL145 HCMV-GFP viruses at two different 
MOIs. Supernatants from infected cells were harvested at 24 hpi and IFNβ concentration 




during infection by both viruses. However, ΔUL145 did not induce significantly more 
IFNβ production compared to WT (Figure 4.10A). In a separate experiment, supernatant 
and cell lysates were collected at the same time 24 hpi. RT-qPCR showed that ΔUL145 
induced significantly more IFNβ transcripts, however, this increase was not translated 
into more IFNβ protein (Figure 4.10B). This may suggest that ΔUL145 did not 




Figure 4.10. ΔUL145 HCMV induced more IFNβ transcripts but not IFNβ protein 
at 24 hpi. 
(A) HFFF-TERT cells were infected with WT and ΔUL145 HCMV-GFP viruses (Merlin 
without tet-on UL128) at MOI 1 or 3. Supernatant was harvested 24 hpi and IFNβ 
protein was detected with ELISA. Error bars show SD of two biological replicates. 
(B) HFFF-TERT cells were infected with WT and ΔUL145 HCMV-GFP viruses at MOI 
of 1 for 24h. IFNβ protein was measured from supernatant while IFNβ mRNA was 
measured with Taqman qPCR, with GAPDH as internal control.  Error bars show SD 





The fact that the HLTF restriction assay was MOI dependent prompted me to examine 
whether ΔUL145 Merlin strain HCMV induced less IFNβ than WT at low MOI. Given that 
measuring low concentration of IFNβ with ELISA could create larger observational error, 
I resorted to analysing IFNβ transcripts using RT-qPCR with FACS sorted cells with 
infection at MOI of 0.03. HCMV-GFP viruses allowed me to isolate infected population 
and uninfected populations at 22 hpi according to their GFP expression.  Isolated cells 
were washed once with PBS and lysed at 24 hpi to extract total RNA (Figure 4.11A). At 
24 hpi, WT virus hardly induced more IFNβ in infected cells compared to uninfected cells. 
ΔUL145 on the other hand induced 6 times more IFNβ transcripts in infected cell 
compared to uninfected cells at 24 hpi. The difference of IFNβ transcripts induced by 
two viruses was statistically significant. Additionally, the bystander uninfected cells in 
ΔUL145 infection produced around half (50.1%) of IFNβ transcripts compared to the 
bystander uninfected cells in WT infection. (Figure 4.11B) 
 
 
Figure 4.11. Low MOI ΔUL145 infection had increased IFNβ induction at 24 hpi. 
(A) Schematic of the FACS sorting of HCMV infection at low MOI. HFFF-TERT cells 




22 hours. Infected cells were concentrated at 106 cells/ml and sorted using 
FACSMelody as shown in the gates above. Total RNA from the sorted cells was 
extracted at 24 hpi for RT-qPCR (B) Reverse transcription and Taq-man qPCR were 
performed to probe IFNβ with GAPDH as internal control. Error bars show SD of 
technical duplicates. 
 
A repeat was attempted with three MOIs (0.3, 0.1, 0.03) of each virus. However, I 
underestimated the time to sort enough infected cells for RNA extraction and RT-qPCR. 
By the time the cells were lysed for RNA extraction, it was around 30 hpi. As shown in 
Figure 4.12, IFNβ induction could not be observed in any infection condition. From this 
experiment, it was difficult to tell whether UL145 deletion had impact on IFNβ induction 
compared to WT HCMV. 
 
Figure 4.12. RT-qPCR analysis of IFNβ transcripts in WT and ΔUL145 at three 
different MOIs. 
HFFF-TERT cells were infected with WT HCMV-GFP (Merlin with tet-on UL128) at 
MOI of 0.3, 0.1, or 0.03 for 22 hours. Infected cells were concentrated at 106 
cells/ml and sorted. Sorted cells were lysed at 30 hpi and subjected to RT-qPCR 








One of the main aims of this project was to characterise the function of HLTF during 
HCMV infection. To investigate whether HLTF regulates IFNβ induction, HFFF-TERT 
shHLTF cell lines were infected with WT HCMV and IFNβ qPCR was perform with RNA 
collections at 3, 6, 12 hpi. The results were not straightforward. In the control shRNA 
cells, IFNβ gradually increased from 3 hpi to 6 hpi, and this induction was dampened at 
12 hpi. When HLTF was knocked down, HCMV triggered IFNβ production at 3 and 12 hpi, 
but not 6 hpi. This pattern was observed in both HLTF knock down cell lines. (Figure 4.13)  
 
 
Figure 4.13. IFNβ transcript analysis in shHLTF cells. 
HFFF-TERT shHLTF cell lines were infected with Merlin WT HCMV (non-GFP) at MOI 
of 1. Mock infection was also performed alongside. Infected cells were harvested 
at 3, 6, and 12 hpi for RT-qPCR (Taqman) measuring IFNβ transcripts, using GAPDH 
as internal control. Here IFNβ fold change against corresponding mock infection is 
graphed. Error bar show SD of technical duplicates.   
 
An enzyme-linked immunosorbent assay (ELISA) assay was followed to examine whether 
this abnormal IFNβ mRNA induction pattern translated into IFNβ protein. Two 
monoclonal CRISPR knocked out HLTF cells were included together with their control 
counterparts. These genetically modified cells were infected with WT and ΔUL145 HCMV, 




was subjected to multiplex beads-based ELISA. However, this method resulted in high 
variation in technical duplicates, in particular because of the simultaneous 
quantification of different cytokines (Figure 4.14A). Thus, the same collection of 
supernatant was analysed again with a highly sensitive 96-well-based ELISA kit. WT and 
ΔUL145 HCMV induced similar levels of IFNβ in all cell lines, similar to what had been 
observed in Figure 4.10. As shown in Figure 4.14B, HCMV induced much less IFNβ in 
CRISPR HLTF cells compared to control cells. This suggested that the decreased IFNβ 
transcription at 6 hpi resulted in less IFNβ protein production. 
 
 
Figure 4.14. ELISA assay of WT and ΔUL145 HCMV infection in HLTF knock out 
cells. 
CRISPR HFFF-TERT cells were infected with WT and ΔUL145 HCMV (non-GFP) at 
MOI of 1. Supernatant of infected cells was collected at 24 hpi and processed 
through IFNβ ELISA. Error bars show SEM of technical duplicates. Single clone 
CRISPR cells were generated by serially diluting polyclonal CRISPR cells and 
antibiotic selection by Dr. Ben Ravenhill, Alice Fletcher-Etherington, and Lior Soday 
from the lab. IFNβ ELISAs were performed with (A) multiplexed bead-based ELISA 
kit and (B) well-based IFNβ ELISA kits. 
 
4.3.4. No evidence for HLTF participation in IFN induction and signalling pathways 
In order to explore further the role of HLTF in IFN induction and signalling pathways, 
reporter assays with IFNβ promoter (pIFNβ), NFκB responsive element, and interferon 




plasmids each contained one of the response elements driving a firefly luciferase gene. 
Plasmids were co-transfected with one of the shHLTF plasmids mentioned in Figure 4.1B 
into 293T cells. Forty-eight hours post transfection, cells were treated with the stimulus 
of the corresponding responsive element for 6 h. The IFNβ promoter was activated with 
Sendai virus infection, NFκB responsive element was activated with TNFα, and ISRE was 
activated with human interferon alpha (IFNα). Promoter activity was measured by 
luciferase production. 
In an experiment performed in biological triplicate, SeV infection induced varied levels 
of IFNβ transcription within shHLTF and control cells, making it difficult to interpret 
whether knocking down HLTF in this context modulated SeV-mediated IFNβ activation 
(Figure 4.15A).Figure 4.15B shows that knocking HLTF gene did not substantially 
modulate NFκB activation by TNFα (Figure 4.15B). In addition, HLTF did not apparently 






Figure 4.15. Luciferase reporter assay with cells transfected with shHLTF and 
treated different stimuli. 
293T cells were transfected with reporter plasmid, and GFP expressing plasmid 
was also transfected as a transfection internal control in a 96-well using liposomal 
transfection reagent (Mirus). Forty-eight hour post transfection, cells were 
infected with Sendai virus (SeV) for 6 hours, followed cell lysis and luciferase 
substrate incubation. Luminescence reading was normalised with GFP 
fluorescence reading to calculate relative luciferase activity. Similar experiments 
were performed with (B) TNFα-induced NFκB reporter plasmid and (C) IFNα 
induced interferon stimulated responsive element (ISRE) reporter plasmid. Error 
bars show SEM of biological triplicates. 
 
Besides the mitochondrial RIG-I viral sensing pathway, Sendai virus also activates IFN 




concerns that liposomal transfection reagents might interfer with Sendai virus-mediated 
pIFNβ activation, I established 293T cell lines that stably expressed shHLTF for reporter 
assays. In transduced cell lines, SeV activated similar level of pIFNβ activity in all 4 cell 




Figure 4.16. Luciferase reporter assay with cells transduced with shHLTF and 
treated different stimuli. 
293T cells stably expressing shHLTF were transfected with luciferase expressing 
plasmid driven by IFNβ promoter, which contains binding sites for activated IRF3 
and NFκB, and GFP expressing plasmid as transfection internal control in a 96-well. 
Forty-eight hpur post transfection, cells were incubated with stimuli-containing 
DMEM for 6 hours, followed cell lysis and luciferase substrate incubation. 
Luminescence reading was normalised with GFP fluorescence reading to calculate 






4.3.5. HLTF bound to HCMV DNA and cellular DNA 
Since HLTF harbours a DNA binding domain that binds to SERPINE1 and HIV1 promoters 
and the SV40 enhancer (Ding et al., 1996; Sheridan et al., 1995), I postulated that HLTF 
might serve as a viral DNA sensor detecting HCMV DNA triggering relevant kinases for 
IFNβ induction signalling. To test whether HLTF selectively binds to HCMV DNA, 
chromatin immunoprecipitation (ChIP) assay was performed in HFFF-TERT cells infected 
with ΔUL145 for 6 hours, the time prior to HCMV DNA replication, and 72 hours, the 
time for a complete lytic cycle, to analyse DNA fragment associated with HLTF.  
Several ChIP conditioning experiments were carried out with HFFF-TERT cell lysates to 
optimise the length of formaldehyde crosslink time, the length of sonication, and the 
repeats of washes. Ideally, after crosslink and sonication, sizes of fragmented DNA 
would be around 1 kb. I tested formaldehyde crosslink for 10 min and 60 min, in 
combination of sonication cycles of 20, 40, 60, and 80 (30 sec on and 30 sec off in each 
cycle). When cell lysates were incubated with formaldehyde for 60 min, not even 40 min 
of sonication (80 cycles) fragmented DNA. A 10-min formaldehyde crosslink, followed 
by 40 cycles of sonication was chosen as most of the fragmented DNA molecules under 
this condition had the size around 1 kb (Figure 4.17A). 
To optimise washing conditions, sonicated DNA from HFFF-TERT was incubated with 
anti-RNA pol III antibody (positive control), which associates with DNA binding RNA pol 
III, or mouse IgG (negative control), which does not specifically bind to any protein. Here 
I was attempting to find a washing condition that allowed DNA to be detected for anti-
RNA pol III precipitants but not IgG precipitants. Six washes with the washing buffer 
supplied by the manufacturer was compared with 12 washes. Twelve washes were too 
rigorous as no DNA could be detected in anti-RNA pol III precipitants and thus 6 washes 





Figure 4.17. ChIP conditioning for crosslink, sonication, and wash steps. 
Conditioning experiments were performed with components from the Imprint 
ChIP kit (Sigma). (A) 1 X 106 HFFF-TERT cells were incubated with 1% (v/v) 
formaldehyde for 10 or 60 min at room temperature. Glycine was added to a final 
concentration of 125 mM to quench formaldehyde after crosslink. Cell nuclei were 
extracted with Nuclei Preparation buffer and then lysed with shearing buffer. DNA 
was sheared by water-cooled sonication (Diagenode Bioruptor), with various 
cycles of 30 sec “on” and 30 sec “off”. 0.2 M NaCl Solution was then added for an 
incubation of 90 min at 65 °C to de-crosslink protein-DNA complex. DNA were 
extracted with a silica-based column and the resulting DNA was subjected to gel 
electrophoresis with SYBR green dye-containing 1% agarose gel in Tris-acetate-
EDTA (TAE) buffer. DNA signal was visualised under UV light. (B) Sonicated cell 
lysates were incubated with mouse anti-RNA pol III antibody or a control mouse 
IgG (mIgG) at 4°C overnight in an antibody binding well. Supernatant was remove 




12 times. 0.2 M NaCl Solution was then added for an incubation of 90 min at 65 °C 
to de-crosslink protein-DNA complex. Precipitant DNA were extracted with a silica-
based column. DNA samples were analysed with PCR probing human genomic 
GAPDH. Resulting DNA samples were subjected to gel electrophoresis with SYBR 
green dye-containing 1% agarose gel in TAE buffer and visualisation under UV light.   
 
After optimisation, an initial attempt at an experimental ChIP assay was performed and 
the resulting DNA samples were analysed using SYPR green QPCR. Histone H3 antibody 
was used IP positive control and rabbit IgG (rIgG) was used as negative control. Histone 
H3 unselectively binds to all DNA and control rabbit IgG does not specifically bind to any 
protein. Precipitant lysates were probed for HCMV major immediate early promoter 
(MIEP) and origin of lytic replication (oriLyt) as HCMV DNA fragments. Primers targeting 
human globin β promoter (HGBP) was used as HLTF DNA binding positive control 
(Mahajan and Weissman, 2002) while genomic GAPDH (gGAPDH) was designed as a 
negative control. The SYBR green melting curve analysis on the end PCR products 
indicated that multiple amplicon products were detected for oriLyt and HGBP, 
suggesting that PCR conditions for these primers were not optimised and non-specific 
primer binding occurred. Thus, I designed two new primers for oriLyt and HGBP, and 
tested them with different annealing temperature.  One of the new primers were 
selected to replace the original (marked in red), and the annealing temperature was 
adjusted to 56 °C (Figure 4.18). 
 
 
Figure 4.18. PCR conditioning for oriLyt and HGBP. 
HFFF-TERT cells were infected with Merlin WT HCMV at MOI of 1 for 72 h. Total 
DNA of the cells were extracted with QIAamp DNA blood mini kit (QIAGEN). PCR 




indicated. Resulting DNA samples were subjected to gel electrophoresis with SYBR 
green dye-containing 1% agarose gel in TAE buffer and visualisation under UV light. 
 
With new sets of primers and optimised annealing temperature, I performed the second 
ChIP assay. The amount of specific DNA fragment associated with a given antibody was 
adjusted according to the total DNA input of the immunoprecipitation. Whether HLTF 
bound to a certain DNA fragment was determined in comparison with that DNA 
fragment precipitated with rabbit IgG, which theoretically should be none. Histone H3 
precipitation was designed to serve as a positive control, being anticipated to 
immunoprecipitate viral and cellular DNA, compared to rIgG immuniprecipitation. 
Overall, histone H3 did not precipitate much more DNA compared to rIgG control, 
especially at 6 hpi. Therefore, technical error easily led to statistical insignificance, as 
demonstrated with HGBP and gGAPDH QPCR analysis of 6 hpi lysates. A better positive 
control antibody could be used to improve this assay. Nonetheless, HLTF still bound to 
significant amounts of oriLyt and HGBP DNA compared to IgG at 6 hpi. At 72 hpi, both 
HLTF and histone H3 associated with a higher percentage of viral DNA, possibly because 
there were more viral DNA in the nucleus at the late stage of HCMV infection. Besides 
viral DNA, HLTF was also found associated with cellular DNA, including gGAPDH, which 
was designed to serve as negative control. One possible conclusion of this experiment 
was that HLTF bound to viral and cellular DNA non-selectively, similarly to histone H3. 
Overall, however, time constraints and COVID-related lockdown precluded further 









Figure 4.19. ChIP assay of HLTF binding DNA during ΔUL145 infection. 
Cell cycle synchronised HFFF-TERT were infected with Merlin ΔUL145 at MOI of 5, 
cell lysates were harvested at 6 and 24 hpi with sonication. Immunoprecipitation 
were performed with rabbit polyclonal anti-HLTF antibody, mouse anti-histone H3 
antibody, and rabbit IgG. Protein associated DNA were extracted and DNA 
fragments of MIEP, OriLyt, HGBP, gGAPDH were measured with SYBR green qPCR, 
in comparison with DNA extraction 20% of IP lysate. Error bars show SD of two 
technical duplicates of qPCR.  
 
 
4.4.  Quantitative proteomics revealed ΔUL145 infection kinetics 
4.4.1. UL145 effects on interferon production over time 
A conclusion of the previous ΔUL145 proteomic analysis was that UL145 might modulate 
IFNβ expression at 72 hpi (Figure 4.3). Increased IFNβ protein production was not 
detected at 24 hpi with ELISA even though IFNβ transcription had increased in RT-qPCR 
analysis (Figure 4.10). These results suggested that it was important to perform a 
detailed analysis on UL145 regulation of IFN and IFN-stimulated proteins over time. Thus, 




4.20). In this 3-h mass spectrometry experiment, 2334 proteins were identified and 
quantified, including 64 HCMV proteins. 
 
 
Figure 4.20. Schematic of a TMT based MS experiment analysing WT and 
ΔUL145 over time. 
HFFF-TERT cells were infected with Merlin strain WT and ΔUL145 HCMV-GFP (with 
tet-on UL128) at MOI of 5. Prior to infection, cells were treated with 
dexamethasone-containing serum free medium for 24 h. Cells lysates were 
harvested at the indicated time points and digested into peptides with trypsin and 
LysC prior to TMT labelling. Digested peptides were subjected to a 3-h MS3 
proteomics analysis. 
 
Fold change comparing protein abundance in WT and ΔUL145 infections at each time 
point was calculated. Proteins that were up-regulated upon UL145 deletion, (i.e. 
proteins decreased by UL145 expression), are shifted to the right side of the graph, while 
proteins that were down-regulated by UL145 deletion, (i.e. the proteins increased by 
UL145 expression), are shifted to the left (Figure 4.21). Most of the interferon-related 
proteins that were previously identified to be affected by UL145 deletion, such as SP100, 
OAS2, and MX2, were not quantified in this single-shot experiment most likely reflecting 
the relative abundance of these proteins in comparison to other cellular proteins. More 
proteins would be anticipated to be quantified by an analysis of fractionated peptide 
samples.  
At 12 and 24 hpi, most of the proteins significantly up- or down-regulated by UL145 
deletion (p<10-10) were HCMV proteins (13/28 at 12 hpi and 7/14 at 24 hpi). Host 




(UNC80), cilia- and flagella-associated protein 100 (CP100), NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex subunit 4 (NDUB4), and NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex subunit 2 (NDUA2) have not previously been found to 
be regulated by interferon. However, at 48 and 72 hpi, interferon-induced protein with 
tetratricopeptide repeats (IFIT) 2 and 3 were found to be rescued by UL145 deletion 
(Figure 4.21), consistent with the previous data (Figure 4.3). Hierarchical clustering of 
fold change comparing protein abundance in WT and ΔUL145 infections at each time 
point identified more interferon inducible proteins, including IFIT1, ubiquitin-like 
interferon stimulated gene 15 (ISG15), and E3 ubiquitin-protein ligase DTX3L that were 
upregulated in cells infected with the UL145 deletion virus (Figure 4.22). A closer look at 
the expression patterns of these proteins characterised a distinctive feature of ΔUL145. 
In WT infection all four proteins peaked at 12 or 24 hpi, then the protein expression 
gradually decreased. In ΔUL145 infection, expression of IFIT proteins peaked at 24 hpi, 
and their decline was slower compared to WT. ISG15 displayed a delayed peak at 48 hpi 
instead at 24 hpi (Figure 4.23). Interferon regulates expression of these proteins. The 
expression profiles observed here suggested a possible trend of higher IFNβ at 48 and 
72 hpi in ΔUL145 infection. However that this would need at least two more biological 
repeats to determine if there was a genuine statistically significant change. 





Figure 4.21. Scatter plots showing proteins up- and down-regulated during 
ΔUL145 infection compared to WT. 
The x-axis represents the fold change of protein expression in ΔUL145 virus 
infection compared to WT infection in log 2 scale. The y-axis represents the 
average intensity of the protein detected, which is the sum of signal to noise, in 
log 10 scale. The colour of the dots represents the significance B of the fold change 
(estimated using a Benjamini-Hochberg-corrected p-value). Proteins that were up-
regulated by UL145 deletion are shown on the right side of the graph while those 
which were down-regulated were shown on the left side. Protein names of some 








Figure 4.22. Hieratical clustering of fold change over time between WT and 
ΔUL145. 
Hierarchical clustering of proteins quantified in WT and ΔUL145 time course 
according the fold change of protein abundance in ΔUL145 infection compared to 








Figure 4.23. Protein abundance of interferon inducible proteins IFIT1, IFIT2, 
IFIT3, and ISG15 during WT and ΔUL145 infection. 
The relative protein abundance of 4 interferon inducible proteins measured in 
TMT based proteomics analysis of WT and ΔUL145 infection at 12, 24, 48, and 72 
hpi. The highest reading of each protein was set as 1. 
 
4.4.2. Possible UL145 kinetic regulation of viral proteins 
In Figure 4.24, many viral proteins significantly dysregulated by UL145 deletion at 12 and 
24 hpi were HCMV Tp5 proteins (13 Tp5 proteins at 12 hpi, 7 Tp5 proteins at 24 hpi, with 
fold change significance p<10-10). In a previous comparison of viral protein expression in 




fold (Figure 4.4), and were enriched in Tp5-class proteins. In my repeat temporal analysis, 
6 of the same proteins were quantified, but none of these were down-regulated by 
UL145 deletion at 72 hpi, weakening the hypothesis that UL145 may regulate HCMV late 
gene expression via its effect on HLTF.  
At 12 and 24 hpi, all viral proteins were significantly up-regulated (p<10-20) by UL145 
deletion, including UL83, UL25, and UL94 were classified as Tp5 proteins (Figure 4.24). 
Their up- or down-regulation was not observed at later time points at 48 and 72 hpi. For 
instance, tegument protein UL94 was up-regulated by 1.5 fold at 12 hpi, but its 
expression in ΔUL145 infection seemed unchanged compared to WT infection at 24, 48, 
and 72 hpi. These proteins are structural tegument proteins that express at the highest 
levels at late stage (~72 h) HCMV infection. Their up-regulation at 12 hpi might merely 
have reflected more input virions in ΔUL145 infection compared to WT or UL145-
mediated viral structural protein degradation. One way to have confirmed or refuted 
this hypothesis would have been to have measured expression of the viral protein the 
virus titration was based on, UL36 by proteomics. However, UL36 was not quantified in 
this 3-h MS analysis. WT and ΔUL145 viruses used in this experiment had GFP tagged to 
UL36, and GFP was used as infection indicator. Another possibility would have been to 
have performed simultaneous infections in T25 flasks to measure the % infection 
contemporaneously with the experiment. However, such additions would have used 
substantial additional amounts of limited stocks of virus, and the titrations had already 
been performed extensively. 
Nonetheless, in this experiment, UL145 deletion did not modulate the expression of 
UL83, UL25, and UL94 at 72 hpi. By comparison, UL83 and UL94 were identified to be 
down-regulated by more than 2-fold during ΔUL145 infection previously (Figure 4.4). 
Further interpretation of this data would require several further biological repeat 
experiments to address whether the changes found in Figure 4.4 or 4.21 were more 





Figure 4.24. Volcano plots of Tp-classfied viral protein fold change and 
significance in ΔUL145 virus infection at multiple time points. 
The x-axis represents the fold change of viral protein expression in ΔUL145 virus 
infection compared to wild-type Merlin infection in Log 2 scale. The y-axis 
represents the significance of the fold change (p-value) in log 10 scale. The colour 
of each dot indicates the Tp class of viral proteins. 
 
 
Figure 4.25. Protein abundance of viral tegument proteins UL83, UL25, and 
UL94 during WT and ΔUL145 infection. 
The relative protein abundance of Tp5 tegument proteins UL83 (phosphoprotein 
65, pp65), UL25 (phosphoprotein 85, pp85), and UL94 (cytoplasmic envelopment 
protein 2) measured in TMT based proteomics analysis of WT and ΔUL145 






The previous comparision between WT and ΔUL145 infection was performed at MOI 
10, and my repeat experiment performed with MOI of 5. To examine whether the 
discrepancy in viral protein regulation mentioned above was MOI dependent, I 
conducted a comparative analysis comparing fold changes derived from comparing 
protein abundance during WT and ΔUL145 infection at 72 hpi in both experiments. 
However, as shown in Figure 4.26, my 3-h MS analysis did not quantify many proteins 
that were dysregulated because of UL145 deletion. Proteins that were down-
regulated in ΔUL145 infection were all viral Tp5 proteins (marked in red rectangles). 
Therefore, it was hard to interpret the effect of using lower MOI. A further analysis 
of the fractionated samples would identify more proteins and might help identify the 
reason causing the difference between the two experiments. However, prior to 
performing fractionation, ideally several further biological repeats of this experiment 





Figure 4.26. Comparative analysis between two MS experiments comparing WT 
and ΔUL145 infection. 
Fold change derived from comparing protein abundance during WT and ΔUL145 
infection at 72 hpi was used in this comparative analysis. X-axis represents the 
original WT vs. ΔUL145 experiment while y-axis represents my repeat experiment. 
(A) Cellular proteins and viral protein quantified in both experiments are shown 
here. Cellular proteins are in blue and viral proteins are in orange. (B) Fold change 
of viral proteins quantified in both experiments are plotted. Viral proteins were 





4.5.  Discussion 
4.5.1. UL145 is not essential for HCMV replication 
As a gene in the UL/b’ region, UL145 is absent in certain laboratory adapted HCMV 
strains, such as AD169 and Towne, suggesting that UL145 is not required for HCMV to 
establish infection and replicate. UL145 has been shown to down-regulated DNA repair 
proteins HLTF and TP53BP1. From my preliminary data, I found that viral DNA replication 
was similar to DNA replication of WT virus during ΔUL145 infection, I observed some 
modulation of IFN induction in comparison to cells infected with WT virus, however 
changes needed further replicate experiments to be reliably interpretable. Results from 
growth curve analysis showed that deletion of UL145 did not consistently impair HCMV 
replication. Even when less infectious particle production was observed, the defect was 
shortly recovered as infection progressed. All of these results so far lead to the 
conclusion that UL145 is not essential for HCMV to replicate in vitro.  
One potential explanation for a lack of restriction of spread of HCMV within fibroblasts 
by increased IFNβ secretion could be the high MOI used. HCMV encodes many viral 
effectors that attenuate IFNβ-triggered JAK-STAT signalling. For example, IE1 binds to 
STAT2 and disrupts the association of STAT2-IFN-stimulated gene factor 3 (ISGF3) 
complex and ISRE sites of ISG promoters (Huh et al., 2008; Paulus et al., 2006), therefore 
restricting ISG transcription. Another immediate early protein tandem repeats 1 (TRS1) 
directly binds to IFNβ-induced protein kinase R (PKR) and prevents the phosphorylation 
of the host eukaryotic translation initiation factor eIF-2α, thus inhibiting further ISG 
activation (Hakki et al., 2006; Vincent et al., 2017). It is therefore possible that the IFNβ 
induction regulation by UL145 deletion was not sufficient to counteract enough to 
downplay the overall attenuation of IFNβ signalling and was easily overcome with high 
virus titre infection. 
Another interesting finding was the interplay between expression of UL145 and IE1, 
which is the only viral protein shown to be affected by UL145 deletion in both proteomic 
analysis. Previously UL145 protein was demonstrated to promote MIEP activity (Raftery 




protein expression (Figure 4.27). IE1 showed significant slower decline in ΔUL145 
infection, and the IE1 increase at 72 hpi was observed before (Figure 4.4). How UL145 
regulates IE1 expression remains an open question. IE1 was not targeted for 
proteasomal degradation during the entire lytic cycle of HCMV, as indicated in our 
MG132 proteomics analysis, suggesting IE1 regulation by UL145 may be solely on a 
transcriptional level. To verify the direct effect of UL145 on IE1, ΔUL145 infection could 
be performed in UL145 overexpressing HFFF-TERT. If UL145 negatively regulates IE1 
expression, there should be less IE1 transcripts in UL145 expressing cells compared to 
control HFFF-TERT.  
 
 
Figure 4.27. Protein abundance of viral immediate early proteins IE1 and IE2 
during WT and ΔUL145 infection. 
The relative protein abundance of immediate early proteins IE1 and IE2 measured 
in TMT based proteomics analysis of WT and ΔUL145 infection at 12, 24, 48, and 
72 hpi. The highest reading of each protein was set as 1. 
 
IE1 cooperates with IE2 to promote transcriptional activation of the viral early genes at 
low MOI infection (Gawn and Greaves, 2002; Greaves and Mocarski, 1998). Besides 
interfering JAK-STAT signalling as mentioned above, IE1 also antagonises apoptosis (Zhu 
et al., 1995), activates p53-related cell cycle arrest (Castillo et al., 2005) and ND10-
related transcription silencing (Korioth et al., 1996; Sanchez and Spector, 2008). The 
experiment described in section 4.4 is a preliminary 3-hour analysis of unfractionated 




kinetic analysis of ΔUL145 with higher resolution. If viral gene regulation, JAK-STAT 
signalling, cell cycle regulation, or anti-apoptosis emerges to be related to UL145, IE1 
should also be taken into consideration. 
 
4.5.2. A delayed, transient IFNβ transcription up-regulation was observed in ΔUL145 
infection 
In Figure 4.10 & Figure 4.11, more IFNβ transcripts were detected in ΔUL145 infection 
compared to WT at 24 hpi, when normally in WT infection IFNβ transcription had already 
been dampened. If this observation repeated in several more replicate experiments, it 
might suggest that UL145 deletion caused higher IFNβ transcriptional activity, or weaker 
suppression of IFNβ induction as discussed in subsection 4.3.1. If UL145 deletion led to 
higher transcriptional activity, higher IFNβ should be detected at 24 hpi, but this was not 
the case in the 2 independent ELISAs I performed, where ΔUL145 did not lead to more 
IFNβ secretion at 24 hpi (Figure 4.10). Overall from the present data, it is possible to 
speculate that UL145 might contribute to suppression of IFNβ induction before 24 hpi, 
although, again this requires further experiments to validate. 
The IFNβ transcriptional up-regulation seen with UL145 deletion seemed to be short-
lived and transient. As in Figure 4.12, the IFNβ induction seemed non-existent on RNA 
level at 30 hpi in both WT and ΔUL145 infection. And in Figure 4.23, the decline of these 
ISGs at 48 and 72hpi might correlate with the decrease of IFNβ at later time points. 
However, there is still the possibility that UL145 deletion resulted in higher IFNβ 
induction at later time points post 24 hpi.  More work should be done to understand 
how UL145 regulates IFN induction over time, and future experimental plans are 
discussed in subsection 6.3.2. 
 
4.5.3. Mechanism of HLTF in anti-HCMV interferon activation 
How HLTF restricts early HCMV infection has yet to be fully elucidated, but current 




shHLTF cell lines showed that loss of HLTF impaired IFNβ transcriptional induction at 6 
hpi, and this regulation was limited to a very short time frame with WT virus inducing 
more IFNβ mRNA in shHLTF cells at 12 hpi (Figure 4.13). Nonetheless, the transcriptional 
regulation affected overall IFNβ production at 24 hpi (Figure 4.14), suggesting HLTF’s 
role in IFNβ activation during early HCMV infection. However, these experiments have 
only been done once and will require repeating. 
In Figure 4.14, gene knock out of HLTF by CRISPR seemed to impair IFNβ production. 
However, the lab established that there was significant biological variability between 
independent monoclonal CRISPR HFFF-TERT cell lines. Lior Soday from the Weekes lab 
established that out of 8 monoclonal control CRISPR cell lines, substantial differences in 
early GFP expression were observed in restriction assays (experimental design for these 
assays shown in Figure 4.1). Upon infection with Merlin-strain UL36-GFP HCMV (MOI 0.1, 
24h), she observed up to 20-fold difference in the percentage of infection between 
control cell lines (0.2%-4%). In an attempt to validate results in Figure 4.14, Dr. Katie 
Nightingale found that the two monoclonal CRISPR control cell lines produced a 
significantly varied amount of IFNβ during HCMV infection. When infected two control 
CRISPR cell lines with Merlin HCMV (MOI 1, 24 h), one control cell line produced 97 
pg/ml IFNβ, while the other CRISPR HLTF cell line secreted 1152 pg/ml IFNβ, suggesting 
that one of the CRISPR control cell line did not have an adequate antiviral response. 
Several reasons may contribute to different infection outcome with different 
monoclonal CRISPR control cell lines.  Off-target effects in CRISPR has been widely 
discussed (Zhang et al., 2015). It is possible that off target effects of the control CRISPR 
guide RNA may lead to suppression of certain antiviral genes. This off target effect may 
be augmented by stable overexpression of Cas9 (Zhang et al., 2015). Furthermore, to 
generate monoclonal CRISPR cell lines, an isolated cell has to be passaged for an 
extended long time, which might create more opportunities for CRISPR system to 
introduce mutations. Therefore, instead of monoclonal CRISPR cell lines, polyclonal 
CRISPR cells as demonstrated in Figure 4.1 might be more reliable, although there may 
be concerns about stability of knockdown in this situation. Alternatively, a CRISPR 
system with an inducible promoter driving Cas9 could be adapted, or Cas9 protein and 




a system without ongoing expression of Cas9 and gRNA, inducible expression of the 
knocked-out gene could be established in independent knockout clones, facilitating 
comparison of cells expressing different levels of the gene of interest on a monogenic 
background. 
HLTF has the preference of binding 3' ends of ssDNA (Kile et al., 2015), which are created 
with abundance during HCMV DNA replication. ChIP results also demonstrated that 
HLTF associated with viral DNA at 72 hpi, although unselectively (Figure 4.19). A series 
of reporter assays in Figure 4.15 suggested that HLTF was not part of IFNβ induction 
signalling pathway downstream of viral sensing. Therefore, HLTF is likely to be detecting 
HCMV replicating DNA and triggering IFN response. Whether this contributes to the 
transient IFNβ up-regulation seen in ΔUL145 infection requires further investigation of 






Chapter 5. Refining protein degradation 
screens 
Previously, the lab had developed a systematic approach to actively search for human 
proteins that are degraded during HCMV early infection, which included proteomics and 
transcriptomic analysis (Section 1.5. ). With high confidence, a shortlist of 35 host 
proteins enriched in antiviral restriction factors (host proteins with the ability to inhibit 
early viral infection), were identified. Harnessing the ability of the proteasome inhibitor 
MG132 and lysosome inhibitor Leupeptin, the previous inhibitor screen identified 53 
proteins rescued by one drug or the other at 12 h post-infection, 8 of which were anti-
HCMV restriction factors known to be degraded by HCMV. Due to documented off-
target effects of MG132 and Leupeptin (Tsubuki et al., 1996; Yasuma et al., 1998), the 
application of these broad, non-selective, potent inhibitors helped us generate a 
comprehensive list of proteins targeted for degradation by HCMV, rather than elucidate 
the precise pathway of degradation of each protein during HCMV infection. I therefore 
investigated the effects of a selective protease inhibitor, Bortezomib, and two lysosome 
protease inhibitors E64 and CA-074, aiming to systematically determine the 
mechanism(s) of host protein degradation during HCMV infection. 
 
5.1.  Proteosomal degradation 
This part of the project represents a collaborative work performed with Dr. Katie 
Nightingale and Lior Soday. Dr. Katie Nightingale performed the infection, treatment, 
and the sample collection. She also completed a preliminary 3-h mass spectrometry 
analysis to check the quality of the samples. I processed the samples with high pH-based 
peptide fractionation and enriched peptide samples for a 36-h mass spectrometry 
analysis by the CIMR proteomics core. Lior Soday processed the mass spectrometry RAW 
data into protein abundance signal:noise values and I carried out all of the subsequent 




MG132 is a peptide aldehyde that potently blocks the proteolytic activity of the 26S 
proteasome and thus has been widely used as an agent to disrupt proteasome activity 
(Kisselev and Goldberg, 2001). Peptide aldehydes are substrate analogues of the 
chymotrypsin-like domain of proteasomes as well as cysteine proteases such as cytosolic 
calpains and several lysosomal cathepsins (Chapman et al., 1997). Although 10-fold 
higher concentrations are required, MG132 inhibits cathepsins and calpains (Tsubuki et 
al., 1996), indicating that the proteins rescued by MG132 might be degraded via 
lysosome. Adding to the complexity, MG132 has been linked to ER-stress-induced 
autophagy (Bao et al., 2016; Wang et al., 2019). In order to identify proteins that are 
truly processed by proteasome, a proteasome inhibitor with higher selectively is 
required. The drug selected, Bortezomib, covalently binds to catalytic core of 26S 
proteasome with increased specificity, which is mediated by the boronate group of the 
drug (Groll et al., 2006). It is now in use for the treatment of multiple myeloma, and its 
use for the treatment of other malignancies is being explored (Kubiczkova et al., 2014).  
 
5.1.1. Optimising Bortezomib concentration 
Bortezomib has been used in human cell line experiments to inhibit proteasome activity, 
however, different studies have employed different concentrations, ranging from 0.1 
µM to 20 µM (Chui et al., 2019; Price et al., 2011). Our first task was to find an 
appropriate Bortezomib concentration to match with MG132 in HFFF-TERT infection 
model.  The ratio comparing protein abundance with and without inhibitor during HCMV 
infection was used to determine inhibitor efficacy. Ratios obtained from different 
concentrations of Bortezomib treatment were compared to those from 10 µM MG132 
treatment, the condition employed in our previous study (Figure 1.11A). Here I was 
hoping to identify a pattern that had a linear correlation with a slope close to 1 and a 
relatively high correlation coefficient (r2). 
Three concentrations of Bortezomib were first tested: 50 nM, 150 nM, and 500 nM. For 
each protein, ratios of (HCMV with Bortezomib) / HCMV and (HCMV with MG132) / 




linear correlation and slope of the trend line both increased with increasing Bortezomib 
concentration (Figure 5.1). Three higher concentrations: 500nM, 1 µM, and 2 µM, were 
then tested. Similar trends were observed when Bortezomib concentration increased 
(Figure 5.2). These three higher concentrations all demonstrated high correlation 
coefficients, and the 2 µM Bortezomib treatment was chosen for further analysis and 







Figure 5.1. Optimisation of Bortezomib concentration by comparison with 10 
µM MG132. 
(A) Schematic of the experimental workflow. HFFF-TERT cells were infected with 
Merlin strain HCMV (MOI 5) or mock infected for 24 h. Cells were treated with 10 
µM MG132, 50 nM, 150 nM or 500 nM Bortezomib 12 h prior to harvest. Whole 
cell lysates were digested into peptides, which were labelled with TMT reagents 
followed by MS3 mass spectrometry. (B&C) Log2 (fold change of protein 
abundance) between the presence and the absence of proteasome inhibitor 







Figure 5.2. Second optimisation of Bortezomib concentration by comparison 
with 10 µM MG132 
(A) Schematic of the experimental workflow. HFFF-TERT cells were infected with 
Merlin strain HCMV (MOI 5) or mock infected and simultaneously treated with 10 
µM MG132, 500 nM, 1 µM or 2 µM Bortezomib. Whole cell lysates were digested 
into peptides, which were labelled with TMT reagents followed by MS3 mass 
spectrometry. (B&C) Log2 (fold change of protein abundance) between the 
presence and the absence of proteasome inhibitor during (B) HCMV infection and 
(C) mock infection 
 
5.1.2. Multiple host proteins are targeted for proteasomal degradation early during 
HCMV infection 
To build a detailed mechanistic picture of host protein degradation early during HCMV 




subjected to high pH-based peptide fractionation, and each fraction analysed by MS3-
based mass spectrometry (Figure 5.1). Overall, 7192 host proteins were quantified, 145 
of which were down-regulated >1.5-fold (with p<0.01) compared to mock infection. 
MG132 and Bortezomib ‘rescue ratios’ were calculated for each protein, obtained by 
comparing protein abundance during HCMV infection +/- inhibitor with protein 
abundance during mock infection +/- inhibitor (Figure 5.3). This ratio enabled us to 
identify proteins with increased expression under drug treatment more during infection 
compared to mock, rather than proteins with high turnover rate naturally.  
Proteins rescued by both MG132 and Bortezomib 
For simplicity and consistency with the previous study (Figure 1.11A), a ratio of 1.5-fold 
with p<0.01 was set as a cut-off to determine whether the proteins were rescued by 
each inhibitor. Under these criteria, 64/145 (44%) of proteins were considered to be 
rescued by either protease inhibitor, which is in line with our previous finding. More 
than half (34/64, Figure 5.3 red dots) of these proteins were rescued by both drugs ( 
Table 5.1). Notably, this group contains several HCMV restriction factors reported 
previously, such as nuclear domain 10 (ND10) components SP100, MORC3, DAXX, cell 
cycle regulating protein ANAPC1 (Figure 5.3B) (Schreiner and Wodrich, 2013; Sloan et 
al., 2016; Tavalai et al., 2011; Weekes et al., 2014). HLTF was also rescued by both 
MG132 and Bortezomib, validating the findings in section 3.1.   
Proteins rescued by either MG132 and Bortezomib only 
Thirty proteins were identified to be rescued by MG132 or Bortezomib only. Of proteins 
exhibiting a greater rescue ratio with Bortezomib compared to MG132 (Figure 5.3 purple 
dots), 8/9 (89%) exhibited MG132 rescue ratios >1.25 but <1.5 (examples in Figure 5.3 
bottom panel & Figure 5.4,  
Table 5.2), suggesting that nearly all proteins in this class were in fact rescued by both 
inhibitors. The one exception was LIM domain-containing protein AJUBA, whose MG132 
rescue ratio was 1.16 in this data (Figure 5.3C bottom panel), but was 1.48 in our 




only two or one peptides, respectively in the two experiments. In conclusion, no proteins 
were rescued by Bortezomib but not MG132, reflecting the selectivity of Bortezomib. 
Twenty-one proteins exhibited a greater degree of rescue with MG132 compared to 
Bortezomib (Figure 5.3, yellow dots). Thirteen (62%) of them exhibited Bortezomib 
rescue ratios of >1.25 and <1.5, suggesting that many of this group of proteins may 
nevertheless be proteasomally degraded. These included the PDZ domain containing 
protein 11 (PDZD11) and transcriptional repressor BEN domain containing 3 (BEND3) 
(Figure 5.4, Table 5.3). In contrast, 8/21 proteins appeared genuinely to be selectively 
rescued by MG132 but not Bortezomib (Bortezomib rescue ratio <1.25), including the 
fibroblast growth factor receptor Golgi glycoprotein 1 (GLG1), E3 ligase neural precursor 
cell expressed, developmentally down-regulated 4 (NEDD4) and carbohydrate 







Figure 5.3. Identification of proteins targeted for degradation by HCMV using 
an inhibitor-based proteomic screen. 
(A) Results of the inhibitor-based screen. All 145 proteins downregulated >1.5 fold 
are plotted, with down regulated proteins divided into 4 groups using rescue ratios 
of >1.5 as cut-offs. The table shows the number of proteins in each group. For 
rescue ratios, the denominator (mock with drug)/mock was limited to a minimum 
of 1 to prevent artificial ratio inflation. (B) Examples of positive controls from the 
existing literature that were validated in this screen. (C) Examples of degraded 
proteins rescued by both inhibitors (top panels), MG132 only (middle panels), or 






Figure 5.4. “Borderline” proteins rescued by both MG132 and Bortezomib 
identified.  
Examples of proteins exhibiting rescue ratios >1.5 with only one of two inhibitors, 
but a rescue ratio between 1.25 – 1.5 fold with the other inhibitor.  
 
Table 5.1. Host proteins rescued by both MG132 and Bortezomib. 
Proteins with rescue ratio >1.5. The number of peptide quantified shows how well 
the proteins is quantified. Benjamini-Hochberg adjusted significance A values 
















CFLAR 1 3.34 1.50E-22 4.30 1.01E-21 
MLKL 1 2.58 6.75E-15 2.58 2.24E-10 
CITED2 3 2.43 2.37E-13 1.57 1.31E-03 
FRMD6 5 2.42 2.83E-13 2.42 2.83E-09 
PTPN14 4 2.23 2.48E-11 2.33 1.25E-08 
CTGF 8 2.05 2.05E-09 1.67 3.16E-04 




SNX16 1 1.97 1.10E-08 2.13 2.64E-07 
LAYN 2 1.93 2.78E-08 1.53 2.30E-03 
SETX 4 1.92 3.29E-08 1.61 8.02E-04 
HOXA11 1 1.90 5.85E-08 2.43 2.49E-09 
ZFP36L2 5 1.88 9.61E-08 2.32 1.41E-08 
ZMYND11 3 1.87 1.07E-07 1.94 5.36E-06 
RPS6KA4 4 1.86 1.46E-07 1.65 4.37E-04 
DAXX 4 1.83 2.94E-07 2.29 2.08E-08 
FAM101B 2 1.81 4.01E-07 2.38 5.52E-09 
RGL2 1 1.78 9.46E-07 2.01 1.71E-06 
HLTF 7 1.77 1.09E-06 2.19 9.91E-08 
TFAP4 1 1.77 1.15E-06 2.26 3.39E-08 
STK32B 2 1.76 1.37E-06 1.70 2.16E-04 
MEN1 3 1.75 1.53E-06 1.56 1.49E-03 
ZBED1 3 1.73 2.48E-06 2.14 2.31E-07 
MED20 1 1.70 5.12E-06 1.86 1.97E-05 
TCEAL4 14 1.69 6.50E-06 1.83 3.08E-05 
TADA1 1 1.68 7.24E-06 1.73 1.28E-04 
RALGPS2 1 1.67 8.67E-06 1.81 4.19E-05 
TOX 3 1.67 9.16E-06 1.64 4.74E-04 
GLS-3 2 1.64 1.70E-05 1.83 2.78E-05 
CCDC71L 2 1.63 2.37E-05 1.93 6.43E-06 




SP100 10 1.59 4.63E-05 1.95 4.88E-06 
MORC3 6 1.52 1.96E-04 1.64 4.68E-04 
CDC42EP3 4 1.52 2.09E-04 1.64 4.74E-04 
ARHGAP35 21 1.51 2.38E-04 1.51 3.03E-03 
 
Table 5.2. Host proteins with greater Bortezomib rescue ratio. 
















SUGP2 14 1.45 8.64E-04 1.69 2.42E-04 
RBPMS 13 1.41 1.66E-03 1.53 2.23E-03 
PCDHGB5 3 1.41 1.85E-03 1.53 2.26E-03 
HOXA13 1 1.41 1.89E-03 2.00 2.20E-06 
NACC2 1 1.36 4.08E-03 1.57 1.28E-03 
DLC1 6 1.33 7.53E-03 1.54 1.89E-03 
LMAN2L 1 1.31 1.12E-02 1.51 3.23E-03 
HACD1 1 1.26 2.38E-02 1.91 8.13E-06 





Table 5.3. Host proteins with greater MG132 rescue ratio.  
















DENND2A 2 1.54 1.34E-04 1.49 3.86E-03 
FAM126A 1 1.91 4.15E-08 1.48 4.39E-03 
ZNF668 1 1.62 2.67E-05 1.47 5.36E-03 
NLGN2 1 1.75 1.74E-06 1.45 6.70E-03 
PCDHGB2 2 1.85 1.97E-07 1.44 8.19E-03 
PKNOX1 1 1.55 1.12E-04 1.43 8.36E-03 
PDZD11 1 1.55 1.08E-04 1.42 1.01E-02 
AHR 1 1.77 1.09E-06 1.39 1.46E-02 
BEND3 4 1.51 2.77E-04 1.39 1.50E-02 
PCDHGC3 2 1.76 1.31E-06 1.34 2.59E-02 
DIMT1 1 1.78 7.75E-07 1.32 3.28E-02 
RNF150 2 1.73 2.80E-06 1.28 5.49E-02 
CNTNAP1 3 1.94 2.09E-08 1.28 5.66E-02 
DAPK2 1 1.54 1.29E-04 1.22 1.02E-01 
NEDD4 10 1.50 3.04E-04 1.16 1.86E-01 
ADAMTS1 9 1.52 2.25E-04 1.07 4.44E-01 
WWP2 1 1.56 9.93E-05 1.04 5.32E-01 
CHST14 1 1.70 4.95E-06 0.98 8.38E-01 
DKK3 3 1.61 3.27E-05 0.89 7.93E-01 




GLT8D1 6 1.75 1.76E-06 0.71 1.94E-01 
 
5.1.3. Three proteins rescued by MG132 only were also rescued by Leupeptin 
The reproducibility of results enabled me to interpret proteomics data better and reject 
poorly quantified data as discussed above. Since treatments of 500 nM and 1 µM 
Bortezomib had similar effects compared to 10 µM MG132, results from these 
conditions were used as biological replicates to assess the reproducibility of results from 
2 µM Bortezomib. As shown in Figure 5.5, Bortezomib truly did not have effects on the 
down-regulation of GLG1, CHST14, and NEDD4 while MG132 rescued their down-
regulation previously. A closer look along with our previous MG132/Leupeptin screen 
revealed that these were the proteins whose down-regulation was reversed by 
Leupeptin and were regarded as proteins degraded by lysosomes (Figure 5.5). 
Interesting, these proteins are membrane-associated, likely became parts of 
intracellular vesicles eventually fused with lysosomes, either through endocytosis and 
autophagy mechanisms, during early HCMV infection.  
 
 
Figure 5.5. Proteins rescued by MG132 but not Bortezomib were also rescued by 
Leupeptin. 
Results for GLG1, CHST14 and NEDD4, proteins selectively rescued by MG132 but 




MG132/Bortezomib screen and the right hand panels show the MG132 (10 µM) 
/Leupeptin (200 µM) screen (12 hpi) from the previous investigation (Figure 1.11). 
 
5.1.4. A shortlist of proteins degraded via proteasome during early HCMV infection 
In the previous MG132/Leupeptin screen (Figure 1.11A), 46 proteins were identified to 
be proteasomally degraded within 12 h of HCMV infection (Appendix table 1). Of these 
46 proteins, 24 exhibited increased degradation in HCMV-infected cells compared with 
mock infection in the pSILAC screen (Figure 1.11B). Additionally, 13/46 proteins 
belonged to the gene cluster that were down-regulated at protein level but not 
transcript in the RNA/protein screen (Figure 1.11C). 7 of these 13 proteins were also 
identified to be degraded during HCMV infection by pSILAC screen (Appendix table 4). 
Of the 46 proteins rescued by MG132 at 12 hpi, 30 proteins was validated by pSILAC 
screen, or RNA/protein screen, or both. These 30 proteins were searched against the 
MG132/Bortezomib screen generated in this section. Seventeen out of these 30 proteins 
were rescued by both MG132 and Bortezomib, with rescue ratios >1.25 and p<0.01 
(Table 5.4). Other “hits” with unidentified roles in HCMV infection were mixed lineage 
kinase domain-like protein (MLKL), tyrosine-protein phosphatase non-receptor type 14 
(PTPN14), ribosomal protein S6 kinase alpha-4 (RPS6KA4), Ras-specific guanine 






Table 5.4. Proteins identified to be proteasomally degraded during HCMV 
infection.  
Four screens were developed to search for proteins that were degraded during 
HCMV infection via proteasome. The first screen, MG132/Leupeptin screen, 
selected proteins with MG132 rescue ratio >1.5 and p<0.01 at 12 hpi.  The second 
screen selected proteins that had 50% higher degradation rate (Kdeg) during 
HCMV infection compared to mock (rdeg >1.5 if Kdegmock<0, FCHCMV>1.5 if 
Kdegmock>0). The third screen defined a group of proteins that were 
downregulated at protein level. Fold changes of protein and RNA at 24 hpi are 
listed here. RNA FC= RNA abundance at 24 hpi/RNA abundance at mock infection. 
Protein FC=protein abundance at 24 hpi/protein abundance at mock infection.  
Rescue ratios from MG132 and Bortezomib treatments were explained in Figure 
5.3. FC=fold change, N/A=not available because it was not quantified.  















MLKL 2.49 11.43 2.86 N/A 2.58 2.58 
PTPN14 3.29 1.77 0.72 0.20 2.23 2.33 
ANAPC1 3.43 10.60 2.60 0.20 2.00 1.84 
RPS6KA4 2.34 2.43 0.77 0.61 1.86 1.65 
HLTF 3.02 1.76 1.88 0.35 1.77 2.19 
RALGPS2 2.85 5.69 1.03 N/A 1.67 1.81 
SP100 2.11 3.40 1.54 0.56 1.59 1.95 
MORC3 2.21 2.57 1.69 0.52 1.52 1.64 
ARHGAP35 3.02 4.20 1.07 0.25 1.51 1.51 
CNTNAP1 2.15 2.61 0.27 0.42 1.94 1.28 
ARMC9 2.41 N/A 0.53 N/A 1.56 1.39 
BEND3 2.14 N/A 14.93 0.47 1.51 1.39 
LMAN2L 4.65 N/A 1.39 0.51 1.31 1.51 
ANAPC4 2.56 5.32 1.78 N/A 1.47 1.42 




MAP3K2 2.05 N/A 1.56 0.32 1.33 1.37 
NEDD4L 2.35 N/A 2.00 0.37 1.27 1.48 
 
5.2.  Lysosomal degradation 
The work presented in this section was performed by myself. I designed and performed 
the experiments and prepared TMT-labelled peptides samples for a 3-h mass 
spectrometry analysis by the CIMR proteomics core. I subsequently carried out all the 
data analysis and interpretation.  
Lysosomes generally contain several cysteine peptidases of the papain family, namely 
cathepsins B, H, L, and S (Turk et al., 2012). Leupeptin is a natural occurring lysosome 
inhibitor extracted from a strain of Streptomyces exfoliates that inhibits cysteine 
proteases as well as serine proteases, resulting in nonselective inhibition (Suda et al., 
1972). In search of a selective cysteine protease inhibitor, E64 was discovered from 
another fungus Aspergillus japonicas (Kazunori Handa, 1978). E64 potently inhibits 
cathepsin B and cathepsin L in an irreversible manner (Towatari et al., 1991). CA-074 is 
the methyl ester derivative of E64 that was developed to selectively inhibit cathepsin B 
but not cathepsin L (Murata et al., 1991). They are used alongside with Leupeptin to 
identify proteins that are degraded via lysosomes during early HCMV infection in this 
project.  
 
5.2.1. Optimising cathepsin inhibitor concentration 
E64 and CA-074 have been used in cell-based experiments to restrict autophagy via 
cathepsin inhibition (Montaser et al., 2002; Zhang et al., 2006). To find the optimal 
concentration for our HFFF-TERT HCMV infection model, I tested three concentrations 
of E64 and CA-074 against 200 µM Leupeptin, the condition used in the previous 





Figure 5.6. Schematic of optimisation of cathepsin inhibitor concentration. 
HFFF-TERT were infected with Merlin strain HCMV at MOI of 5. Cells were treated 
with serum-free DMEM for 24 h prior to infection. Inhibitors were added to the 
cells from the point of infection. Proteins were harvested 12 hpi and split into two 
groups for proteolysis and TMT labelling. Labelled peptides underwent a 3-h mass 
spectrometry and data analysis reveal how well each treatment performed 
compared to 200 µM Leupeptin.    
 
A ratio comparing protein abundance with or without inhibitor treatment during HCMV 
infection was derived to monitor the efficacy of each concentration compared to 200 
µM Leupeptin. Dot plots with linear trend lines were generated to estimate the 
correlation between treatments (Figure 5.7).  All comparison showed positive 
correlation with r2 values between 0.36-0.5, possibly because lysosome inhibitors did 
not influence the expression of many proteins during HCMV infection. Nevertheless, 100 
µM E64 and 100 µM CA-074 were chosen because their comparison trend line had the 






Figure 5.7. Optimisation of cathepsin inhibitor concentration. 
Log2 (fold change of protein abundance) between the presence and the absence 
of lysosome inhibitor during HCMV infection 
 
5.2.2. Identification of proteins degraded via lysosome during HCMV infection 
In order to search for proteins that were lysosomally degraded during HCMV infection, 
cells were treated with Leupeptin, CA-074, or E64 simultaneously with HCMV infection. 
Cells were harvested at 12 hpi and TMT-based mass spectrometry analysis was 
performed. Overall, 1676 proteins were quantified, including 2657 host proteins and 19 






Figure 5.8. Schematic of the Leupeptin/cathepsin inhibitor screen. 
Cell cycle synchronised HFFF-TERT were infected with HCMV (non-GFP) at MOI of 
5 and treated with inhibitors simultaneously. Proteins were harvested 12 hpi for 
proteolysis and TMT labelling. Labelled peptides underwent a 3-h mass 
spectrometry analysis. 
 
Efficacy of cathepsin inhibitors  
The efficacy of each cathepsin inhibitor was compared again with 200 µM Leupeptin. 
Surprisingly, CA-074 performed just as well as Leupeptin, reaching a trend line slope 
nearly to 1 and relatively high r2. Even though E64 also performed much better than the 
conditioning experiments, the trend line slope indicated that it was less effective 
compared to 200 µM Leupeptin and 100 µM CA-074 (Figure 5.9). Therefore, CA-074 was 






Figure 5.9. Efficacy of 100 µM CA-074 and E64 compared to 200 µM Leupeptin 
during HCMV infection. 
Log2(fold change of protein abundance) between the presence and the absence of 
lysosome inhibitor during HCMV infection. Trend lines were generated along with 
their slope and coefficient of correlation.  
 
Finding proteins rescued by Leupeptin and CA-074 
Among the 2657 host proteins quantified, 70 proteins were downregulated by HCMV 
infection at least by 30% with p-value <0.05. Rescue ratios of these proteins by 
Leupeptin and CA-074 were compared (Figure 5.10).  65/70 of these down-regulated 
proteins were not affected by either Leupeptin or CA-074. Four proteins had Leupeptin 
rescue ratio>1.25 (p<0.05), two were also rescued by CA-074 (rescue ratio>1.25, p<0.05). 
The downregulations of heterogeneous nuclear ribonucleoprotein U (HNRNPU) and RNA 
binding motif protein 4 (RBM4) were rescued by both Leupeptin and CA-074. The two 
nuclear proteins might be processed through autophagy. 
 
 
Figure 5.10. Identification of proteins targeted for lysosomal degradation by 
HCMV.  
Results of crossing lysosomal inhibitor-based screens. All 70 proteins 
downregulated >1.3 fold are plotted, with down regulated proteins divided into 4 
groups using rescue ratios of >1.25 as cut-offs (p<0.05). For each given protein, 






5.2.3. Proteins previously identified to be lysosomally degraded 
MG132/Leupeptin screen 
In the previous MG132/Leupeptin screen, 12 proteins were identified to be rescued by 
Leupeptin at 12 hpi. All of them unfortunately were not quantified in this screen. 
MG132/Bortezomib screen 
GLG1, CHST14 and NEDD4 are membrane proteins suggested to be degraded via the 
lysosome (Figure 5.5). Unfortunately, they were not quantified in this experiment. In the 
previous 12 h MG132/Leupeptin screen (Figure 1.11A), 8033 proteins were quantified 
and 12 (0.15%) proteins were identified to be rescued by Leupeptin (rescue ratio>1.5 
and p<0.01). In the current dataset performed with unfractionated peptide samples, a 
similar percentage (0.15%, 4/2657) of quantified proteins was identified to be rescue by 
Leupeptin (rescue ratio>1.25 and p<0.05). I would expect to identify ~12 proteins 
rescued by Leupeptin with fractionated peptide sample analysis and a smaller 
proportion would be expected to be rescued by CA-074. Upon fractionated analysis of 
an optimised experiment, it would be anticipated that the lysosomal degradation of 
GLG1, CHST14, or NEDD4 during HCMV infection would be validated. 
 
5.3.  Discussion 
5.3.1. How to consider a rescue ratio significant? 
In the MG132/Bortezomib screen, the fold change cut-off of 1.5 was adapted for both 
downregulation by HCMV, and rescue by either inhibitor, however it had the effect of 
excluding proteins with ‘borderline’ rescue ratios of >1.25 but <1.5. 39/81 proteins with 
MG132 and Bortezomib rescue ratios <1.5 exhibited rescue ratios for MG132 or 
Bortezomib or both that were nevertheless >1.25, suggesting that this group of proteins 
included some candidates that were downregulated by degradation. Therefore the p-




(subsection 2.4.7). The significance A algorithm calculates p values according to the 
distribution of all the rescue ratios measured in an experiment, fitting ratios to a normal 
distribution but with separate standard deviation estimates for ratios greater and less 
than 1 to account for global differences in protein up- or down-regulation. A rescue ratio 
of 1.5 would have a more significant p-value estimated by significance A value if the 
inhibitor induces fewer changes.  For instance, in the MG132/Bortezomib screen, to 
achieve significance A p<0.01, the MG132 rescue ratio needed to be >1.32, in 
comparison to a Bortezomib rescue ratio of >1.42.  
There are several other factors to help determine the confidence in a measurement. For 
example, one should always be cautious about when interpreting measurement derived 
from a single quantified peptide. Similar rationale is applied to the calculation of 
significance B p value, which adjusts significance A value according to the ion intensity 
measurement when there are >700 proteins identified (proteins are grouped into sets 
of 350 proteins based on ion intensity). As always, biological replicates boost the 
reliability of an experiment. Now the lab and I have generated 3 datasets detailing 
protein changes in MG132-treated HCMV infection at 12 hpi. Those proteins that have 
been routinely identified as targets of virus-mediated proteasomal degradation, 
including HLTF and PTPN14, are the top targets to investigate their roles in HCMV 
infection. 
 
5.3.2. Proteasomal degradation is the major protein degradation pathway during 
HCMV infection 
HCMV orchestrates the regulation of host gene expression to facilitate viral replication 
while evading immune defences. At 12 h of HCMV infection, 2-5% of host proteins were 
down-regulated for more than 1.5 fold (369/7688 in temporal analysis of HCMV-infected 
whole cell lysate published in (Weekes et al., 2014), 281/8034 in MG132/Leupeptin 
screen, and 146/7162 in MG132/Bortezomib screen).  I was interested in proteins 
degraded at this time point because within 12 h of infection HCMV needs to circumvent 
intrinsic barriers such as cytosolic viral DNA sensor cGAS and viral transcription repressor 




MG132 is a less selective proteasomal inhibitor than Bortezomib, having previously been 
reported to inhibit lysosomal degradation pathways via inhibition of calpains and 
cathespsins (Kisselev and Goldberg, 2001), in addition to the proteasome. In the 
previous MG132/Leupeptin screen (Figure 1.11A), 75% (9/12) of proteins rescued by 
Leupeptin at 12 h of infection were also rescued by MG132. The usefulness of comparing 
this broad proteasomal/lysosomal inhibitor with the specific proteasomal inhibitor 
Bortezomib is the identification that 62-85% (using 1.25 or 1.5 as rescue ratio cut off 
respectively) of proteins rescued by MG132 were also rescued by Bortezomib, 
suggesting that the proteasome is the predominant route for early protein degradation 
during HCMV infection. Overall, of all downregulated proteins, 44% (64/145 using 1.5 as 
the cut-off)-59% (85/145 using 1.25 as the cut-off) were rescued by at least one of 
MG132 or Bortezomib. Previously Dr. Katie Nightingale calculated the median protein 
half-life of 58.4 h in uninfected fibroblasts with pulsed SILAC (Figure 1.11B). HCMV is 
characterised with a prolonged replication cycle (>72 h). It is possible that in order to 
downregulate certain proteins, HCMV must employ degradative pathways in order to 
achieve sufficiently rapid change in protein abundance.  
Comparison of data from this study with the previous transcriptional analysis of host 
gene expression during infection (Figure 1.11C) suggested that 54% of the 81 proteins 
with MG132 and Bortezomib rescue ratios <1.5 were more than 1.5-fold 
transcriptionally downregulated, which would be expected to be a major mechanism of 
protein downregulation in the absence of degradation. In the previous RNA/protein 
screen (Figure 1.11C), 1%–5% of proteins were degraded and also had reduced mRNA 
levels, suggesting that multiple regulatory mechanisms may be employed by HCMV for 
effective control of certain targets. For example, gap junction alpha-1 protein (GJA1) has 
been reported to be degraded in the proteasome (Stanton et al., 2007). Even though the 
current MG132/Bortezomib screen did not identified GJA1 as a down-regulated protein, 
possibly because it was only quantified by a single peptide, previous MG132/Leupeptin 
and pSILAC screens confirmed that GJA1 was degraded during HCMV infection. The RNA-





Figure 5.11. GJA1 results from 4 screens. 
GJA1 results from (A) MG132/Leupeptin screen (Figure 1.11A), (B) pSILAC analysis 
(Figure 1.11B), (C) RNA/protein screen (Figure 1.11C), and (D) MG132/Bortezomib 
(Figure 5.2A) are shown here. (E) Numbers of peptides identified in each 
proteomic experiments are listed. 
 
5.3.3. Lysosomal degradation during HCMV infection 
Studies have shown that membrane proteins are targeted for lysosomal degradation 
during HCMV infection. HCMV latency-associated UL138 targets the multidrug 
resistance protein 1 (MRP1, ABCC1) for lysosomal degradation (Weekes et al., 2013). 
Four members of the US12 gene family contribute to the HCMV evasion from natural 
killer (NK) cells. For example, US18 and US20 concordantly target the membrane protein 
B7-H6 that serves as the infection alert molecule to NK cells for lysosomal degradation 




sequesters plasma membrane proteins in the cytosol to evade NK cell 
immunosurveillance. For example, HCMV UL141 retains the poliovirus receptor in the 
endoplasmic reticulum, inhibiting cell-surface expression and preventing interaction 
with activating NK receptor DNAM-1 (Prod'homme et al., 2010; Tomasec et al., 2005; 
Weekes et al., 2014).  
Data here identified that 8 proteins rescued by MG132 but not Bortezomib had a 
membrane origin. Certain proteins were exclusively degraded by a non-proteasomal 
route, including GLG1 and CHST14. Extension of these inhibitor studies to examining 
membrane-enriched samples, for example samples enriched for plasma membrane 
proteins (Weekes et al., 2013; Weekes et al., 2014) would therefore be of substantial 
interest, and may identify a distinct degradative route for proteins originating from 
these compartments. Autophagy delivers intracellular protein cargos to the lysosomes 
while integral membrane proteins reach lysosomes through endocytic pathway (Yang 
and Klionsky, 2010).  
Besides disposal of protein aggregates and damaged organelles, lysosomal degradation 
pathways serve a much broader function, including the regulation of cell signalling, 
metabolism, pathogen clearance, and immune responses. For example, mammalian 
target of rapamycin complex 1 (mTORC1) kinase complex regulates lysosome activity in 
response to amino acid deprivation (Laplante and Sabatini, 2012). When levels of leucine 
and arginine are low, mTORC1 cannot dock on the lysosome membrane to be activated 
(Bar-Peled et al., 2012). Transcription factor EB (TFEB) is dephosphorylated and 
translocates to the nucleus where it functions as a master gene regulator of lysosome 
biogenesis (Hesketh G.G., 2018). Lysosomal regulation of the antiviral immune response 
has been established with autophagy. Toll/interleukin-1 receptor homology (TIR) 
domain containing adaptor molecule 1 (TRIF1) is an adaptor that associates with 
endosomal dsRNA toll-like receptor 3 (TLR3) and activates NFκB for the synthesis of 
inflammatory cytokines and interferon regulatory factors (IRFs) (Lee and Kim, 2007). 
TRIF is targeted by selective autophagy by the tripartite motif-containing protein 32 
(TRIM32)-human T-cell leukemia virus 1 TAX1 protein (TAX1)-binding protein 1 
(TAX1BP1) complex for degradation upon induction of poly(I:C) and LPS (Yang et al., 









Chapter 6. Discussion 
6.1.  Identification of novel antiviral factor 
Viruses need to resolve many restrictions imposed by host cells to replicate successfully. 
Before infectious particles enter cells, a panoply of factors are in place to hinder viral 
infection, with roles in sensing of pathogen-associated molecular pattern (PAMP), 
antiviral response through interferon (IFN) and the inflammasome via direct antiviral 
activity. As the paradigm of viral evasion and persistent infection, HCMV is an excellent 
model to study the host-pathogen interface and search for novel antiviral factors.  
 
6.1.1. Proteasomally degraded proteins as antiviral factors 
The previous and my current inhibitor screens were designed on the basis that HCMV 
targets antiviral factors for degradation via proteasome. Previously, employing three 
orthogonal proteomic screens 35 proteins were identified to be degraded during HCMV 
infection with high confidence (Appendix table 4). Of these 35 proteins, 9 proteins (MLKL, 
PTPN14, ANAPC1, RPS6KA4, HLTF, RALGPS2, SP100, MORC3, ARHGAP35) passed the 
selection of MG132/Bortezomib screen (using rescue ratio >1.5 and p<0.01 as selection 
criteria for both MG132 and Bortezomib). Three of them (ANAPC1, SP100, MORC3) are 
known anti-HCMV restriction factors (Kim et al., 2011; Sloan et al., 2016; Tran et al., 
2010a). Although the mechanism of HLTF restricting HCMV infection is not fully 
elucidated, my results have suggested that HLTF may be restricting early HCMV infection 
by regulating type I IFN induction. Besides HLTF, the function of mixed lineage kinase 
domain-like protein (MLKL) was explored by Alice Fletcher-Etherington in the lab. HCMV 
tegument protein UL36 was found responsible for degradation of MLKL and this helps 
the subversion of necroptosis in infected cells (Fletcher-Etherington et al., 2020). With 
majority of the proteins on the list having antiviral roles, the remaining four proteins 
(PTPN14, RPS6KA4, RALGPS2, ARHGAP35) may have undiscovered antiviral potential, 




Interestingly, these proteins have been associated with regulation of cell growth and 
tumorigenesis. Non-receptor tyrosine phosphatase 14 (PTPN14) and Rho GTPase-
activating protein 35 (ARHGAP35) both negatively regulate yes-associated protein 1 
(YAP1) (Frank et al., 2018; Liu et al., 2013), which inhibits the nuclear retention of YAP 
and decreases the YAP-dependent cell growth and proliferation (Meng et al., 2016; Zhao 
et al., 2007). The YAP1 pathway has been shown to contribute to tumorigenesis of 
oncogenic herpesviruses including EBV and KSHV (He et al., 2017; Kang et al., 2018; Liu 
et al., 2015). Degradation of PTPN14 and ARHGAP35 might result in YAP1-mediated cell 
growth and proliferation. Function of Ras-specific guanine nucleotide-releasing factor 2 
(RALGPS2) is poorly understood but it has been loosely implicated with cytoskeleton 
remodelling (Ceriani et al., 2007). Mitogen- and stress-activated kinase 2 (MSK2, 
RPS6KA4) is the downstream effector of extracellular signal-regulated kinases 1/2 
(ERK1/2) and p38 mitogen-activated protein kinase (p38 MAPK) (Wiggin et al., 2002). 
Less apoptosis was observed in RPS6KA4 knockout mice when treated with epidermal 
growth factor or ultraviolet C radiation (Wiggin et al., 2002).  Loss of RPS6KA4 might be 
a method HCMV has adapted to subvert apoptosis. Besides antagonising intrinsic and 
innate immune responses, HCMV reprograms numerous host pathways such as 
metabolic signalling pathways, programmed cell deaths, and cell cycle progression to 
create an optimal environment for viral replication. HCMV infection is known to arrest 
cells in the G0/G1 phase to allow viral gene expression (Fortunato et al., 2002; Salvant 
et al., 1998). Virally induced cell cycle arrest seems to contradict to what has already 
been proposed for the loss of PTPN14, ARHGAP35, or RALGPS2. Their roles in HCMV 
infection require further investigation. 
 
6.1.2. Other strategies HCMV adapts to manipulate host factors 
In addition to degradation of host proteins, HCMV also mislocalises host factors to 
achieve the optimal replication environment. For example, HCMV glycoprotein UL37 
directly associates with IFN-inducible viperin resulting in translocation from the 
endoplasmic reticulum to the mitochondria. There fatty acid metabolism is inhibited, 
which benefits viral envelope acquisition and virion release, thus enhancing infection at 




IFN induction pathway by misplacing host factors such as innate nuclear viral DNA sensor 
IFI16 and key adaptor protein STING (Dell'Oste et al., 2014; Fu et al., 2017). HCMV 
glycoprotein UL16 retains natural killer (NK) receptor NKG2D ligands in the endoplasmic 
reticulum (ER) and cis-Golgi apparatus while glycoprotein UL144 retains NK receptor 
DNAM-1 ligand poliovirus receptor in the ER, contributing to the evasion 
immunosurveillance and cytotoxicity imposed by NK cells (Dunn et al., 2003; Tomasec 
et al., 2005). By 24 h of HCMV infection, such sequestered proteins were 
downregulated >2-fold from the plasma membrane (PM) analysis but were not 
downregulated in whole cell lysates analysis (Weekes et al., 2014). Overall, this trend 
was observed for only 1.6% of PM proteins, suggesting that the predominant 
mechanism HCMV employs to downregulate proteins during the early phase of infection 
is proteasomal degradation. 
 
6.2.  Viral DNA sensors 
Sensing viral DNA has been regarded as a key event during initiation of antiviral innate 
immune response. The recognition of viral dsDNA results in the activation of an array of 
signalling cascades that ultimately lead to the production of IFNs and pro-inflammatory 
cytokines. Besides the IFN induction discussed in Chapter 1, the inflammasome pathway 
contributes to the production and secretion of inflammatory cytokines interleukin (IL) 
1β and IL18 (Guo et al., 2015). Absent in melanoma 2 (AIM2) is the main inflammasome 
sensor that detects intracellular DNA. AIM2 binds to viral DNA with pyrin and HIN-20 
domain, which subsequently activates caspase-1, acting as the protease that cleaves 
pro-IL1β pro-IL18 into mature IL1β and IL18 (Lugrin and Martinon, 2018). Even though 
AIM2 inflammasome is triggered by MCMV infection (Rathinam et al., 2010), it is 
functionally attenuated in HCMV infection since IE2 protein inhibits transcription and 
induces degradation of the pro-IL1β (Botto et al., 2019). This coincided with the 
preliminary result of a beads-based ELISA assay (subsection 2.2.4) I performed with 
supernatant of HCMV-infected cells that IL1β was barely detected. Therefore, IFNβ 





6.2.1. Redundancy of viral DNA sensors 
Although not yet convincing, my data showed that UL145 and HLTF might regulate IFNβ 
induction during HCMV infection. One potential explanation for the difficulties I 
encountered exploring the possibility of HLTF becoming a viral DNA sensor might be the 
functional redundancy among several reported receptors. IFI16, cyclic GMP-AMP 
synthase (cGAS), DNA-dependent activator of IFN-regulatory factor (DAI), DEAD-box 
helicase 41 (DDX41), DNA-dependent protein kinase (DNA-PK) all detect viral DNA and 
trigger IFNβ transcription through activation of STING-TANK-binding kinase 1 (TBK1)-
interferon regulatory factor 3 (IRF3) axis (Dempsey and Bowie, 2015). One of the 
remaining open questions is whether these sensors work cooperatively. Their functions 
are addressed with RNA interference (RNAi)-based cells and gene knock out mice 
individually in different host type with different stimuli, yet a systematic approach to 
address their functions in a single viral infection is lacking. Such cooperation has been 
proposed with DDX41 and IFI16, which both react to DNA transfection and HSV1 
infection in human monocyte THP-1 cells (Unterholzner et al., 2010; Zhang et al., 2011). 
The fact that IFI16 is upregulated transcriptionally while DDX41 expression stays the 
same throughout the course of DNA transfection and HSV1 infection leads to the 
hypothesis that DDX41 might be more important in the initial sensing while IFI16 takes 
over this function at later stage (Unterholzner, 2013). 
If HLTF is one of the viral DNA sensors, its functional redundancy should be considered 
with IFI16, the viral DNA sensor that recognises foreign DNA in the nucleus (Stratmann 
et al., 2015), since HLTF was found predominately expressed in the nucleus (Figure 3.4). 
In 2012, Gariano et al. demonstrated that transduction of IFI16 increased IFNβ 
production during HCMV infection in human embryonic lung fibroblasts (HELF) cells 
(Gariano et al., 2012). To determine whether IFI16 requires HLTF to induce IFNβ, an 
experiment could be envisaged whereby HLTF was depleted using siRNA with 
concomitant overexpression of IFI16 (i.e. via lentivirus / adenovirus), then infection with 
HCMV for 24 h. If HLTF cooperates with IFI16 in IFNβ induction, depletion of HLTF should 





6.2.2. Is HLTF a bona fide viral DNA sensor? 
Several findings in Chapter 4 led to the hypothesis that HLTF might be a viral DNA sensor, 
but more work needs to be done to first validate that HLTF modulates IFNβ induction 
during HCMV infection. Furthermore, two key questions need to be addressed before 
identifying HLTF as a bona fide viral DNA sensor, should HLTF’s regulation of IFNβ 
transcription be confirmed. 
One of the questions is about whether HLTF associates with HCMV DNA. Intracellular 
DNA sensors are assumed to have the ability to discern exogenous DNA from a cell’s 
own genome. To date, no clear rationale has been provided to explain how the viral DNA 
sensor distinguish between host and foreign DNA. RNA polymerase III specifically 
recognises AT-rich dsDNA, which is not a common feature of dsDNA virus genome 
(Ablasser et al., 2009; Chiu et al., 2009). Structural analysis of IFI16 DNA binding domain 
reveals that IFI16 binds to the dsDNA sugar-phosphate backbone, suggesting a viral 
detection regardless of genome sequence (Jin et al., 2012). As a dsDNA repair protein, 
DNA-PK specifically binds to ends of dsDNA during IFNβ induction (Ferguson et al., 2012). 
HLTF contains a HIRAN (HIP116, Rad5p, N-terminal) domain that associates specifically 
to the 3’-end of ssDNA (Achar et al., 2015; Hishiki et al., 2015; Kile et al., 2015), but how 
this feature coordinates viral DNA sensing remain elusive.  
The other question is how HLTF activates the signal cascade that eventually results in 
IRF3 phosphorylation. IFI16, DDX41, and cGAS all achieve this through interacting with 
STING. IFI16 and DDX41 both directly binds to STING even though they do not share any 
domain homology, while cGAS synthesises a secondary messenger cyclic guanosine 
monophosphate–adenosine monophosphate (cGAMP) to communicate with STING (Sun 
et al., 2013; Unterholzner et al., 2010; Zhang et al., 2011). When studying UL145-
mediated HLTF degradation, I performed immunoprecipitation of endogenous HLTF in 
MG132 treated HFFF-TERT (Figure 3.7). During that experiment, components identified 
associated with HLTF were not previously reported related to IFN induction signalling 
transduction. Nonetheless, there is possibility that HLTF associates with IFN induction 
signalling molecules such as STING and IRF3. In order to immuneprecipitate HLTF and its 




immunoprecipitation analysis of HLTF during ΔUL145 virus infection, which may help 
discover which signalling proteins are co-opted to signal infection.   
 
6.3.  Future work for this project 
6.3.1. How does UL145 degrade HLTF? 
In this project I identified UL145 to be responsible for HCMV-mediated HLTF degradation. 
In collaboration with Dr. Katie Nightingale, we discovered that the CUL4A E3 ligase 
complex is subverted by UL145 to degrade HLTF. Recently, UL145-mediated STAT2 
degradation was characterised and the interaction between STAT2, UL145, and CRL4 
adaptor protein DDB1 was identified (Le-Trilling et al., 2020). It is possible that UL145 
uses the same mechanism to target HLTF, however I lack convincing evidence to 
demonstrate the interaction between HLTF and UL145. Unexpectedly, the IP experiment 
in which I identified the interaction between HLTF and UL145 was performed by 
immunoprecipitating endogenous as opposed to overexpressed, HA-tagged HLTF. The 
interaction between UL145 and HLTF was identified in 293T cells by SILAC but not 
conventional IP, suggesting that the affinity between HLTF and UL145 might be weak, or 
alternatively that UL145 degraded HLTF indirectly and did not bind to HLTF.  
To determine whether HLTF and UL145 interact directly, I propose to perform 
fluorescence resonance energy transfer (FRET) microscopy. FRET is a distance-
dependent physical process in which a donor fluorophore in its excited state non-
radioactively transfers its excitation energy to a neighbouring acceptor fluorophore, 
thereby causing the acceptor to emit its characteristic fluorescence (Bajar et al., 2016). 
Since FRET is only observed when a donor fluorophore and an acceptor fluorophore are 
within the 1–10 nm range, the fluorophores can be conjugated with proteins to identify 
protein association (Miyawaki, 2011). In a cell expressing both cyan fluorescent protein 
(CFP) tagged UL145 and yellowish-green fluorescent protein (YFP) tagged HLTF, if UL145 






Figure 6.1. Diagram of a FRET assay examining UL145 and HLTF interaction. 
UL145 is fused with CFP (donor fluorophore) and HLTF is fused with YFP (donor 
fluorophore). If UL145 interacts with HLTF, triggering CFP results in YFP emission. 
IF the two proteins do not interact, no YFP signal can be observed. 
 
However, this method requires overexpression of fluorescent protein-tagged HLTF, 
which in my own experience was difficult. Overexpressing HLTF might result in cell death, 
therefore HLTF should be driven by a conditionally regulated promoter (i.e. tetracycline 
regulated promoter) instead of a constitutively active promoter (spleen focus-forming 
virus promoter [pSFFV] was used in current experiments). If a tet-regulated system could 
overcome the difficulty in HLTF overexpression, it can be used in FRET microscopy and 
HLTF IP as previously described (subsection 3.3.2). 
 
6.3.2. Confirmation that UL145 regulates IFNβ induction and investigation of 
mechanism 
Temporal analysis of infection with the UL145 deletion virus suggested that UL145 might 
regulate IFNβ production during HCMV infection at later time points (Figure 4.22). The 
first follow up experiment should be an ELISA comparing WT and ΔUL145 at multiple 
time points throughout HCMV infection. If an increase of IFNβ production in ΔUL145 
infection was validated and the acting timeframe identified, corresponding RT-qPCR 
should be performed to see whether UL145 regulates IFNβ induction at the 




lines. If HLTF participates in UL145-mediated IFNβ regulation, knocking down the HLTF 
gene should attenuate the up-regulation of IFNβ in ΔUL145 infection. 
 
6.3.3. RNA/protein screen at earlier time points 
In the MG132/Bortezomib screen, a shortlist of proteins that were degraded through 
proteasome was identified. Although incomplete, the analysis of fractionated peptides 
in the Leupeptin/CA-074 screen has the potential to identify host proteins degraded by 
lysosomes during HCMV infection. Together these screens broaden our view on HCMV-
mediated protein degradation. The aim of these screens were to investigate how host 
proteins were down-regulated during infection. Previously the RNA/protein screen 
published in Nightingale et al. (Nightingale et al., 2018) identified that ∼18% of proteins 
downregulated >3-fold within 24 hr of infection were regulated primarily by mRNA 
levels (Figure 1.11C). However, the corresponding transcriptomic analysis at early time 
points is lacking. Currently the earliest time point of the RNA/protein screen is 24 hpi 
and all of the inhibitor screens were performed with 12 hpi samples. Therefore, a 
RNA/protein screen coupling RNA-sequencing and whole cell lysate proteomic analysis 
at multiple time points prior to 24 hpi (6, 12, 18 hpi) would provide further orthogonal 
data for comparison to the earlier inhibitor-based screens. 
 
6.4.  Concluding remarks 
This work combined multiplexed proteomic techniques with proteasomal and lysosomal 
inhibitors, in search of host proteins that were actively degraded during HCMV infection. 
Although the lysosomal part of the project remained incomplete, the studies of HCMV-
mediated proteasomal degradation led me to the discovery of a novel anti-HCMV 
restriction factor, HLTF. While exploring the roles of HLTF in HCMV infection, how 
deletion of UL145, the viral protein responsible for HLTF degradation, affects HCMV 
replication was intensively explored. In particular, my data pointed out a potential role 
of UL145 in regulation of IFNβ induction. As the main protein regulated by UL145 during 




much work still needs to be done before this hypothesis could be validated. Overall, 
work presented here expands the range of powerful screening technologies to identify 
HCMV restriction factor candidates by identifying virally degraded host proteins. Further 
investigation of these candidates will contribute to our understanding of how HCMV 
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Appendix table 1. Proteins identified to be rescued by MG132 at 12, 18, 24 hpi. 
The uniprot accession code, gene name, full gene name, number of peptide identified, MG132 rescued ratio, and Benjimini corrected 
significance A p value of proteins identified to be rescued by MG132 at 12, 18, or 24 hpi are listed. A given protein was considered 
rescued by MG132 if its MG132 rescue ratio was greater than 1.5 and p value was less than 0.01.  
Proteins rescued by MG132 at 12hpi 
Uniprot Gene 
Symbol 
Description Peptides MG132 rescue ratio Rescue ratio p-value 
Q9H0V9-2 LMAN2L Isoform 2 of VIP36-like protein 1 4.65 6.73E-08 
Q6ZN30 BNC2 Zinc finger protein basonuclin-2 6 3.75 2.72E-06 
Q9H1A4 ANAPC1 Anaphase-promoting complex subunit 1 6 3.43 1.09E-05 
Q15678 PTPN14 Tyrosine-protein phosphatase non-receptor type 14 9 3.29 2.04E-05 
Q9NRY4 ARHGAP35 Rho GTPase-activating protein 35 20 3.02 6.91E-05 
Q14527 HLTF Helicase-like transcription factor 5 3.02 6.91E-05 
Q9Y485 DMXL1 DmX-like protein 1 5 3.01 7.23E-05 
Q15392 DHCR24 Delta(24)-sterol reductase 9 2.99 7.92E-05 
O43734 TRAF3IP2 Adapter protein CIKS 1 2.95 9.52E-05 
Q86X27 RALGPS2 Ras-specific guanine nucleotide-releasing factor 
RalGPS2 
4 2.85 1.51E-04 
Q96NE9 FRMD6 FERM domain-containing protein 6 6 2.78 2.09E-04 
Q9UKI2 CDC42EP3 Cdc42 effector protein 3 4 2.77 2.19E-04 
Q9H3M7 TXNIP Thioredoxin-interacting protein 7 2.74 2.53E-04 
Q7Z2Z1 TICRR Treslin 1 2.71 2.91E-04 
Q96SB3 PPP1R9B Neurabin-2 15 2.64 4.04E-04 
Q3MIT2 PUS10 Putative tRNA pseudouridine synthase Pus10 1 2.56 5.90E-04 




Q9UJX4 ANAPC5 Anaphase-promoting complex subunit 5 3 2.55 6.18E-04 
P46934-4 NEDD4 Isoform 4 of E3 ubiquitin-protein ligase NEDD4 8 2.51 7.48E-04 
Q86SQ0 PHLDB2 Pleckstrin homology-like domain family B member 2 26 2.50 7.84E-04 
Q8NB16 MLKL Mixed lineage kinase domain-like protein 3 2.49 8.22E-04 
Q7Z3E5 ARMC9 LisH domain-containing protein ARMC9 11 2.41 1.20E-03 
Q9HAU0-6 PLEKHA5 Isoform 6 of Pleckstrin homology domain-containing 
family A member 5 
10 2.38 1.39E-03 
Q8WV24 PHLDA1 Pleckstrin homology-like domain family A member 1 1 2.37 1.46E-03 
Q9UHI8 ADAMTS1 A disintegrin and metalloproteinase with 
thrombospondin motifs 1 
12 2.37 1.46E-03 
Q96PU5 NEDD4L E3 ubiquitin-protein ligase NEDD4-like 3 2.35 1.61E-03 
O75676 RPS6KA4 Ribosomal protein S6 kinase alpha-4 4 2.34 1.68E-03 
Q9Y4F9 FAM65B Protein FAM65B 5 2.33 1.77E-03 
O75486 SUPT3H Transcription initiation protein SPT3 homolog 1 2.31 1.94E-03 
Q9HA65 TBC1D17 TBC1 domain family member 17 4 2.29 2.14E-03 
Q96J02 ITCH E3 ubiquitin-protein ligase Itchy homolog 5 2.24 2.72E-03 
Q14149 MORC3 MORC family CW-type zinc finger protein 3 13 2.21 3.15E-03 
Q86XF0 DHFRL1 Dihydrofolate reductase, mitochondrial 3 2.16 4.00E-03 
P78357 CNTNAP1 Contactin-associated protein 1 10 2.15 4.20E-03 
Q5T5X7 BEND3 BEN domain-containing protein 3 3 2.14 4.41E-03 
P30307 CDC25C M-phase inducer phosphatase 3 1 2.11 5.10E-03 
P23497-4 SP100 Isoform Sp100-C of Nuclear autoantigen Sp-100 17 2.11 5.10E-03 
Q9P0V3 SH3BP4 SH3 domain-binding protein 4 14 2.09 5.61E-03 
P17302 GJA1 Gap junction alpha-1 protein 9 2.05 6.81E-03 
P84022 SMAD3 Mothers against decapentaplegic homolog 3 2 2.05 6.81E-03 
Q9Y2U5 MAP3K2 Mitogen-activated protein kinase kinase kinase 2 3 2.05 6.81E-03 
Q14865 ARID5B AT-rich interactive domain-containing protein 5B 13 2.04 7.15E-03 
Q99962 SH3GL2 Endophilin-A1 1 2.04 7.15E-03 




Q14511 NEDD9 Enhancer of filamentation 1 3 1.98 9.55E-03 
Q8TAM2 TTC8 Tetratricopeptide repeat protein 8 2 1.98 9.55E-03 
Proteins rescued by MG132 at 18hpi 
Uniprot Gene Symbol Description Peptides MG132 rescue ratio Rescue ratio p-value 
Q9H0V9-2 LMAN2L Isoform 2 of VIP36-like protein 1 4.65 6.73E-08 
Q6ZN30 BNC2 Zinc finger protein basonuclin-2 6 3.75 2.72E-06 
Q9H1A4 ANAPC1 Anaphase-promoting complex subunit 1 6 3.43 1.09E-05 
Q15678 PTPN14 Tyrosine-protein phosphatase non-receptor type 14 9 3.29 2.04E-05 
Q9NRY4 ARHGAP35 Rho GTPase-activating protein 35 20 3.02 6.91E-05 
Q14527 HLTF Helicase-like transcription factor 5 3.02 6.91E-05 
Q9Y485 DMXL1 DmX-like protein 1 5 3.01 7.23E-05 
Q15392 DHCR24 Delta(24)-sterol reductase 9 2.99 7.92E-05 
O43734 TRAF3IP2 Adapter protein CIKS 1 2.95 9.52E-05 
Q86X27 RALGPS2 Ras-specific guanine nucleotide-releasing factor 
RalGPS2 
4 2.85 1.51E-04 
Q96NE9 FRMD6 FERM domain-containing protein 6 6 2.78 2.09E-04 
Q9UKI2 CDC42EP3 Cdc42 effector protein 3 4 2.77 2.19E-04 
Q9H3M7 TXNIP Thioredoxin-interacting protein 7 2.74 2.53E-04 
Q7Z2Z1 TICRR Treslin 1 2.71 2.91E-04 
Q96SB3 PPP1R9B Neurabin-2 15 2.64 4.04E-04 
Q3MIT2 PUS10 Putative tRNA pseudouridine synthase Pus10 1 2.56 5.90E-04 
Q9UJX5-3 ANAPC4 Isoform 3 of Anaphase-promoting complex subunit 4 3 2.56 5.90E-04 
Q9UJX4 ANAPC5 Anaphase-promoting complex subunit 5 3 2.55 6.18E-04 
P46934-4 NEDD4 Isoform 4 of E3 ubiquitin-protein ligase NEDD4 8 2.51 7.48E-04 
Q86SQ0 PHLDB2 Pleckstrin homology-like domain family B member 2 26 2.50 7.84E-04 
Q8NB16 MLKL Mixed lineage kinase domain-like protein 3 2.49 8.22E-04 
Q7Z3E5 ARMC9 LisH domain-containing protein ARMC9 11 2.41 1.20E-03 
Q9HAU0-6 PLEKHA5 Isoform 6 of Pleckstrin homology domain-containing 
family A member 5 




Q8WV24 PHLDA1 Pleckstrin homology-like domain family A member 1 1 2.37 1.46E-03 
Q9UHI8 ADAMTS1 A disintegrin and metalloproteinase with 
thrombospondin motifs 1 
12 2.37 1.46E-03 
Q96PU5 NEDD4L E3 ubiquitin-protein ligase NEDD4-like 3 2.35 1.61E-03 
O75676 RPS6KA4 Ribosomal protein S6 kinase alpha-4 4 2.34 1.68E-03 
Q9Y4F9 FAM65B Protein FAM65B 5 2.33 1.77E-03 
O75486 SUPT3H Transcription initiation protein SPT3 homolog 1 2.31 1.94E-03 
Q9HA65 TBC1D17 TBC1 domain family member 17 4 2.29 2.14E-03 
Q96J02 ITCH E3 ubiquitin-protein ligase Itchy homolog 5 2.24 2.72E-03 
Q14149 MORC3 MORC family CW-type zinc finger protein 3 13 2.21 3.15E-03 
Q86XF0 DHFRL1 Dihydrofolate reductase, mitochondrial 3 2.16 4.00E-03 
P78357 CNTNAP1 Contactin-associated protein 1 10 2.15 4.20E-03 
Q5T5X7 BEND3 BEN domain-containing protein 3 3 2.14 4.41E-03 
P30307 CDC25C M-phase inducer phosphatase 3 1 2.11 5.10E-03 
P23497-4 SP100 Isoform Sp100-C of Nuclear autoantigen Sp-100 17 2.11 5.10E-03 
Q9P0V3 SH3BP4 SH3 domain-binding protein 4 14 2.09 5.61E-03 
P17302 GJA1 Gap junction alpha-1 protein 9 2.05 6.81E-03 
P84022 SMAD3 Mothers against decapentaplegic homolog 3 2 2.05 6.81E-03 
Q9Y2U5 MAP3K2 Mitogen-activated protein kinase kinase kinase 2 3 2.05 6.81E-03 
Q14865 ARID5B AT-rich interactive domain-containing protein 5B 13 2.04 7.15E-03 
Q99962 SH3GL2 Endophilin-A1 1 2.04 7.15E-03 
Q96JM2-3 ZNF462 Isoform 3 of Zinc finger protein 462 1 2.01 8.26E-03 
Q14511 NEDD9 Enhancer of filamentation 1 3 1.98 9.55E-03 
Q8TAM2 TTC8 Tetratricopeptide repeat protein 8 2 1.98 9.55E-03 
Proteins rescued by MG132 at 24 hpi 
Uniprot Gene Symbol Description Peptides MG132 rescue ratio Rescue ratio p-value 
Q5T5X7 BEND3 BEN domain-containing protein 3 1 5.62 5.54E-19 
P54756 EPHA5 Ephrin type-A receptor 5 2 3.66 1.44E-11 




P01100 FOS Proto-oncogene c-Fos 3 2.91 2.08E-08 
P09603 CSF1 Macrophage colony-stimulating factor 1 2 2.75 1.03E-07 
O95067 CCNB2 G2/mitotic-specific cyclin-B2 2 2.72 1.39E-07 
O76061 STC2 Stanniocalcin-2 1 2.61 4.18E-07 
P52799 EFNB2 Ephrin-B2 4 2.51 1.15E-06 
P55040 GEM GTP-binding protein GEM 1 2.36 5.21E-06 
Q14527 HLTF Helicase-like transcription factor 9 2.33 7.05E-06 
P28360 MSX1 Homeobox protein MSX-1 3 2.18 3.20E-05 
P54753 EPHB3 Ephrin type-B receptor 3 6 2.17 3.53E-05 
Q13322 GRB10 Growth factor receptor-bound protein 10 3 2.13 5.28E-05 
A6ZKI3 FAM127A Protein FAM127A 2 2.08 8.71E-05 
P48740-2 MASP1 Isoform 2 of Mannan-binding lectin serine protease 1 7 2.07 9.63E-05 
Q96JG8-4 MAGED4 Isoform 4 of Melanoma-associated antigen D4 5 2.04 1.30E-04 
Q9NTJ4-4 MAN2C1 Isoform 4 of Alpha-mannosidase 2C1 1 2.03 1.43E-04 
Q15048 LRRC14 Leucine-rich repeat-containing protein 14 1 1.99 2.14E-04 
P08697 SERPINF2 Alpha-2-antiplasmin 1 1.95 3.17E-04 
Q86Y39 NDUFA11 NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 11 
5 1.91 4.71E-04 
O95243 MBD4 Methyl-CpG-binding domain protein 4 7 1.90 5.19E-04 
O15194 CTDSPL CTD small phosphatase-like protein 1 1.89 5.73E-04 
Q15014 MORF4L2 Mortality factor 4-like protein 2 13 1.87 6.96E-04 
Q9Y561 LRP12 Low-density lipoprotein receptor-related protein 12 3 1.85 8.46E-04 
Q9Y4G2 PLEKHM1 Pleckstrin homology domain-containing family M 
member 1 
3 1.82 1.13E-03 
Q14149 MORC3 MORC family CW-type zinc finger protein 3 11 1.81 1.25E-03 
O43164 PJA2 E3 ubiquitin-protein ligase Praja-2 7 1.81 1.25E-03 
Q86VI3 IQGAP3 Ras GTPase-activating-like protein IQGAP3 20 1.81 1.25E-03 
Q9BRS2 RIOK1 Serine/threonine-protein kinase RIO1 3 1.80 1.37E-03 




Q7Z5L7-3 PODN Isoform 3 of Podocan 2 1.79 1.51E-03 
Q9H2G9 BLZF1 Golgin-45 12 1.79 1.51E-03 
O75689-2 ADAP1 Isoform 2 of Arf-GAP with dual PH domain-
containing protein 1 
1 1.77 1.83E-03 
Q86YV9 HPS6 Hermansky-Pudlak syndrome 6 protein 2 1.76 2.02E-03 
Q9Y5G0 PCDHGB5 Protocadherin gamma-B5 7 1.76 2.02E-03 
O14939 PLD2 Phospholipase D2 1 1.75 2.22E-03 
Q66K89 E4F1 Transcription factor E4F1 1 1.74 2.44E-03 
Q6PID6 TTC33 Tetratricopeptide repeat protein 33 4 1.74 2.44E-03 
P23497-4 SP100 Isoform Sp100-C of Nuclear autoantigen Sp-100 21 1.74 2.44E-03 
Q8IX01 SUGP2 SURP and G-patch domain-containing protein 2 17 1.74 2.44E-03 
Q9H1A4 ANAPC1 Anaphase-promoting complex subunit 1 11 1.71 3.25E-03 
Q15831 STK11 Serine/threonine-protein kinase STK11 1 1.70 3.57E-03 
P55899 FCGRT IgG receptor FcRn large subunit p51 4 1.69 3.92E-03 
Q99962 SH3GL2 Endophilin-A1 1 1.69 3.92E-03 
Q9NYF3 FAM53C Protein FAM53C 3 1.68 4.31E-03 
Q8N4S0 CCDC82 Coiled-coil domain-containing protein 82 4 1.68 4.31E-03 
Q9BY41 HDAC8 Histone deacetylase 8 1 1.67 4.73E-03 
O60238 BNIP3L BCL2/adenovirus E1B 19 kDa protein-interacting 
protein 3-like 
2 1.67 4.73E-03 
O14730 RIOK3 Serine/threonine-protein kinase RIO3 7 1.67 4.73E-03 
Q8NB16 MLKL Mixed lineage kinase domain-like protein 7 1.64 6.26E-03 
Q03113 GNA12 Guanine nucleotide-binding protein subunit alpha-12 6 1.64 6.26E-03 
Q99715 COL12A1 Collagen alpha-1(XII) chain 147 1.63 6.87E-03 
Q9UKU6 TRHDE Thyrotropin-releasing hormone-degrading 
ectoenzyme 
9 1.63 6.87E-03 
Q8N0W4-2 NLGN4X Isoform 2 of Neuroligin-4, X-linked 1 1.63 6.87E-03 
O96006 ZBED1 Zinc finger BED domain-containing protein 1 5 1.62 7.53E-03 




Q13671 RIN1 Ras and Rab interactor 1 9 1.61 8.26E-03 
Q14094 CCNI Cyclin-I 2 1.60 9.05E-03 
P01008 SERPINC1 Antithrombin-III 2 1.59 9.91E-03 
Q53HC5 KLHL26 Kelch-like protein 26 2 1.59 9.91E-03 
 
Uniprot Gene Symbol Description Peptides MG132 rescue ratio Rescue ratio p-value 
Q99418 CYTH2 Cytohesin-2 1 3.57 1.11E-19 
Q5T7W7 TSTD2 Thiosulfate sulfurtransferase/rhodanese-like 
domain-containing protein 2 
1 2.70 1.11E-12 
P12107 COL11A1 Collagen alpha-1(XI) chain 1 2.61 6.07E-12 
Q5T5X7 BEND3 BEN domain-containing protein 3 3 2.48 7.07E-11 
Q9UJX6 ANAPC2 Anaphase-promoting complex subunit 2 1 2.26 4.44E-09 
Q6UUV9-2 CRTC1 Isoform 2 of CREB-regulated transcription 
coactivator 1 
1 2.23 7.78E-09 
Q9BRT8 CBWD1 COBW domain-containing protein 1 1 2.00 5.48E-07 
Q14527 HLTF Helicase-like transcription factor 8 1.95 1.36E-06 
Q9NZ94 NLGN3 Neuroligin-3 1 1.88 4.78E-06 
P09603 CSF1 Macrophage colony-stimulating factor 1 1 1.86 6.82E-06 
Q8N4S0 CCDC82 Coiled-coil domain-containing protein 82 5 1.85 8.14E-06 
A6ZKI3 FAM127A Protein FAM127A 3 1.77 3.31E-05 
A1A4S6 ARHGAP10 Rho GTPase-activating protein 10 7 1.76 3.94E-05 
Q8IX01 SUGP2 SURP and G-patch domain-containing protein 2 12 1.76 3.94E-05 
O00221 NFKBIE NF-kappa-B inhibitor epsilon 3 1.72 7.82E-05 
Q14653 IRF3 Interferon regulatory factor 3 3 1.70 1.10E-04 
Q86XP1 DGKH Diacylglycerol kinase eta 1 1.69 1.30E-04 
Q8IVF5-2 TIAM2 Isoform 2 of T-lymphoma invasion and metastasis-
inducing protein 2 
1 1.69 1.30E-04 
Q9UHW5-2 GPN3 Isoform 2 of GPN-loop GTPase 3 1 1.68 1.54E-04 




P98174 FGD1 FYVE, RhoGEF and PH domain-containing protein 1 4 1.67 1.82E-04 
Q9UK97 FBXO9 F-box only protein 9 2 1.66 2.15E-04 
Q9Y4K3 TRAF6 TNF receptor-associated factor 6 2 1.65 2.54E-04 
Q8IYR2 SMYD4 SET and MYND domain-containing protein 4 1 1.65 2.54E-04 
P52799 EFNB2 Ephrin-B2 4 1.64 3.00E-04 
Q15038 DAZAP2 DAZ-associated protein 2 1 1.64 3.00E-04 
O14641 DVL2 Segment polarity protein dishevelled homolog DVL-2 11 1.63 3.54E-04 
Q86VP3-2 PACS2 Isoform 2 of Phosphofurin acidic cluster sorting 
protein 2 
2 1.63 3.54E-04 
Q8WWN8 ARAP3 Arf-GAP with Rho-GAP domain, ANK repeat and PH 
domain-containing protein 3 
3 1.61 4.91E-04 
Q8WV24 PHLDA1 Pleckstrin homology-like domain family A member 1 1 1.61 4.91E-04 
Q8N2Q7 NLGN1 Neuroligin-1 2 1.59 6.79E-04 
O60566-3 BUB1B Isoform 3 of Mitotic checkpoint serine/threonine-
protein kinase BUB1 beta 
1 1.56 1.10E-03 
O95243 MBD4 Methyl-CpG-binding domain protein 4 6 1.55 1.29E-03 
Q96JK2 DCAF5 DDB1- and CUL4-associated factor 5 6 1.54 1.51E-03 
P32754 HPD 4-hydroxyphenylpyruvate dioxygenase 1 1.54 1.51E-03 
Q13490 BIRC2 Baculoviral IAP repeat-containing protein 2 7 1.54 1.51E-03 
Q12882 DPYD Dihydropyrimidine dehydrogenase [NADP(+)] 6 1.53 1.76E-03 
Q53GA4 PHLDA2 Pleckstrin homology-like domain family A member 2 3 1.52 2.06E-03 
Q6PID6 TTC33 Tetratricopeptide repeat protein 33 6 1.52 2.06E-03 
Q8IWZ6 BBS7 Bardet-Biedl syndrome 7 protein 2 1.52 2.06E-03 
Q15678 PTPN14 Tyrosine-protein phosphatase non-receptor type 14 3 1.51 2.40E-03 
Q8TDX6 CSGALNACT1 Chondroitin sulfate N-
acetylgalactosaminyltransferase 1 
1 1.51 2.40E-03 
Q03113 GNA12 Guanine nucleotide-binding protein subunit alpha-12 1 1.51 2.40E-03 
P48740-2 MASP1 Isoform 2 of Mannan-binding lectin serine protease 1 11 1.51 2.40E-03 
Q9HAD4 WDR41 WD repeat-containing protein 41 4 1.50 2.80E-03 










Appendix table 2. Proteins identified to be degraded by pSILAC screen. 
The uniprot accession code, gene name, full gene name of proteins identified to be degraded over 6 or 18 h of HCMV infection are listed. 
The rate of protein decline in mock- and HCMV-infected samples was therefore estimated using exponential regression in Excel and the 
formula: [relative protein abundance] (t) = eKdeg ∙ t where Kdeg is the rate constant for degradation, and should be negative for degraded 
proteins.  In cases where Kdegmock was greater than 0, a fold change (FCCMV) in protein abundance in the HCMV-infected sample at 6 or 18 
hpi was instead used, defined by FCHCMV = e-Kdeg(CMV) ∙ t A protein was considered down-regulated if rdeg = KdegHCMV/Kdegmock > 1.5 (when 
Kdegmock <0) or FCHCMV > 1.5 (when Kdegmock >0). P-values of rdeg (when Kdegmock <0) and FCHCMV (when Kdegmock >0) were estimated and 








6h rdeg or 
FCHCMV 







Q14527 HLTF Helicase-like transcription factor 10 5 4.26 1.76 1.14E-09 4.83E-02 
Q8IX01 SUGP2 SURP and G-patch domain-
containing protein 2 
17 16 9.59 2.30 2.25E-02 5.12E-12 
Q96J02 ITCH E3 ubiquitin-protein ligase Itchy 
homolog 
9 12 2.34 2.46 3.38E-02 6.32E-05 
Q14149 MORC3 MORC family CW-type zinc finger 
protein 3 
9 11 2.45 2.57 6.46E-05 5.36E-11 
Q9Y485 DMXL1 DmX-like protein 1 1 6 2.09 5.32 1.81E-02 5.22E-12 
Q92896-2 GLG1 Isoform 2 of Golgi apparatus 
protein 1 
35 36 3.22 4.75 1.08E-25 6.02E-20 
Q8NB16 MLKL Mixed lineage kinase domain-like 
protein 
5 3 1.82 11.43 6.68E-07 8.88E-04 
Q99832 CCT7 T-complex protein 1 subunit eta 50 50 2.69 1.70 4.67E-02 4.31E-04 
P16070 CD44 CD44 antigen 64 62 3.73 6.83 1.79E-06 1.15E-02 
Q9UER7 DAXX Death domain-associated protein 6 2 3 3.46 4.28 1.14E-06 6.43E-03 
P11717 IGF2R Cation-independent mannose-6-
phosphate receptor 




Q8NEM7-3 SUPT20H Isoform 3 of Transcription factor 
SPT20 homolog 
3 2 6.94 3.68 8.10E-03 4.16E-03 
Q53ET0 CRTC2 CREB-regulated transcription 
coactivator 2 
4 2 1.70   1.19E-02 8.03E-01 
P16403 HIST1H1C Histone H1.2 9 17 2.53 0.52 2.80E-02 4.67E-01 
P51805 PLXNA3 Plexin-A3 1 1 1.98 0.79 4.25E-02 5.67E-01 
Q7Z333-4 SETX Isoform 4 of Probable helicase 
senataxin 
3 1 3.88 2.41 2.78E-02 1.96E-01 
Q9Y4K3 TRAF6 TNF receptor-associated factor 6 3 2 3.13 6.92 2.56E-02 4.28E-01 
O00257 CBX4 E3 SUMO-protein ligase CBX4 4 
 
2.14   2.37E-02 
 
Q9Y4F5 CEP170B Centrosomal protein of 170 kDa 
protein B 
1 5 24.09 2.02 7.90E-04 7.21E-01 
P41240 CSK Tyrosine-protein kinase CSK 10 10 6.35 1.16 3.20E-02 7.31E-01 
P27707 DCK Deoxycytidine kinase 7 8 4.01 0.89 3.10E-02 8.05E-02 
Q8N9I9-2 DTX3 Isoform 2 of Probable E3 ubiquitin-
protein ligase DTX3 
1 
 
1.75   1.14E-02 
 
Q70Z53-3 FRA10AC1 Isoform 3 of Protein FRA10AC1 3 3 3.74 0.77 3.19E-02 7.83E-02 
P14649 MYL6B Myosin light chain 6B 8 21 2.69 0.33 3.62E-02 1.88E-01 
P55209 NAP1L1 Nucleosome assembly protein 1-
like 1 
58 35 1.98 0.57 6.59E-03 4.00E-01 
O43776 NARS Asparagine--tRNA ligase, 
cytoplasmic 
22 39 1.54 4.66 3.89E-02 1.57E-01 
P36639 NUDT1 7,8-dihydro-8-oxoguanine 
triphosphatase 
6 3 10.44 -5.97 1.05E-02 9.67E-01 
Q9H5K3 POMK Protein O-mannose kinase 2 3 1.67 1.36 1.94E-02 5.42E-01 
Q9Y371 SH3GLB1 Endophilin-B1 7 8 1.56 1.11 3.14E-02 5.54E-01 
P52630 STAT2 Signal transducer and activator of 
transcription 2 
7 6 3.21 1.29 7.15E-04 1.01E-04 
P16949 STMN1 Stathmin 29 49 1.60 4.51 8.71E-03 2.84E-01 




Q9Y2K1 ZBTB1 Zinc finger and BTB domain-
containing protein 1 
1 
 
1.78   1.15E-02 
 
O43707 ACTN4 Alpha-actinin-4 179 259 1.74 1.32 2.33E-02 2.16E-05 
P54819 AK2 Adenylate kinase 2, mitochondrial 24 30 2.55 -1.61 9.94E-03 2.20E-01 
Q9UIJ7 AK3 GTP:AMP phosphotransferase AK3, 
mitochondrial 
9 13 2.23 -0.93 1.72E-02 2.44E-03 
Q13740-2 ALCAM Isoform 2 of CD166 antigen 64 46 2.59 3.30 1.22E-02 7.24E-01 
Q9NVI7-2 ATAD3A Isoform 2 of ATPase family AAA 
domain-containing protein 3A 
8 18 2.67 -3.73 3.39E-02 6.09E-02 
P78537 BLOC1S1 Biogenesis of lysosome-related 
organelles complex 1 subunit 1 
3 1 2.47 0.51 1.07E-02 7.14E-01 
Q12830 BPTF Nucleosome-remodeling factor 
subunit BPTF 
15 33 1.61 0.46 1.08E-02 6.00E-08 
Q05682-4 CALD1 Isoform 4 of Caldesmon 4 8 2.24   2.16E-03 2.50E-01 
Q05682-3 CALD1 Isoform 3 of Caldesmon 3 1 3.21 0.57 1.34E-03 4.64E-01 
Q76M96-2 CCDC80 Isoform 2 of Coiled-coil domain-
containing protein 80 
3 9 1.63 1.06 1.51E-03 3.53E-01 
Q9ULG6-5 CCPG1 Isoform 5 of Cell cycle progression 
protein 1 
3 6 2.42 0.85 1.22E-02 1.66E-04 
Q9H3Q1 CDC42EP4 Cdc42 effector protein 4 10 6 3.22 0.90 1.12E-02 4.33E-01 
Q9NZZ3 CHMP5 Charged multivesicular body 
protein 5 
9 9 1.75 0.45 1.57E-02 4.67E-01 
Q9Y3Y2-3 CHTOP Isoform 2 of Chromatin target of 
PRMT1 protein 
9 7 1.82 0.22 4.82E-02 2.79E-01 
P20674 COX5A Cytochrome c oxidase subunit 5A, 
mitochondrial 
7 17 1.58 -1.18 4.87E-02 3.51E-01 
P51398 DAP3 28S ribosomal protein S29, 
mitochondrial 
13 13 14.88 -0.23 1.60E-03 3.12E-01 
Q9NX74 DUS2 tRNA-dihydrouridine(20) synthase 
[NAD(P)+]-like 
8 3 1.75 0.61 8.37E-03 3.09E-01 




Q96AY2-2 EME1 Isoform 2 of Crossover junction 
endonuclease EME1 
1 2 6.26   1.07E-02 7.69E-01 
P06733 ENO1 Alpha-enolase 209 220 3.90   4.54E-04 3.21E-02 
P58107 EPPK1 Epiplakin 6 4 1.62 6.15 3.56E-02 2.13E-01 
P60520 GABARAPL2 Gamma-aminobutyric acid 
receptor-associated protein-like 2 
9 10 6.16 1.14 4.45E-02 2.09E-01 
Q8NBF1 GLIS1 Zinc finger protein GLIS1 1 
 
2.35   1.44E-02 
 
Q5T3I0-3 GPATCH4 Isoform 3 of G patch domain-
containing protein 4 
6 5 2.82 0.48 3.22E-02 3.94E-02 
Q6P1K8 GTF2H2C General transcription factor IIH 
subunit 2-like protein 
3 4 2.78   1.57E-02 8.30E-01 
P16402 HIST1H1D Histone H1.3 40 60 1.66 0.41 2.99E-02 2.88E-01 
P31943 HNRNPH1 Heterogeneous nuclear 
ribonucleoprotein H 
24 45 9.99 -0.96 1.31E-02 4.96E-01 
P55795 HNRNPH2 Heterogeneous nuclear 
ribonucleoprotein H2 
4 19 2.03   2.49E-02 9.47E-03 
Q9HBG6-5 IFT122 Isoform 5 of Intraflagellar transport 
protein 122 homolog 
7 5 1.86 5.50 7.86E-03 4.82E-01 
Q16891-2 IMMT Isoform 2 of MICOS complex 
subunit MIC60 
3 8 4.11 1.06 4.33E-02 3.69E-03 
Q14678 KANK1 KN motif and ankyrin repeat 
domain-containing protein 1 
10 3 1.61 1.27 5.31E-03 7.34E-01 
O60870 KIN DNA/RNA-binding protein KIN17 5 5 10.02 0.49 2.95E-02 5.04E-04 
Q9UHV7 MED13 Mediator of RNA polymerase II 
transcription subunit 13 
3 2 12.70 1.32 3.63E-02 6.53E-01 
P42568 MLLT3 Protein AF-9 1 2 6.13 0.58 1.92E-03 9.19E-03 
P82650 MRPS22 28S ribosomal protein S22, 
mitochondrial 
14 9 15.82 0.35 1.33E-02 2.40E-01 
P35579 MYH9 Myosin-9 632 738 17.58 1.46 1.50E-03 1.44E-05 




O00483 NDUFA4 Cytochrome c oxidase subunit 
NDUFA4 
4 9 2.63 0.95 1.48E-04 4.21E-01 
P08651 NFIC Nuclear factor 1 C-type 8 10 2.15 0.86 4.60E-03 1.00E+00 
O60551 NMT2 Glycylpeptide N-
tetradecanoyltransferase 2 
12 14 1.51 0.06 3.26E-02 9.62E-01 
O95478 NSA2 Ribosome biogenesis protein NSA2 
homolog 
2 3 2.77 0.77 2.21E-02 3.38E-02 
P22059 OSBP Oxysterol-binding protein 1 13 19 3.79 0.71 3.99E-02 3.35E-01 
Q8TE49-2 OTUD7A Isoform 2 of OTU domain-
containing protein 7A 
1 2 1.62 1.14 1.64E-02 4.22E-02 
Q9UKK3 PARP4 Poly [ADP-ribose] polymerase 4 33 33 1.61 0.91 2.32E-02 1.31E-01 
P57721 PCBP3 Poly(rC)-binding protein 3 25 17 5.26 1.23 9.28E-03 1.07E-01 
Q9Y263 PLAA Phospholipase A-2-activating 
protein 
14 15 1.87 0.79 2.54E-02 4.96E-01 
Q9UNA4 POLI DNA polymerase iota 4 
 
2.20   5.80E-03 
 
P24928 POLR2A DNA-directed RNA polymerase II 
subunit RPB1 
29 31 2.12 1.11 4.65E-05 9.81E-07 
O15514 POLR2D DNA-directed RNA polymerase II 
subunit RPB4 
5 4 6.94 0.77 3.93E-02 2.55E-01 
O15355 PPM1G Protein phosphatase 1G 15 19 2.18 0.32 9.74E-03 7.67E-01 
P63151-2 PPP2R2A Isoform 2 of Serine/threonine-
protein phosphatase 2A 55 kDa 
regulatory subunit B alpha isoform 
12 21 59.69 0.38 2.28E-02 1.94E-01 
Q99460 PSMD1 26S proteasome non-ATPase 
regulatory subunit 1 
78 67 2.38 5.76 5.50E-04 5.14E-02 
Q15185 PTGES3 Prostaglandin E synthase 3 22 27 1.75   2.93E-02 1.41E-01 
P51149 RAB7A Ras-related protein Rab-7a 36 33 2.60 3.58 2.04E-02 6.87E-02 
C9J798 RASA4B Ras GTPase-activating protein 4B 5 3 1.72 0.99 7.30E-03 5.30E-01 
Q9H7B2 RPF2 Ribosome production factor 2 
homolog 
7 4 3.84 1.94 4.79E-03 4.36E-01 




P62424 RPL7A 60S ribosomal protein L7a 52 57 3.16 1.18 2.09E-03 1.48E-01 
P46783 RPS10 40S ribosomal protein S10 38 42 6.02 -0.46 1.14E-02 3.17E-01 
P62841 RPS15 40S ribosomal protein S15 22 18 1.73 -0.90 4.41E-03 8.76E-03 
P62244 RPS15A 40S ribosomal protein S15a 22 13 4.14   2.70E-03 3.17E-01 
Q9UBE0 SAE1 SUMO-activating enzyme subunit 1 27 26 3.09 -0.12 1.60E-02 9.16E-02 
O00422 SAP18 Histone deacetylase complex 
subunit SAP18 
14 10 4.18 0.35 4.47E-02 1.70E-01 
Q9HCN8 SDF2L1 Stromal cell-derived factor 2-like 
protein 1 
1 2 2.15   3.42E-02 3.13E-01 
Q9BRK5 SDF4 45 kDa calcium-binding protein 16 11 1.57 0.52 3.49E-04 4.64E-04 
O94979-8 SEC31A Isoform 8 of Protein transport 
protein Sec31A 
46 57 1.80 0.93 3.02E-02 1.99E-03 
O43765 SGTA Small glutamine-rich 
tetratricopeptide repeat-containing 
protein alpha 
8 15 4.38 0.97 2.76E-02 8.37E-01 
Q5HYK7 SH3D19 SH3 domain-containing protein 19 11 10 1.88 0.41 2.88E-02 9.45E-03 
P48067-2 SLC6A9 Isoform GlyT-1A of Sodium- and 
chloride-dependent glycine 
transporter 1 
2 1 1.68 1.73 1.12E-02 8.86E-01 
O75391 SPAG7 Sperm-associated antigen 7 13 8 1.81 0.71 2.52E-02 1.89E-02 
Q96I99 SUCLG2 Succinate--CoA ligase [GDP-
forming] subunit beta, 
mitochondrial 
40 46 1.72 0.61 3.96E-02 3.32E-01 
Q96BN2 TADA1 Transcriptional adapter 1 1 
 
2.61   2.07E-03 
 
Q6I9Y2 THOC7 THO complex subunit 7 homolog 10 4 1.68 -0.43 9.11E-03 7.88E-03 
O94972 TRIM37 E3 ubiquitin-protein ligase TRIM37 1 
 
2.26   8.31E-03 
 
Q969M7-2 UBE2F Isoform 2 of NEDD8-conjugating 
enzyme UBE2F 
2 2 1.89 0.55 3.98E-02 1.67E-01 
Q9NVE5-3 USP40 Isoform 3 of Ubiquitin carboxyl-
terminal hydrolase 40 
6 5 3.52 -1.06 3.24E-02 6.37E-02 




Q7Z5K2-3 WAPL Isoform 3 of Wings apart-like 
protein homolog 
15 17 3.02 0.86 4.96E-02 1.53E-02 
Q9H1J7 WNT5B Protein Wnt-5b 9 4 2.92 0.72 6.22E-03 2.46E-01 
Q68DK2 ZFYVE26 Zinc finger FYVE domain-containing 
protein 26 
6 4 2.69 -1.78 4.10E-02 3.84E-01 
Q15326 ZMYND11 Zinc finger MYND domain-
containing protein 11 
6 7 2.27 1.66 3.94E-04 3.51E-01 
Q9H1A4 ANAPC1 Anaphase-promoting complex 
subunit 1 
6 6 1.24 10.60 3.20E-02 9.86E-09 
Q9UJX4 ANAPC5 Anaphase-promoting complex 
subunit 5 
6 2 1.67 4.63 1.20E-01 3.38E-03 
Q9NRY4 ARHGAP35 Rho GTPase-activating protein 35 18 36 1.83 4.20 1.02E-02 1.09E-21 
Q9HAU0-6 PLEKHA5 Isoform 6 of Pleckstrin homology 
domain-containing family A 
member 5 
7 10   4.40 5.11E-01 2.60E-03 
Q96SB3 PPP1R9B Neurabin-2 8 11 1.50 5.56 5.52E-03 5.12E-12 
Q15392 DHCR24 Delta(24)-sterol reductase 13 15   9.24 3.28E-01 1.29E-07 
P16333 NCK1 Cytoplasmic protein NCK1 13 10 0.18 2.40 4.13E-01 2.09E-06 
P13797 PLS3 Plastin-3 109 94   2.47 4.83E-01 9.41E-06 
P17612 PRKACA cAMP-dependent protein kinase 
catalytic subunit alpha 
6 8   1.61 4.88E-02 2.55E-02 
P60891 PRPS1 Ribose-phosphate 
pyrophosphokinase 1 
14 11 1.68 30.28 3.30E-01 3.47E-02 
P23497-4 SP100 Isoform Sp100-C of Nuclear 
autoantigen Sp-100 
13 5 1.14 3.40 7.33E-03 8.96E-05 
Q9H4A3-7 WNK1 Isoform 6 of Serine/threonine-
protein kinase WNK1 
28 29 1.34 2.24 3.96E-01 4.57E-04 
Q9UJX5-3 ANAPC4 Isoform 3 of Anaphase-promoting 
complex subunit 4 
2 3 -0.38 5.32 7.37E-01 4.30E-03 
P78357 CNTNAP1 Contactin-associated protein 1 3 4 1.26 2.61 1.18E-02 2.50E-03 




Q15678 PTPN14 Tyrosine-protein phosphatase non-
receptor type 14 
4 3 1.83 1.77 2.59E-01 2.68E-02 
Q86X27 RALGPS2 Ras-specific guanine nucleotide-
releasing factor RalGPS2 
7 7   5.69 3.14E-02 2.42E-05 
O75676 RPS6KA4 Ribosomal protein S6 kinase alpha-
4 
7 6 1.78 2.43 1.50E-01 1.17E-05 
O96006 ZBED1 Zinc finger BED domain-containing 
protein 1 
4 3 1.15 2.06 8.00E-02 6.47E-03 
Q2M2I8 AAK1 AP2-associated protein kinase 1 12 26 0.57 14.39 4.51E-01 4.26E-02 
Q9Y6D5 ARFGEF2 Brefeldin A-inhibited guanine 
nucleotide-exchange protein 2 
8 13 -1.07 2.79 2.61E-01 4.81E-03 
P31939 ATIC Bifunctional purine biosynthesis 
protein PURH 
45 49 1.18 2.95 9.37E-01 1.86E-04 
Q7L1Q6-3 BZW1 Isoform 3 of Basic leucine zipper 
and W2 domain-containing protein 
1 
35 47   2.34 6.78E-01 3.37E-02 
P16152 CBR1 Carbonyl reductase [NADPH] 1 46 26   4.60 4.63E-01 4.21E-02 
P14324 FDPS Farnesyl pyrophosphate synthase 7 12   1.62 7.56E-01 1.60E-02 
Q4V328 GRIPAP1 GRIP1-associated protein 1 12 14 1.48 1.85 7.88E-01 5.06E-03 
Q13907-2 IDI1 Isoform 2 of Isopentenyl-
diphosphate Delta-isomerase 1 
10 12   1.94 4.87E-01 2.86E-03 
P46821 MAP1B Microtubule-associated protein 1B 184 246 -0.56 2.36 2.36E-01 1.38E-08 
Q15691 MAPRE1 Microtubule-associated protein 
RP/EB family member 1 
27 27   2.85 2.11E-01 1.33E-02 
P61244 MAX Protein max 1 1 1.50 2.03 9.69E-01 4.64E-02 
Q96RE7 NACC1 Nucleus accumbens-associated 
protein 1 
6 8 -8.43 10.58 1.11E-01 2.56E-02 
Q16537 PPP2R5E Serine/threonine-protein 
phosphatase 2A 56 kDa regulatory 
subunit epsilon isoform 
4 5   2.72 7.86E-02 4.64E-03 




P04049-2 RAF1 Isoform 2 of RAF proto-oncogene 
serine/threonine-protein kinase 
3 7 -4.00 2.08 5.62E-01 7.72E-03 
P08134 RHOC Rho-related GTP-binding protein 
RhoC 
16 20   2.88 2.66E-01 7.64E-09 
Q9NR31 SAR1A GTP-binding protein SAR1a 9 10   5.20 6.15E-01 1.76E-02 
Q8IXJ6 SIRT2 NAD-dependent protein 
deacetylase sirtuin-2 
2 1 1.26 9.80 4.77E-01 4.70E-02 
Q14258 TRIM25 E3 ubiquitin/ISG15 ligase TRIM25 24 35   4.07 5.05E-01 6.88E-06 
Q16222 UAP1 UDP-N-acetylhexosamine 
pyrophosphorylase 
20 22 0.77 1.61 3.80E-01 3.73E-02 
P61088 UBE2N Ubiquitin-conjugating enzyme E2 N 30 23   4.81 3.36E-04 1.02E-05 
Q5T4S7-2 UBR4 Isoform 2 of E3 ubiquitin-protein 
ligase UBR4 
78 80   1.54 7.76E-01 5.25E-03 
P23381 WARS Tryptophan--tRNA ligase, 
cytoplasmic 
30 38   4.01 6.36E-01 4.16E-05 
P54577 YARS Tyrosine--tRNA ligase, cytoplasmic 60 63   12.40 1.12E-02 4.91E-03 
P31946 YWHAB 14-3-3 protein beta/alpha 27 22 -1.13 4.73 6.30E-01 7.87E-04 
Q9Y6B6 SAR1B GTP-binding protein SAR1b 16 12   1.54 5.05E-02 2.58E-03 
P35611-3 ADD1 Isoform 3 of Alpha-adducin 29 19 -83.43 2.64 6.82E-01 1.32E-05 
Q9UEY8 ADD3 Gamma-adducin 15 20 0.39 1.64 9.24E-01 3.83E-05 
P63010-2 AP2B1 Isoform 2 of AP-2 complex subunit 
beta 
65 101   2.50 4.09E-01 4.16E-05 
Q8N392 ARHGAP18 Rho GTPase-activating protein 18 27 27 2.60 4.47 3.64E-01 9.68E-03 
Q9NVJ2 ARL8B ADP-ribosylation factor-like protein 
8B 
15 9   11.11 8.47E-01 5.19E-04 
Q8NHH9 ATL2 Atlastin-2 4 8 1.50 2.29 1.21E-01 4.43E-02 
P20020-3 ATP2B1 Isoform B of Plasma membrane 
calcium-transporting ATPase 1 
49 82 1.95 16.03 9.53E-01 4.80E-02 
O75964 ATP5L ATP synthase subunit g, 
mitochondrial 
9 5 -1.46 40.92 4.31E-01 2.84E-02 




P54289 CACNA2D1 Voltage-dependent calcium 
channel subunit alpha-2/delta-1 
17 21 -3.96 2.28 2.51E-01 1.57E-03 
Q86VP6 CAND1 Cullin-associated NEDD8-
dissociated protein 1 
65 66   5.94 6.17E-01 9.54E-04 
P17655 CAPN2 Calpain-2 catalytic subunit 52 44 -5.18 3.40 7.77E-01 1.02E-05 
P40227 CCT6A T-complex protein 1 subunit zeta 59 30 1.53 2.81 2.50E-03 2.90E-04 
P14209 CD99 CD99 antigen 4 9 0.79 1.70 6.27E-02 2.06E-02 
P60953 CDC42 Cell division control protein 42 
homolog 
25 23   4.89 6.19E-01 2.66E-05 
Q9Y5S2 CDC42BPB Serine/threonine-protein kinase 
MRCK beta 
16 33   2.80 8.82E-02 7.59E-04 
Q8NCH0 CHST14 Carbohydrate sulfotransferase 14   2   1.97   3.98E-02 
Q07065 CKAP4 Cytoskeleton-associated protein 4 67 88 2.47 4.18 2.56E-01 2.49E-02 
O96005 CLPTM1 Cleft lip and palate transmembrane 
protein 1 
5 18   1.58 4.48E-01 4.20E-03 
Q00610 CLTC Clathrin heavy chain 1 165 133   4.41 6.67E-01 2.46E-10 
P21964 COMT Catechol O-methyltransferase 15 8   90.75 2.79E-02 4.31E-03 
Q9Y678 COPG1 Coatomer subunit gamma-1 51 59   2.83 8.24E-02 8.46E-04 
Q9BT78 COPS4 COP9 signalosome complex subunit 
4 
25 23   3.43 3.48E-04 1.33E-02 
Q9ULV4-3 CORO1C Isoform 3 of Coronin-1C 53 80 1.35 1.77 2.00E-01 2.06E-02 
Q99829 CPNE1 Copine-1 14 16 1.56 4.57 3.24E-01 2.85E-02 
O75718 CRTAP Cartilage-associated protein 22 30   32.40 2.31E-02 2.16E-02 
P35221 CTNNA1 Catenin alpha-1 48 57 1.22 1.59 1.56E-01 6.55E-15 
Q14247 CTTN Src substrate cortactin 61 74 -0.26 2.03 7.38E-01 3.36E-02 
Q96KC8 DNAJC1 DnaJ homolog subfamily C member 
1 
2 6 2.54 1.58 5.71E-01 4.83E-02 
Q96N67 DOCK7 Dedicator of cytokinesis protein 7 30 38   2.39 3.39E-01 4.23E-02 
Q9Y3R5 DOPEY2 Protein dopey-2 7 8   1.85 9.73E-01 3.58E-02 
P26641-2 EEF1G Isoform 2 of Elongation factor 1-
gamma 




P13639 EEF2 Elongation factor 2 256 285   2.29 9.82E-02 3.40E-05 
Q9NZN4 EHD2 EH domain-containing protein 2 76 61   2.42 9.96E-01 8.32E-03 
Q9NZN3 EHD3 EH domain-containing protein 3 19 12   124.38 5.65E-01 2.38E-02 
Q15717-2 ELAVL1 Isoform 2 of ELAV-like protein 1 17 17   2.96 2.59E-01 4.27E-02 
P50402 EMD Emerin 9 14 7.37 2.29 6.44E-01 3.60E-02 
Q9H2F5 EPC1 Enhancer of polycomb homolog 1 2 4 0.93 2.89 9.77E-01 4.43E-02 
Q96CN4-2 EVI5L Isoform 2 of EVI5-like protein 9 5   4.83 3.00E-01 1.16E-03 
Q8IWE2 FAM114A1 Protein NOXP20 32 37 0.53 20.67 9.79E-01 2.87E-02 
Q96TA1 FAM129B Niban-like protein 1 61 71   8.08 8.54E-03 6.06E-08 
Q96AC1-3 FERMT2 Isoform 3 of Fermitin family 
homolog 2 
57 54   2.29 7.46E-02 2.63E-04 
P07954 FH Fumarate hydratase, mitochondrial 49 51   3.09 4.03E-02 3.50E-02 
Q9NZ56 FMN2 Formin-2 5 14   2.02 8.45E-02 3.88E-02 
Q13283 G3BP1 Ras GTPase-activating protein-
binding protein 1 
38 37 0.45 2.00 6.13E-02 1.68E-02 
P11413-2 G6PD Isoform Long of Glucose-6-
phosphate 1-dehydrogenase 
41 44 1.27 2.34 1.23E-01 3.73E-02 
Q8N4A0 GALNT4 Polypeptide N-
acetylgalactosaminyltransferase 4 
3 7   3.42 1.91E-01 4.28E-02 
P04062 GBA Glucosylceramidase 11 7   1.79 8.92E-01 2.40E-02 
Q92820 GGH Gamma-glutamyl hydrolase 5 10   1.60 4.75E-01 2.35E-02 
O94923 GLCE D-glucuronyl C5-epimerase 3 5 1.51 2.59 3.11E-01 3.32E-02 
O94925 GLS Glutaminase kidney isoform, 
mitochondrial 
20 30 -5.43 1.86 1.22E-01 1.14E-02 
Q68CQ7 GLT8D1 Glycosyltransferase 8 domain-
containing protein 1 
9 14 1.39 3.32 9.82E-01 1.70E-03 
P04899-4 GNAI2 Isoform sGi2 of Guanine 
nucleotide-binding protein G(i) 
subunit alpha-2 




P62879 GNB2 Guanine nucleotide-binding 
protein G(I)/G(S)/G(T) subunit 
beta-2 
27 15   1.65 3.29E-01 1.19E-05 
Q9HAV0 GNB4 Guanine nucleotide-binding 
protein subunit beta-4 
3 3   3.43 5.15E-01 4.87E-02 
P63218 GNG5 Guanine nucleotide-binding 
protein G(I)/G(S)/G(O) subunit 
gamma-5 
2 4 -3.49 2.04 6.48E-01 1.16E-03 
Q14789-2 GOLGB1 Isoform 2 of Golgin subfamily B 
member 1 
83 124 0.59 2.72 4.81E-02 8.81E-16 
O00461 GOLIM4 Golgi integral membrane protein 4 15 17 3.91 3.70 1.91E-01 1.88E-02 
P17174 GOT1 Aspartate aminotransferase, 
cytoplasmic 
18 18   3.16 1.59E-01 6.26E-03 
Q8TED1 GPX8 Probable glutathione peroxidase 8 9 14 -0.52 1.70 5.44E-01 6.51E-03 
O43390-2 HNRNPR Isoform 2 of Heterogeneous 
nuclear ribonucleoprotein R 
51 56 1.60 7.15 2.18E-01 3.85E-02 
P34932 HSPA4 Heat shock 70 kDa protein 4 133 151 1.50 26.40 2.28E-01 1.63E-02 
P38646 HSPA9 Stress-70 protein, mitochondrial 102 138 0.85 100.73 2.03E-01 6.51E-03 
Q9Y547 HSPB11 Intraflagellar transport protein 25 
homolog 
5 2   2.12 2.98E-01 2.45E-02 
Q7Z6Z7 HUWE1 E3 ubiquitin-protein ligase HUWE1 45 56 1.76 1.54 1.91E-01 1.98E-02 
O00410-3 IPO5 Isoform 3 of Importin-5 51 63   1.66 4.91E-01 1.50E-03 
P23229-6 ITGA6 Isoform Alpha-6X1X2A of Integrin 
alpha-6 
14 16 0.11 2.39 4.03E-01 4.02E-02 
Q14571 ITPR2 Inositol 1,4,5-trisphosphate 
receptor type 2 
12 18   2.05 2.32E-01 4.70E-02 
P52294 KPNA1 Importin subunit alpha-5 10 12 -7.10 2.16 5.96E-01 8.06E-03 
Q14974 KPNB1 Importin subunit beta-1 36 39 1.55 4.49 1.36E-01 2.63E-04 
P42704 LRPPRC Leucine-rich PPR motif-containing 
protein, mitochondrial 
82 86   4.92 9.60E-01 8.74E-08 
P78559-2 MAP1A Isoform 2 of Microtubule-
associated protein 1A 




P27816-4 MAP4 Isoform 4 of Microtubule-
associated protein 4 
6 11 0.29 2.09 1.11E-02 6.80E-03 
Q99549-2 MPHOSPH8 Isoform 2 of M-phase 
phosphoprotein 8 
9 7   1.84 7.36E-02 4.93E-02 
Q9NZW5 MPP6 MAGUK p55 subfamily member 6 5 8 1.45 2.09 7.34E-01 3.47E-02 
Q86UE4 MTDH Protein LYRIC 39 47 -0.27 4.91 5.64E-01 3.83E-03 
Q15746-2 MYLK Isoform 2 of Myosin light chain 
kinase, smooth muscle 
84 82   1.74 4.21E-01 2.21E-02 
P54920 NAPA Alpha-soluble NSF attachment 
protein 
26 18 0.48 3.54 8.24E-01 7.91E-03 
Q6ZNB6 NFXL1 NF-X1-type zinc finger protein 
NFXL1 
7 12 1.45 3.26 5.62E-01 2.57E-02 
Q13423 NNT NAD(P) transhydrogenase, 
mitochondrial 
51 56 -4.23 4.68 4.06E-01 7.01E-03 
P46459 NSF Vesicle-fusing ATPase 54 51 -0.51 3.64 3.92E-01 5.89E-03 
Q02818 NUCB1 Nucleobindin-1 24 19 0.94 1.63 1.85E-02 3.01E-03 
P80303-2 NUCB2 Isoform 2 of Nucleobindin-2 36 28   13.35 1.23E-01 5.09E-07 
Q13177 PAK2 Serine/threonine-protein kinase 
PAK 2 
27 31 0.41 2.72 6.00E-01 1.26E-02 
O95340-2 PAPSS2 Isoform B of Bifunctional 3'-
phosphoadenosine 5'-
phosphosulfate synthase 2 
12 26 0.83 2.27 8.38E-01 3.90E-04 
Q9NVD7 PARVA Alpha-parvin 15 21 0.65 2.32 7.28E-01 1.17E-02 
O95613 PCNT Pericentrin 18 21 1.44 1.55 1.05E-01 2.23E-02 
P42356 PI4KA Phosphatidylinositol 4-kinase alpha 17 22 5.00 1.58 2.60E-01 2.44E-02 
Q8IY17-4 PNPLA6 Isoform 4 of Neuropathy target 
esterase 
6 9 1.13 5.62 5.74E-05 1.10E-05 
O75569 PRKRA Interferon-inducible double-
stranded RNA-dependent protein 
kinase activator A 
3 14   2.05 1.51E-01 1.87E-02 




P62333 PSMC6 26S protease regulatory subunit 
10B 
22 21 0.22 6.87 7.90E-01 1.55E-02 
Q13200 PSMD2 26S proteasome non-ATPase 
regulatory subunit 2 
48 63   3.05 2.14E-01 3.33E-03 
Q9Y3E5 PTRH2 Peptidyl-tRNA hydrolase 2, 
mitochondrial 
7 8   2.49 2.83E-02 2.97E-02 
P61106 RAB14 Ras-related protein Rab-14 14 20   3.50 8.19E-01 1.33E-02 
Q9ULC3 RAB23 Ras-related protein Rab-23 6 10 -4.14 7.09 6.39E-02 2.58E-04 
P51148-2 RAB5C Isoform 2 of Ras-related protein 
Rab-5C 
36 22   3.83 9.37E-01 1.87E-02 
P61006 RAB8A Ras-related protein Rab-8A 17 30   6.36 3.48E-01 2.08E-03 
P61224 RAP1B Ras-related protein Rap-1b 11 29   4.76 4.45E-02 1.63E-03 
P54136 RARS Arginine--tRNA ligase, cytoplasmic 52 85   28.33 2.29E-01 2.80E-02 
Q9NWS8 RMND1 Required for meiotic nuclear 
division protein 1 homolog 
3 6   1.52 3.01E-01 7.04E-03 
Q96AT9 RPE Ribulose-phosphate 3-epimerase 4 2 0.04 4.27 6.87E-01 2.64E-02 
P62829 RPL23 60S ribosomal protein L23 32 20 0.56 4.21 3.09E-02 2.94E-02 
Q9P2E9 RRBP1 Ribosome-binding protein 1 141 165 0.86 2.61 2.23E-01 2.48E-26 
Q9NQC3 RTN4 Reticulon-4 32 15   3.23 1.36E-02 1.77E-02 
P06703 S100A6 Protein S100-A6 40 36   20.63 1.68E-02 1.63E-05 
P55735-3 SEC13 Isoform 3 of Protein SEC13 
homolog 
17 14   5.49 2.83E-03 2.72E-03 
Q92503-2 SEC14L1 Isoform 2 of SEC14-like protein 1 4 2 1.20 1.84 2.64E-02 1.33E-02 
O75396 SEC22B Vesicle-trafficking protein SEC22b 20 18 0.32 1.60 1.32E-01 1.62E-02 
O94855-2 SEC24D Isoform 2 of Protein transport 
protein Sec24D 
18 24   4.08 3.14E-01 4.15E-03 
Q8NC51-3 SERBP1 Isoform 3 of Plasminogen activator 
inhibitor 1 RNA-binding protein 
3 10   2.45 6.69E-02 3.32E-02 
O75368 SH3BGRL SH3 domain-binding glutamic acid-
rich-like protein 




Q2TAY7 SMU1 WD40 repeat-containing protein 
SMU1 
8 10 2.00 8.62 1.89E-01 8.33E-03 
P57768 SNX16 Sorting nexin-16 1 2 0.88 4.74 6.63E-02 2.15E-02 
Q9H930 SP140L Nuclear body protein SP140-like 
protein 
3 1 1.23 1.87 5.27E-02 2.88E-02 
Q13813-2 SPTAN1 Isoform 2 of Spectrin alpha chain, 
non-erythrocytic 1 
217 226 0.83 2.51 4.89E-01 9.15E-14 
P43307 SSR1 Translocon-associated protein 
subunit alpha 
14 15   11.63 2.14E-02 4.02E-02 
P50502 ST13 Hsc70-interacting protein 41 29 0.70 1.51 2.63E-02 2.64E-03 
P55854-2 SUMO3 Isoform 2 of Small ubiquitin-related 
modifier 3 
7 6 -0.05 3.62 9.59E-02 6.00E-03 
O94901-9 SUN1 Isoform 9 of SUN domain-
containing protein 1 
2 12 11.33 2.48 1.19E-01 1.28E-02 
Q8WXH0-2 SYNE2 Isoform 2 of Nesprin-2 92 95 3.73 3.16 5.59E-01 2.00E-07 
O75529 TAF5L TAF5-like RNA polymerase II 
p300/CBP-associated factor-
associated factor 65 kDa subunit 5L 
  2   4.97   2.10E-03 
Q99805 TM9SF2 Transmembrane 9 superfamily 
member 2 
6 9 1.39 3.28 1.05E-01 1.15E-04 
P49755 TMED10 Transmembrane emp24 domain-
containing protein 10 
25 19 -1.72 5.45 1.39E-01 7.73E-04 
Q15363 TMED2 Transmembrane emp24 domain-
containing protein 2 
13 22   1.51 1.26E-02 4.42E-07 
Q9BVC6 TMEM109 Transmembrane protein 109 3 5 2.18 5.78 2.31E-01 3.96E-02 
Q86WV6 TMEM173 Stimulator of interferon genes 
protein 
3 16   8.33 4.99E-01 1.29E-03 
Q6NUQ4 TMEM214 Transmembrane protein 214 18 31   1.67 8.80E-02 1.21E-02 
Q53FP2 TMEM35A Transmembrane protein 35A 3 3   1.81 3.59E-01 3.47E-02 
Q6ZXV5 TMTC3 Transmembrane and TPR repeat-
containing protein 3 




Q9Y320 TMX2 Thioredoxin-related 
transmembrane protein 2 
5 10 -1.64 1.88 4.28E-02 1.01E-02 
Q9H496 TOR1AIP2 Torsin-1A-interacting protein 2, 
isoform IFRG15 
  1   26.03   2.50E-02 
P09493-6 TPM1 Isoform 6 of Tropomyosin alpha-1 
chain 
8 11 0.36 3.93 8.74E-02 1.03E-05 
P09493-3 TPM1 Isoform 3 of Tropomyosin alpha-1 
chain 
27 46 0.90 1.98 5.39E-06 2.96E-07 
P07951-2 TPM2 Isoform 2 of Tropomyosin beta 
chain 
10 35 0.14 2.21 2.92E-05 8.55E-04 
P07951 TPM2 Tropomyosin beta chain 7 13 0.47 4.76 1.28E-04 1.87E-02 
O95361 TRIM16 Tripartite motif-containing protein 
16 
14 9 1.19 1.56 3.31E-01 1.65E-02 
Q13630 TSTA3 GDP-L-fucose synthase 4 4   1.76 7.55E-01 2.00E-02 
Q9UHD9 UBQLN2 Ubiquilin-2 4 5   1.51 1.59E-01 7.14E-03 
Q8IWV7 UBR1 E3 ubiquitin-protein ligase UBR1 10 13   3.14 8.39E-01 2.72E-02 
Q9NZ43 USE1 Vesicle transport protein USE1 6 7 1.97 1.56 2.57E-01 4.78E-02 
O95183 VAMP5 Vesicle-associated membrane 
protein 5 
1 9 1.07 6.89 9.89E-02 3.01E-02 
Q6EMK4 VASN Vasorin 1 4 1.24 1.64 1.24E-01 7.80E-03 
O75436 VPS26A Vacuolar protein sorting-associated 
protein 26A 
16 22   9.37 2.54E-02 1.19E-02 
Q9H6S0 YTHDC2 Probable ATP-dependent RNA 
helicase YTHDC2 
13 9 1.85 1.81 4.37E-02 2.99E-02 
Q9UBQ5 EIF3K Eukaryotic translation initiation 
factor 3 subunit K 
7 9   1.59 1.05E-01 4.54E-02 






Appendix table 3. Proteins identified to be downregulated on protein level but not RNA level at 24 or 72 hpi. 
The uniprot accession code, gene name, full gene name, number of peptide identified, fold changes of protein and RNA abundance and p-
values of fold changes are listed here. p-values that a given protein was expressed significantly differently at 24 or 72 h compared to mock 
infection were estimated using Benjamini-Hochberg-corrected significance A value. A Benjamini-Hochberg corrected student’s t-test was 
used to estimate the p-value for the hypothesis that a given transcript was expressed significantly differently at 24 or 72 h compared to 
mock infection 







RNA FC 24h Protein 24h 
vs mock p-
value 
RNA 24h vs 
mock p-value 
Q8WW38 ZFPM2 Zinc finger protein ZFPM2 1 0.11 6.50 4.73E-06 1.52E-02 
P51587 BRCA2 Breast cancer type 2 
susceptibility protein 
1 0.12 1.91 4.86E-06 2.76E-03 
Q9H1A4 ANAPC1 Anaphase-promoting complex 
subunit 1 
1 0.20 2.60 5.53E-04 1.84E-03 
Q16670 ZSCAN26 Zinc finger and SCAN domain-
containing protein 26 
1 0.21 1.11 6.80E-04 1.67E-01 
Q9NRY4 ARHGAP35 Rho GTPase-activating protein 
35 
11 0.25 1.07 2.69E-03 4.42E-01 
Q9Y5G0 PCDHGB5 Protocadherin gamma-B5 1 0.25 1.08 3.03E-03 5.55E-01 
P15531-2 NME1 Isoform 2 of Nucleoside 
diphosphate kinase A 
1 0.27 1.30 4.69E-03 2.09E-01 
Q15003 NCAPH Condensin complex subunit 2 1 0.27 1.27 4.83E-03 2.09E-01 
Q7Z333-4 SETX Isoform 4 of Probable helicase 
senataxin 
4 0.27 1.21 4.94E-03 6.88E-02 
Q6PIY7 PAPD4 Poly(A) RNA polymerase GLD2 1 0.28 1.41 5.25E-03 5.48E-03 
Q9H4A3-7 WNK1 Isoform 6 of Serine/threonine-
protein kinase WNK1 




Q99759-2 MAP3K3 Isoform 2 of Mitogen-activated 
protein kinase kinase kinase 3 
1 0.28 1.90 5.54E-03 3.76E-02 
Q99961 SH3GL1 Endophilin-A2 10 0.28 1.02 6.06E-03 9.55E-01 
P16333 NCK1 Cytoplasmic protein NCK1 6 0.30 1.06 8.10E-03 4.48E-01 
P16403 HIST1H1C Histone H1.2 3 0.30 1.16 8.72E-03 9.19E-01 
P23921 RRM1 Ribonucleoside-diphosphate 
reductase large subunit 
15 0.30 1.71 9.10E-03 3.33E-04 
Q9Y2U5 MAP3K2 Mitogen-activated protein 
kinase kinase kinase 2 
1 0.32 1.56 1.24E-02 5.40E-03 
O75815 BCAR3 Breast cancer anti-estrogen 
resistance protein 3 
1 0.32 1.21 1.34E-02 1.19E-01 
Q9UJX4 ANAPC5 Anaphase-promoting complex 
subunit 5 
3 0.33 1.29 1.60E-02 8.82E-03 
P50748 KNTC1 Kinetochore-associated protein 
1 
3 0.34 1.05 1.66E-02 6.69E-01 
Q9HAW0 BRF2 Transcription factor IIIB 50 kDa 
subunit 
2 0.34 2.60 1.91E-02 3.33E-01 
Q99685 MGLL Monoglyceride lipase 8 0.35 1.10 1.98E-02 1.57E-01 
O95081 AGFG2 Arf-GAP domain and FG repeat-
containing protein 2 
1 0.35 1.40 2.03E-02 1.12E-01 
P17812 CTPS1 CTP synthase 1 14 0.35 1.73 2.07E-02 1.51E-02 
P49327 FASN Fatty acid synthase 80 0.35 1.15 2.08E-02 6.81E-01 
Q9P2D6 FAM135A Protein FAM135A 1 0.35 2.43 2.20E-02 6.22E-04 
Q14527 HLTF Helicase-like transcription factor 3 0.35 1.88 2.23E-02 3.44E-03 
Q14790-9 CASP8 Isoform 9 of Caspase-8 2 0.36 1.50 2.28E-02 1.15E-02 
Q9BPX3 NCAPG Condensin complex subunit 3 5 0.36 1.46 2.39E-02 1.05E-02 
Q9BVJ7 DUSP23 Dual specificity protein 
phosphatase 23 
1 0.36 1.00 2.52E-02 9.98E-01 
A1A4S6 ARHGAP10 Rho GTPase-activating protein 
10 




Q05209 PTPN12 Tyrosine-protein phosphatase 
non-receptor type 12 
8 0.37 1.07 2.75E-02 3.97E-01 
Q96PU5 NEDD4L E3 ubiquitin-protein ligase 
NEDD4-like 
3 0.37 2.00 2.77E-02 4.25E-03 
Q8IXW5 RPAP2 Putative RNA polymerase II 
subunit B1 CTD phosphatase 
RPAP2 
1 0.37 1.17 2.81E-02 1.21E-01 
Q9P1F3 ABRACL Costars family protein ABRACL 1 0.37 1.46 2.95E-02 2.84E-03 
Q14558-2 PRPSAP1 Isoform 2 of Phosphoribosyl 
pyrophosphate synthase-
associated protein 1 
5 0.38 1.26 3.14E-02 1.68E-01 
P60891 PRPS1 Ribose-phosphate 
pyrophosphokinase 1 
4 0.39 2.13 3.49E-02 2.26E-03 
Q9BV44 THUMPD3 THUMP domain-containing 
protein 3 
3 0.39 1.42 3.52E-02 2.18E-02 
O60879 DIAPH2 Protein diaphanous homolog 2 4 0.39 1.08 3.78E-02 2.96E-01 
Q13480-2 GAB1 Isoform 2 of GRB2-associated-
binding protein 1 
1 0.39 1.03 3.83E-02 7.08E-01 
O94804 STK10 Serine/threonine-protein kinase 
10 
10 0.39 1.03 3.85E-02 9.27E-01 
O60610 DIAPH1 Protein diaphanous homolog 1 19 0.40 1.66 4.06E-02 1.84E-02 
P11908-2 PRPS2 Isoform 2 of Ribose-phosphate 
pyrophosphokinase 2 
7 0.40 1.57 4.13E-02 1.80E-03 
P56945-6 BCAR1 Isoform 6 of Breast cancer anti-
estrogen resistance protein 1 
4 0.40 1.17 4.20E-02 3.24E-01 
P13797 PLS3 Plastin-3 43 0.40 1.01 4.25E-02 9.49E-01 
O60281 ZNF292 Zinc finger protein 292 1 0.40 1.15 4.27E-02 1.07E-01 
Q13509 TUBB3 Tubulin beta-3 chain 55 0.40 3.67 4.28E-02 1.00E-01 
P48163 ME1 NADP-dependent malic enzyme 14 0.40 1.41 4.32E-02 1.20E-03 
Q9NR46-2 SH3GLB2 Isoform 2 of Endophilin-B2 2 0.40 1.78 4.34E-02 3.75E-01 
Q6ZUT9-2 DENND5B Isoform 2 of DENN domain-
containing protein 5B 




P18510-3 IL1RN Isoform 3 of Interleukin-1 
receptor antagonist protein 
1 0.41 1.65 4.44E-02 2.63E-02 
Q14142 TRIM14 Tripartite motif-containing 
protein 14 
1 0.41 1.90 4.45E-02 5.73E-03 
Q9NWQ9 C14orf119 Uncharacterized protein 
C14orf119 
1 0.41 1.24 4.47E-02 9.16E-02 
O95772 STARD3NL MLN64 N-terminal domain 
homolog 
3 0.41 1.63 4.55E-02 2.79E-03 
Q8IVD9 NUDCD3 NudC domain-containing 
protein 3 
4 0.41 1.25 4.88E-02 6.11E-01 
Q92882 OSTF1 Osteoclast-stimulating factor 1 3 0.41 1.32 4.93E-02 1.96E-02 
Q8IX01 SUGP2 SURP and G-patch domain-
containing protein 2 
8 0.41 1.49 4.93E-02 1.17E-01 
Q6AWC2-6 WWC2 Isoform 6 of Protein WWC2 1 0.41 1.49 4.96E-02 5.66E-03 
 







RNA FC 72h Protein 72h 
vs mock p-
value 
RNA 72h vs 
mock p-value 
Q9H1A4 ANAPC1 Anaphase-promoting complex 
subunit 1 
1 0.07 1.54 5.34E-04 2.83E-02 
P78348-1 ASIC1 Isoform 1 of Acid-sensing ion 
channel 1 
2 0.08 1.53 8.72E-04 2.64E-01 
Q8WW38 ZFPM2 Zinc finger protein ZFPM2 1 0.09 56.68 1.65E-03 1.94E-03 
P16403 HIST1H1C Histone H1.2 3 0.09 2.65 1.98E-03 4.61E-01 
Q96SB3 PPP1R9B Neurabin-2 8 0.10 1.36 2.91E-03 1.56E-01 
O95081 AGFG2 Arf-GAP domain and FG repeat-
containing protein 2 
1 0.11 3.21 3.41E-03 3.25E-03 
Q7Z333-4 SETX Isoform 4 of Probable helicase 
senataxin 
4 0.14 1.14 9.52E-03 2.28E-01 
Q53ET0 CRTC2 CREB-regulated transcription 
coactivator 2 




Q8WUI4-8 HDAC7 Isoform 8 of Histone 
deacetylase 7 
1 0.14 1.15 1.05E-02 5.72E-01 
Q9UJX4 ANAPC5 Anaphase-promoting complex 
subunit 5 
3 0.14 1.12 1.07E-02 5.60E-02 
P51587 BRCA2 Breast cancer type 2 
susceptibility protein 
1 0.14 1.31 1.09E-02 7.60E-02 
Q8IX01 SUGP2 SURP and G-patch domain-
containing protein 2 
8 0.15 2.33 1.32E-02 2.10E-03 
P51805 PLXNA3 Plexin-A3 2 0.15 1.70 1.38E-02 7.13E-02 
Q9P2D6 FAM135A Protein FAM135A 1 0.16 1.79 1.70E-02 5.99E-04 
P02458 COL2A1 Collagen alpha-1(II) chain 13 0.16 102.16 1.80E-02 1.74E-03 
Q00537-2 CDK17 Isoform 2 of Cyclin-dependent 
kinase 17 
1 0.17 1.35 1.87E-02 5.01E-03 
Q08AD1 CAMSAP2 Calmodulin-regulated spectrin-
associated protein 2 
3 0.17 1.52 2.06E-02 3.63E-04 
Q9H4A3-7 WNK1 Isoform 6 of Serine/threonine-
protein kinase WNK1 
7 0.17 1.99 2.11E-02 5.52E-04 
Q8N5C8 TAB3 TGF-beta-activated kinase 1 and 
MAP3K7-binding protein 3 
1 0.17 2.35 2.17E-02 3.77E-04 
Q9Y2U5 MAP3K2 Mitogen-activated protein 
kinase kinase kinase 2 
1 0.17 1.96 2.22E-02 9.81E-04 
Q99576 TSC22D3 TSC22 domain family protein 3 2 0.18 1.23 2.31E-02 2.61E-02 
Q14527 HLTF Helicase-like transcription factor 3 0.18 2.08 2.45E-02 8.10E-05 
P06753 TPM3 Tropomyosin alpha-3 chain 24 0.19 2.58 3.14E-02 2.08E-04 
O76041 NEBL Nebulette 1 0.22 75.62 4.56E-02 1.17E-04 
Q9HAU0-6 PLEKHA5 Isoform 6 of Pleckstrin 
homology domain-containing 
family A member 5 
4 0.22 1.68 4.66E-02 5.07E-03 
P17612 PRKACA cAMP-dependent protein kinase 
catalytic subunit alpha 
6 0.22 1.01 4.67E-02 9.25E-01 
Q86WN1 FCHSD1 F-BAR and double SH3 domains 
protein 1 




P05413 FABP3 Fatty acid-binding protein, heart 5 0.22 2.12 4.78E-02 1.80E-02 
P22694-2 PRKACB Isoform 2 of cAMP-dependent 
protein kinase catalytic subunit 
beta 
9 0.22 1.45 4.83E-02 8.48E-04 
Q8WU10 PYROXD1 Pyridine nucleotide-disulfide 
oxidoreductase domain-
containing protein 1 






Appendix table 4. Proteins identified to be degraded during HCMV infection in at least two out of three screens (high confidence). 
Seven proteins passed the selection criteria of all 3 screens and 28 proteins passed 2 screens. “Y” means the protein was identified to be 




Description Screens degraded 
(stringent 
criteria) 
MG132 Screen pSILAC screen RNA/Protein 
Q9H1A4 ANAPC1 Anaphase-promoting complex subunit 1 3 Y Y Y 
Q9UJX4 ANAPC5 Anaphase-promoting complex subunit 5 3 Y Y Y 
Q9NRY4 ARHGAP35 Rho GTPase-activating protein 35 3 Y Y Y 
Q14527 HLTF Helicase-like transcription factor 3 Y Y Y 
Q9HAU0-6 PLEKHA5 Isoform 6 of Pleckstrin homology domain-
containing family A member 5 
3 Y Y Y 
Q96SB3 PPP1R9B Neurabin-2 3 Y Y Y 
Q8IX01 SUGP2 SURP and G-patch domain-containing 
protein 2 
3 Y Y Y 
Q53ET0 CRTC2 CREB-regulated transcription coactivator 2 2 N Y Y 
Q15392 DHCR24 Delta(24)-sterol reductase 2 Y Y N 
P16403 HIST1H1C Histone H1.2 2 N Y Y 
Q96J02 ITCH E3 ubiquitin-protein ligase Itchy homolog 2 Y Y N 
Q9Y2U5 MAP3K2 Mitogen-activated protein kinase kinase 
kinase 2 
2 Y Y N 
Q14149 MORC3 MORC family CW-type zinc finger protein 3 2 Y Y N 
P16333 NCK1 Cytoplasmic protein NCK1 2 N Y Y 
P13797 PLS3 Plastin-3 2 N Y Y 
P51805 PLXNA3 Plexin-A3 2 N Y Y 
P17612 PRKACA cAMP-dependent protein kinase catalytic 
subunit alpha 
2 N Y Y 




Q7Z333-4 SETX Isoform 4 of Probable helicase senataxin 2 N Y Y 
P23497-4 SP100 Isoform Sp100-C of Nuclear autoantigen Sp-
100 
2 Y Y N 
Q9Y4K3 TRAF6 TNF receptor-associated factor 6 2 Y Y N 
Q9H4A3-7 WNK1 Isoform 6 of Serine/threonine-protein 
kinase WNK1 
2 N Y Y 
Q9UJX5-3 ANAPC4 Isoform 3 of Anaphase-promoting complex 
subunit 4 
2 Y Y N/A 
A1A4S6 ARHGAP10 Rho GTPase-activating protein 10 2 Y N Y 
P78357 CNTNAP1 Contactin-associated protein 1 2 Y Y N 
Q9Y485 DMXL1 DmX-like protein 1 2 Y Y N/A 
Q8TE73 DNAH5 Dynein heavy chain 5, axonemal 2 Y Y N 
Q92896-2 GLG1 Isoform 2 of Golgi apparatus protein 1 2 N Y Y 
Q8NB16 MLKL Mixed lineage kinase domain-like protein 2 Y Y N/A 
Q96PU5 NEDD4L E3 ubiquitin-protein ligase NEDD4-like 2 Y N/A Y 
Q9Y5G0 PCDHGB5 Protocadherin gamma-B5 2 Y N/A Y 
Q15678 PTPN14 Tyrosine-protein phosphatase non-receptor 
type 14 
2 Y Y N 
Q86X27 RALGPS2 Ras-specific guanine nucleotide-releasing 
factor RalGPS2 
2 Y Y N/A 
O75676 RPS6KA4 Ribosomal protein S6 kinase alpha-4 2 Y Y N 
O96006 ZBED1 Zinc finger BED domain-containing protein 1 2 Y Y N/A 
 
 
 
 
